

1975 AUTHOR INDEX

Asterisk indicates abstract

- Abe, M.**
 see Matsui, K.
 see Murata, H.
- Albert, S. N.** Blood volume measurements, 961
- Abramovici, J.** see Ectors, M.
- Ackerman, M. J.** see Pritchard, J. H.
- Ackery, D. M.** see Goddard, B. A.
- Adams, D. F.**
 see Holman, B. L.
 see See, J. R.
- Adelstein, S. J., Jansen, C. and Wagner, H. N.** Studies of the heart and circulation, 959
- Adelstein, S. J.**
 see Bloomer, W. D.
 see McNeil, B. J.
- Adler, R. A.** see McCowen, K. D.
- Adler, S., Parthasarathy, K. L., Bakshi, S. P. and Stutzman, L.** ^{113}Ga -citrate scanning of lymphomas, 255
- Adolph, R. J.** see Nishiyama, H.
- Agee, R. N.** see Lull, R. J.
- Agress, H., Pearlman, A. S., Brody, W. R., Myers, R. W., Itscoitz, S. B., Green, M. V., Bailey, J. J., Johnston, G. S. and Redwood, D. R.** Stress-induced myocardial perfusion, 510*
- Agress, H.**
 see Bacharach, S.
 see Green, M. V.
- Ahmed, S. A.** see Coleman, R. E.
- Akalin, H. E.** see English, D. K.
- Alagarsamy, V.** see DePuey, E. G.
- Alavi, A.** see Alexander, J. M.
- Alazraki, N. P., Thomas, R., Verba, J. W., Daniel, D., Resnick, D. and Greenfield, R.** Bone scanning in arthritis, 510*
- Alazraki, N. P., Verba, J. W., Henry, J. E., Becker, R., Taylor, A. and Halpern, S. E.** GFR by x-ray fluorescence, 510*
- Alazraki, N. P.**
 see Chauncey, D.
 see Epstein, J.
 see Hagan, P. L.
 see Hurwitz, S. R.
 see Taylor, A.
- Alba, J.** see Sarmiento, A. H.
- Alderman, E. L.** see Berndt, T.
- Alderson, P. D., Boonvisut, S., McKnight, R. and Hartman, A. F.** Ventilation and perfusion in tetralogy of Fallot, 510*
- Alderson, P. O., Gilday, D. L. and Wilkie, A.** Rapid-sequence brain imaging in pediatrics, 511*
- Alderson, P. O., Jost, R. G., Strauss, A. W., Boonvisut, S. and Markham, J.** Left-to-right cardiac shunts in children, 511*
- Alderson, P. O.**
 see Harwig, J. F.
 see Secker-Walker, R. H.
- Alexander, J. L.** see Gillespie, P. J.
- Alexander, J. M., Alavi, A. and Hansell, J. R.** Bone imaging in jaw lesions, 511*
- Alford, C. A.** see Gams, R. A.
- Ali, A.** see Rayudu, G. V. S.
- Aloia, J. F., Ellis, K., Zanzi, I. and Cohn, S. H.** Photon absorptiometry in osteoporosis, 196
- Alpert, N. M., Burnham, C. A., Devault, L. A., Correll, J. E., Chesser, D. A., Pizer, S. M. and Brownell, G. L.** System for online data processing, 386
- Andersen, B. R.** see English, D. K.
- Anderson, B. G., Beierwaltes, W. H., Nishiyama, R. H. and Ice, R. D.** ^{131}I -iodocholesterol effect on adrenal cortical hyperplasia, 928
- Anderson, O.** see Pavel, D. G.
- Anderson, P. J.** see Ronai, P. M.
- Andrews, J. W.** see Lull, R. J.
- Anger, H. O.** see Weber, P. M.
- Anger, R. T.** see Kavula, M. P.
- Anghilieri, L. J.** Erythrocyte labeling with ^{103}Ru -ruthenium red, 795
- Ansari, A. N., Atkins, H. L., Briggs, J., Christman, D., Fowler, J., Gallagher, B., MacGregor, R. and Wolf, A. P.** Metabolism of ^{11}C -aliphatic acids, 511*
- Ansari, A. N., Atkins, H. L., Smith, T. D. and Richards, P.** BNL ^{99m}Tc -RBC labeling kit, 512*
- Ansari, A. N.**
 see Atkins, H. L.
 see Bradley-Moore, P. R.
 see Lebowitz, E.
- Anselmi, O. E.** see Taplin, G. V.
- Aoki, C. T.** Construction of a lead bar phantom, 441
- Aragon, S.** see Dunnick, J. K.
- Arnold, J. E. and Pinsky, S. M.** Thyroid imaging with ^{99m}Tc and ^{131}I , 512*
- Arnold, J. E., Pinsky, S. M., Ryo, U. Y., Colman, M., Frohman, L. A., Schneider, A., Favus, M., Stachura, M. and Arnold, M.** ^{99m}Tc thyroid imaging in history of x-ray therapy, 512*
- Arnold, J. E.**
 see Johnstone, A. S.
 see Ryo, U. Y.
- Arnold, J. S., Barnes, W. E., Frazin, L. and Kaplan, E.** ^{99m}Tc -pyrophosphate in myocardial infarcts and bone, 512*
- Arnold, J. S.** see Kaplan, E.
- Arnold, M.** see Arnold, J. E.
- Arnold, R. W., Subramanian, G., McAfee, J. G., Blair, R. J. and Thomas, F. D.** ^{99m}Tc -complexes for renal imaging, 357
- Ash, J. M., Gilday, D. L. and Reilly, B. J.** Pinhole imaging of hip in children, 512*
- Ashare, A. B., Dubuque, G., Rauf, C. G. and Kereiakes, J. G.** Lesion detection with photopeak plus backscatter energy, 513*
- Ashare, A. B., Padikal, T., Cohen, G. and Kereiakes, J. G.** Scintillation camera field flood uniformity correction, 513*
- Ashare, A. B.**
 see Holder, L. E.
 see Nishiyama, H.
- Ashburn, W. L.** Book review: *Cardiovascular Nuclear Medicine*, 966
- Ashburn, W. L.**
 see Schelbert, H.
 see Taylor, A.
- Ashkar, F. S., Heal, A. and Turner, T.** Hepatitis B antigen and antibody studies, 513*
- Ashkar, F. S.** see Rosenthal, S.
- Ashley, S. J.** see Guarin, U.
- Athanasiou, C. A.** see Shapiro, S. H.
- Atkins, F. B. and Beck, R. N.** Scatter subtraction effects on image contrast, 102
- Atkins, H. L., Ansari, A. N., Lebowitz, E., Greene, E. W., Fairchild, R. and Budinger, T. F.** Distribution and properties of ^{201}Tl , 513*
- Atkins, H. L., Cloutier, R. J., Lathrop, K. A., Freeman, L. M., McAfee, J. G., Nelip, W. B., Patton, D. D. and Smith, E. M.** Radiation dose estimates for ^{99m}Tc -S colloid in liver disease, 109
- Atkins, H. L.**
 see Ansari, A. N.
 see Bradley-Moore, P. R.
 see Lebowitz, E.
 see Packer, S.
- Atmaran, S. H., Ganatra, R. D., Sharma, S. M. and Ramanna, L.** Thyroid carcinoma metastases in liver, 919
- Ayres, P. R.** see Hagan, P. L.
- Azueta, V.** see Sham, R.
- Bacharach, S., Agress, H., Hammock, M. K., Green, M. V., Pongpatirojana, A., Johnston, G. S. and DiChiro, G.** ^{133}Xe blood flow in induced cerebral infarction, 514*
- Bachur, N. R.** see Puri, S.
- Bailey, J. J.**
 see Agress, H.
 see Green, M. V.
- Baily, N. A.** see Taylor, A.
- Baker, J. D.**
 see Levy, L. M.
 see Marta, J. B.
- Baker, R. J., Bellen, J. C. and Ronai, P. M.** ^{99m}Tc -pyridoxylidene-glutamate for hepatobiliary studies, 720
- Baker, R. J.** see Ronai, P. M.

- Baker, S. I.** see Johnston, A. S.
Bakshi, S. P.
 see Adler, S.
 see Lunia, S.
Balachandran, S., Beierwaltes, W. H., Ice, R. D., Fajans, S. S., Ryo, U. Y., Redmond, M. J., Hetzel, K. R., Mosley, S. T. and Feldstein, B. Distribution of ^{14}C - ^{131}I - and ^{131}I -diphenylhydantoin, 775
Balachandran, S., Moses, D. C., Sisson, J. C. and Patel, S. R. Evaluation of a new T₁ kit, 514*
Balch, C. M. see Dubovsky, E. V.
Balint, R. see Ruetz, P. P.
Banna, M. see Nahmias, C.
Bardy, A., Fouyé, H., Gobin, R., Beydon, J., de Tovar, G., Bannaciére, C. and Hégésippe, M. ^{99m}Tc labeling using Sn(II) pyrophosphate, 435
Barnes, M. F. see Bell, E. G.
Barnes, W. E.
 see Arnold, J. S.
 see Kaplan, E.
Barrett, H. H., Simpson, R. G. and Fisher, H. D. Data processing with annular coded apertures, 514*
Barrett, H. H. see Farmelant, M. H.
Barth, R. F. and Singla, O. Distribution of ^{99m}Tc - and ^{51}Cr -thymocytes, 633
Barth, R. F. see Gobuty, A. H.
Barthe, J. see Blanquet, P.
Basmadjian, G. P., Hetzel, K. R., Ice, R. D. and Beierwaltes, W. H. Synthesis of a new adrenal agent, 514*
Basmadjian, G. P. see Sarkar, S. D.
Bass, J. C. see Sfakianakis, G. N.
Bautovich, G. see Lathrop, K. A.
Beabout, J. W. see Wahner, H. W.
Beal, W. see Soin, J. S.
Beardon, A. J. see Hambright, P.
Beauchamp, J. M., Belanger, M. A. and Neitzschman, H. R. "Doughnut" sign in brain imaging, 432
Beauchamp, J. M. see Belanger, M. A.
Beaver, J. E. see Serafini, A. N.
Beck, R. N.
 see Atkins, F. B.
 see Brunsden, B.
 see Hoffer, P. B.
Becker, R. see Alazraki, N. P.
Beekhuis, H. see Rasker, J. J.
Beierwaltes, W. H., Ice, R. D., Shaw, M. J. and Ryo, U. Y. Myocardial uptake of labeled oleic and linoleic acids, 842
Beierwaltes, W. H.
 see Anderson, B. G.
 see Balachandran, S.
 see Basmadjian, G. P.
 see Ice, R. D.
 see Gill, S. P.
 see Kirschner, A. S.
 see Ryo, U. Y.
 see Sarker, S. D.
 see Seabold, J. E.
 see Sturman, M. F.
Beihn, R. M.
 see DeLand, F. H.
see Simmons, G. H.
 see Theodorakis, M. C.
Bekerman, C. and Hoffer, P. B. Salivary gland uptake of ^{99}Ga -citrate, 514*
Bekerman, C. see Hoffer, P. B.
Bekier, A. Displacement of anterior cerebral vessels in subdural hematoma, 86
Belanger, M. A., Beauchamp, J. M. and Neitzschman, H. R. Ga uptake in benign liver tumor, 470
Belanger, M. A. see Beauchamp, J. M.
Belgrave, E. see Lebowitz, E.
Belko, J. S.
 see Frisbie, J. H.
 see O'Connell, D. J.
Bell, E. G., Mahon, D. F., Henry, C. A., Barnes, M. F., McAfee, J. G., Turcotte, R. E., Wolff, J. R. and White, W. Light-weight overhead scintillation camera, 515*
Bell, G. see DeNardo, S. J.
Bell, P. R. see DeLand, F. H.
Bell, W. E. see Conway, J. J.
Bellen, J. C.
 see Baker, R. J.
 see Ronai, P. M.
Belliveau, R. E. see Puri, S.
Bender, M. A. see Lunia, S.
Benedetto, A. R. see Nusynowitz, M. L.
Bennett, L. R.
 see Horn, N. L.
 see Robinson, G. D.
 see Touya, J. J.
 see Verma, R. C.
Benua, R. S.
 see Tilbury, R. S.
 see Yeh, S. D. J.
v. d. Berg, C. J. M. see Jambroes, G.
Bergan, J. J. see Henkin, R. E.
Berman, D. S., Salel, A. F., DeNardo, G. L., Bogren, H. G. and Mason, D. T. High-resolution gated left ventricular flow studies, 865
Berman, D. S., Salel, A. F., DeNardo, G. L. and Mason, D. T. Rest and exercise ^{82}Rb myocardial imaging, 515*
Berman, J. A. see Wolf, W.
Berman, M., Braverman, L. E., Burke, J., DeGroot, L., McCormack, K. R., Oddie, T. H., Rohrer, R. H., Wellman, H. N. and Smith, E. M. Radiation dose estimates for ^{123}I , ^{124}I , ^{125}I , ^{126}I , ^{127}I , ^{131}I and ^{132}I as sodium iodide, 857
Berndt, T., Alserman, E. L., Waschnich, R., Hsieh, S. C., Van Dyke, D. and Harrison, D. C. Portable probe cardiac flow studies, 289
Berquist, T. H., Nolan, N. G., Stephens, D. H. and Carlson, H. C. ^{99m}Tc specificity in Meckel's diverticulum, 515*
Bessent, R. G. see Citrin, D. L.
Beydon, J. see Bardy, A.
Bigler, R. E., Russ, G. A. and Laughlin, J. S. Radiation do-
 simetry of ^{203}Bi - and ^{206}Bi -citrate, 515*
Bigler, R. E. see Woodard, H. Q.
Billinghurst, M. W. Behavior of ^{99m}Tc -diphosphonate on Sephadex and Bio-gel, 1089
Billinghurst, M. W. and Palser, R. F. Lung retention of ^{99m}Tc -S colloid, 440
Bing, R. J. see Ikeda, S.
Binkhorst, R. A. see Yap, S. H.
Bittikofer, F. see Matin, P.
Bjork, L. see McNeil, B. J.
Blahd, W. H.
 see Krishnamurthy, G. T.
 see Pritchard, J. H.
Blair, R. J., Schroeder, E. T., McAfee, J. G. and Duxbury, C. E. Muscle uptake of bone agents in rhabdomyolysis, 515*
Blair, R. J.
 see Arnold, R. W.
 see Subramanian, G.
 see Yeates, M. G.
Blanc, D. see Blanquet, P.
Blanquet, P., Blanc, D., Safi, N., Thoreson, E., Barthe, J. and Lerebeller, M. J. Cerenkov effect for endocular tumor detection, 516*
Blau, M. Radiation dosimetry of ^{131}I -iodocholesterol, 247
Blau, M., McAfee, J. G., Rohrer, R. H., Synder, W. S. and Smith, E. M. Radiation dose estimates for ^{197}Hg - and ^{203}Hg -chlormerodrin, 1095
Blau, M.
 see Chang, W.
 see Owunwanne, A.
Blafox, M. D. see Chervu, L. R.
Bloch, B. see Malmud, L. S.
Bloomer, W. D. and Adelstein, S. J. Antineoplastic activity of ^{123}I -iododeoxyuridine, 516*
Blum, M. and Goldman, A. B. Oblique view in cold thyroid nodule diagnosis, 713
Blumgart, L. H.
 see Karan, S. J.
 see Leach, K. G.
Bobinet, D. see Spolter, L.
Bofilias, I., Hofer, J., Pabst, H. W. and Platzer, H. Coherent optical scintiscan processing, 516*
Bogren, H. G. see Berman, D. S.
Bok, B. D. and Fonroget, F. New whole-body unidirectional scanner, 516*
Bonoguro, E. see Mincey, E.
Bonte, F. J., Parkey, R. W., Graham, K. D. and Moore, J. G. Distribution of myocardial infarct imaging agents, 132
Bonte, F. J.
 see Parkey, R. W.
 see Stokeley, E. M.
Boonvisut, S. see Alderson, P. O.
Botvinick, E. see Shames, D. M.
Bowen, B. M., Coates, G. and Garbett, E. S. ^{99m}Tc -S colloid lung scan in histiocytosis X, 332
Bowen, B. M. see Coates, G.

AUTHOR INDEX

- Boyd, C. M.** see Vieras, F.
- Bradley-Moore, P. R., Lebowitz, E., Greene, M. W., Atkins, H. L. and Ansari, A. N.** ^{99m}Tl for medical use, 156
- Bradley-Moore, P. R.** see Lebowitz, E.
- Brady, L. W.**
see Heindel, N. D.
see Honda, T.
see Lantieri, R. L.
see Risch, V. R.
- Brahmaver, S. M., Zu'bi, S. M. and Sullivan, J. P.** Procedures for medical byproduct material licenses, 517*
- Branch, W. T.** see McNeil, B. J.
- Braun, E. J.** see Finney, C. E.
- Braunstein, P.** see Goldman, A. B.
- Braverman, L. E.** see Berman, M.
- Brickman, A. S.** see Krishnamurthy, G. T.
- Briggs, J.** see Ansari, A. N.
- Brill, A. B.**
see Patton, J. A.
see Price, R.
- Brodey, P. A.** see Richman, S. D.
- Brody, W. R.**
see Agress, H.
see Green, M. V.
- Bronzino, J., O'Rourke, J., Miller, C. and D'Amato, D.** Microvascular dysfunction in the eye, 517*
- Bronzino, J.** see D'Amato, D.
- Brooke, P., Decostre, P. and Cantraine, F.** Early I and Tc thyroid kinetics, 517*
- Brookeman, V. A.** Component resolution indices for scintillation cameras, 228
- Brookeman, V. A. and Morin, R. L.** Dosimetry of DTPA cisternography agents, 1177
- Brooks, W. H. and Mortara, R. H.** Brain scanning in metastatic disease, 961
- Brown, F.** see Pearson, D.
- Brown, M.** see Spies, S. M.
- Brown, M. J.** see Stauffer, J. C.
- Brownell, G. L.**
see Alpert, N. M.
see Hoop, B.
- Brunsdon, B., Harper, P. V. and Beck, R. N.** Elimination of collimator-hole pattern, 517*
- Bruun, P.** Lung retention of $^{99m}\text{Tc-S}$ colloid, 440
- Buchanan, J.** see Kim, H-R.
- Bucher, J. E.** see Moore, M. M.
- Buddemeyer, E. U.** Continuous measurement of in vitro metabolism, 517*
- Budinger, T. F.** Simple superposition tomography, 517*
- Budinger, T. F. and Macdonald, B.** Fresnel-coded scintillation camera images, 309
- Budinger, T. F., Yano, Y. and Hoop, B.** Myocardial positron scintigraphy, 429
- Budinger, T. F.** see Atkins, H. L.
- see Derenzo, S. F.
see Zaklad, H.
- Buhl, M., Charles, P. and Jensen, F. T.** Headband for scalp blood flow elimination, 679
- Buja, L. M.** see Stokeley, E. M.
- Burdine, J. A. and Murphy, P. H.** Large-field-of-view scintillation camera, 1158
- Burdine, J. A., Murphy, P. H. and Galen, T.** Large-field-of-view scintillation camera, 518*
- Burdine, J. A.**
see DePuey, E. G.
see Dhekne, R. D.
see Moyer, R. A.
see Murphy, P. H.
see Soin, J. S.
- Burke, J.** see Berman, M.
- Burman, K. D., Wright, F. D., Earll, J. M. and Wartofsky, L.** Radioimmunoassay of T₃, 662
- Burnham, C. A.** see Alpert, N. M.
- Burns, H. D.**
see Heindel, N. D.
see Honda, T.
see Risch, V. R.
- Busick, D. D.** see DeGrazia, J. A.
- Buyx, W. C. A. M.** see Yap, S. H.
- Buzzi, K. W.** see Weinraub, J. M.
- Callahan, R. J.** see Shapiro, S. H.
- Callery, P. S.** see Loberg, M. D.
- Camargo, E. E., Larson, S. M., Charache, P., Tepper, B. S. and Wagner, H. N.** Radiometric detection of M. tuberculosis and M. lepraeumium, 518*
- Camargo, E. E.** see Cummings, D. M.
- Campbell, J. J.** see Siegel, M. E.
- Campeau, R. J., Gottlieb, S., Chandraratna, S. K. C., Mayorga-Cortes, A. and Miale, A.** ^{99m}Tc -phosphates for myocardial infarction, 518*
- Cantor, R. E.** see Shapiro, B.
- Cantraine, F.** see Brooke, P.
- Capon, A.** see Verbiest, A.
- Capps, S. J.** see O'Mara, R. E.
- Capurro, P. U.** see Eldridge, J. E.
- Capuzzi, J.** see Malmud, L. S.
- Caretta, R. F.** see Rosenthal, S.
- Caride, V. J.** see Spencer, R. P.
- Carlson, H. C.** see Berquist, T. H.
- Carretta, R. F.** see DeNardo, S. J.
- Castenada, A.** see Treves, S.
- Castor, W. R.** see Lentle, B. C.
- Castronovo, F. P.** see Shapiro, S. H.
- Catz, Z.** see Holder, L. E.
- Cavalieri, R. R.** ^{75}Se -selenite brain scanning, 331
- Celis, C.** see Skromme-Kadlubik, G.
- Chan, J. K.** see Cho, Z. H.
- Chan, P., Firnau, G. and Garnett, E. S.** ^{18}F -fluoro-DOPA for brain scanning, 518*
- Chandraratna, S. K. C.** see Campeau, R. J.
- Chandler, W. M. and Schuck, L. D.** Abnormal $^{99m}\text{TcO}_4^-$ brain image following $^{99m}\text{Tc-Sn}$ -pyrophosphate, 518*
- Chandler, W. M. and Schuck, L. D.** Effects of tin on $^{99m}\text{TcO}_4^-$ distribution, 690
- Chandra, S. and Laor, Y. G.** Lung scan and wide mediastinum, 324
- Chang, C. C.** see Spolter, L.
- Chang, W. and Blau, M.** Optimum gray scale for photoscanners, 519*
- Chang, Y. C.** see Lowenthal, I. S.
- Charache, P.**
see Camargo, E. E.
see Larson, S. M.
- Charkes, N. D., Philips, C. and Malmud, L. S.** Model for bone agent uptake, 519*
- Charles, P.** see Buhl, M.
- Chaudhuri, Tapan K.** ^{85}Sr and ^{99m}Tc -polyphosphate secretion in serous fluids, 1208
- Chaudhuri, Tapan K.** $^{99m}\text{TcO}_4^-$ secretion in the stomach, 1204
- Chaudhuri, Tapan K., May, L. G., Dwyer, R. D. and de los Santos, G.** Effect of parathormone on ^{32}P bone metastases therapy, 519*
- Chaudhuri, Tapan K., Saparoff, G. R., Dolan, K. D. and Chaudhuri, Tuhin K.** Comparison of contrast and nuclear lacrimal drainage studies, 605
- Chaudhuri, Tuhin K.** see Chaudhuri, Tapan K.
- Chauncey, D. M., Halpern, S. E. and Alazraki, N. P.** ^{131}I -tetracycline for tumor scanning, 519*
- Chauncey, D. M., Halpern, S. E., Hagan, P. L. and Alazraki, N. P.** ^{131}I -tetracycline for tumor scanning, 520*
- Chauncey, D. M.**
see Hagan, P. L.
see Schelbert, H.
- Chelliah, M.** see Eckelman, W. C.
- Chen, M., Rhodes, B. A. and Wagner, H. N.** Radiometric sterility assay, 798
- Chen, M.**
see Larson, S. M.
see Tran, N.
- Chervu, L. R., Goyal, Q. R. and Blaufox, M. D.** $^{99m}\text{Tc-Cu-HEDSPA}$ for bone imaging, 520*
- Chesler, D. A., Hales, C., Hnatowich, D. J. and Hoop, B.** 3D reconstruction of positron lung perfusion image, 80
- Chesler, D. A.**
see Alpert, N. M.
see Hoop, B.
- Chesnut, C. H.** see Lewellen, T. K.
- Chiba, K.**
see Matsui, K.
see Murata, H.
- Chiottellis, E., Subramanian, G. and McAfee, J. G.** $^{99m}\text{Tc-Schiff's bases}$, 520*
- Chisholm, G. D.** Radiozinc for prostate, 496
- Cho, Z. H., Chan, J. K., Ericksson, L., Singh, M., Graham, S., MacDonald, N. S. and Yano, Y.** Positron ranges of biomedically important radionuclides, 1167
- Cho, Z. H.** see Profio, A. E.

- Christensen, J.** see James, A. E.
Christman, D. see Ansari, A. N.
Chu, D. see Lim, C. B.
Citrin, D. L., Bessent, R. G., McGinley, E. and Gordon, D. Dynamic studies with 99m Tc-HEDP, 886
Clark, E. E. and Hattner, R. S. Brain imaging in recurrent medulloblastoma, 520*
Clark, R. B. and Fair, W. R. Radioactive putrescine metabolism in rats, 337
Clements, J. P. see Dickerman, J. D.
Cloutier, R. J., Freeman, L. M., McAfee, J. G., McCormack, K. R., Patton, D. D., Rosenthal, L. and Smith, E. M. Radiation dose estimates for 198 Au in liver disease, 173
Cloutier, R. J.
 see Atkins, H. L.
 see Watson, E. E.
Coates, G., Bowen, B. M., Nahmias, C. and Garnett, E. S. Parameters of bone agent uptake, 520*
Coates, G., DeNardo, S. J., DeNardo, G. L. and Troy, F. A. Pharmacokinetics of radioiodinated streptokinase, 136
Coates, G. see Bowen, B. M.
Coberly, J. C. see Hunter, D.
Coble, C. S. see Phelps, M. E.
Coco, M. see Subramanian, G.
Codd, J. E. see George, E. A.
Coel, M. see Epstein, J.
Cohen, G. see Ashare, A. B.
Cohen, M. B. see Spolter, L.
Cohn, P. F.
 see Holman, B. L.
 see See, J. R.
Cohn, S. H. see Aloia, J. F.
Coleman, R. E., Harwig, S. S. L., Harwig, J. F., Sherman, L. A. and Welch, M. J. Radioiodinated fibrin for thrombus, 521*
Coleman, R. E., Harwig, S. S. L., Harwig, J. F., Siegel, B. A. and Welch, M. J. Fibrinogen uptake by thrombi, 370
Coleman, R. E., Hoffman, E. J., Phelps, M. E., Welch, M. J. and Ter-Pogossian, M. M. Transaxial tomography with positron emitters, 521*
Coleman, R. E., Klein, M. S., Ahmed, S. A., Roberts, R. and Sobel, B. E. 99m Tc-pyrophosphate and serum MB CPK for myocardial infarction, 521*
Coleman, R. E.
 see Harwig, S. L.
 see Welch, D. M.
Colley, D. P. see Holder, L. E.
Collins, P. J. see Ronai, P. M.
Colman, M. see Arnold, J. E.
Colombetti, L. G.
 see Johnston, A. S.
 see Mohammedzadeh, A.
 see Ryo, U. Y.
Colvin, J. T. see Klein, E. W.
Comar, D., Maziere, M., Marazano, C. and Raynaud, C. 113 C-psychoactive drugs, 521*
Connolly, R. J. see Dewanjee, M. K.
Conway, J. J., Gooneratne, N. and Simon, G. Femoral metaphyseal irregularities in children, 521*
Conway, J. J. and Kruglik, G. D. Direct and indirect radionuclide cystography, 522*
Conway, J. J., Seibert, J. J., Kuhn, G. P. and Bell, W. E. Evaluation of central nervous system complications from chemotherapy, 522*
Conway, J. J. see Gooneratne, N.
Cooper, J. F. and Harbert, J. C. Aseptic meningitis after radionuclide cisternography, 809
Cooper, M. D.
 see Harvey, E. B.
 see Loberg, M. D.
 see Quinlan, J.
 see Termini, B.
Corcoran, R. C., Thrall, J., Kyle, R. and Johnson, M. Solitary bone lesions, 522*
Corcoran, R. C. see Thrall, J.
Correll, J. E. see Alpert, N. M.
Corrigan, J. see O'Mara, R. E.
Cortes, E. P. see Sham, R.
Coune, A. see Fröhling, J.
Counsell, R. E. see Skinner R. W. S.
Coupal, J. Abstracts of current literature, 500, 501
Cowan, R. J., Murphy, M. P. and Maynard, C. D. 99m Tc activity artifact in 113 In cisternography, 434
Cox, R. S., Turner, D. A. and Fordham, E. W. Rectilinear scanner modification to improve 67 Ga scans, 1192
Crawford, M. see Schelbert, H.
Creutzig, H. Bone imaging after total hip replacement, 522*
Creutzig, H. 99m Tc-polyprophosphate and 18 F kinetics, 688
Crocker, E. F., McLaughlin, A. F., Uren, R. F., Morris, J. G., Jellins, J. and Kossoff, G. Echography and 131 Cs scanning of non-functioning thyroid nodules, 522*
Cullison, R. C. see Krishnamurthy, G. T.
Cummings, D. M., Ristroph, D., Camargo, E. E., Larson, S. M. and Wagner, H. N. Radiometric detection of the metabolism of Mycobacterium tuberculosis, 1189
Custer, J. R. and Shafter, R. B. Changes in liver scan following splenectomy, 194
Czerniak, P. see Zwas, S. T.
Daly, J. L., Herbig, F. K. and Fletcher, J. W. A nuclear medicine information network, 523*
Daly, J. L.
 see Fletcher, J. W.
 see Henry, R. E.
D'Amato, D., Bronzino, J., Miller, C. and O'Rourke, J. System of dynamic studies of the eye, 523*
D'Amato, D. see Bronzino, J.
Damm, D. W. see Reinke, D. B.
Damoulaki-Sfakianaki, E. see Sfakianakis, G. N.
Dance, D. see Parker, R.
Daniel, D. see Alazraki, N. P.
Daniels, D. see Pick, R. O.
D'Antonio, R. see Kim, H.-R.
Davis, M. A. Editorial; nomenclature of 99m Tc bone agents, 1
Davis, M. A. and Holman, B. L. Acute myocardial infarct imaging agents, 523*
Davis, M. A. see Jones, A. G.
Davson, H. see James, A. E.
Decostre, P. see Brooke, P.
DeGrazia, J. A., Rodden, A. F., Teresi, J. D., Busick, D. D. and Walz, D. R. Imaging of 113 C-ethanol distribution, 73
DeGroot, L. see Berman, M.
Deisenhammer, E., Gund, A., Hammer, B. and Steinhäusl, H. Unilateral ventricular reflux, 716
DeLand, F. H. Abstracts of current literature, 500, 502, 503, 697, 802, 851, 968, 1092, 1210
DeLand, F. H. Book review: *Atlas of Cerebral Angiography: Anatomic Correlation*, 801
DeLand, F. H. Book report: *New Techniques in Tumor Localization and Radioimmunoassay*, 498
DeLand, F. H. Book review: *Physician's Desk Reference for Radiology and Nuclear Medicine*, 499
DeLand, F. H. Editor's letter, 449, 1103
DeLand, F. H., Beihn, R. M., Simmons, G. H. and Hafner, T. V. Tumor detection by the subtraction technique, 523*
DeLand, F. H., Fisher, D., Bell, P. R., McClain, W. J., Dillon, R. S. and Ross, D. A. Computer correction of image errors, 523*
DeLand, F. H.
 see Simmons, G. H.
 see Theodorakis, M. C.
de los Santos, G. see Chaudhuri, Tapan K.
DeLuca, S. A. and Kolodny, G. M. Spleen-lung interface, 822
DeMeester, G. see Farmelant, M. H.
de Moss, E. V. see Richman, S. D.
DeNardo, G. I. Bone scans and 32 P in thyroid adenocarcinoma, 963
DeNardo, G. L., DeNardo, S. J., Meyers, J. and Krohn, L. A. Tumor localization with 131 I- and 131 I-bleomycin, 524*
DeNardo, G. L.
 see Berman, D. S.
 see Coates, G.
 see DeNardo, S. J.
 see Dublin, A. B.
 see Hines, H. H.
 see Meyers, J.
 see Rosenthal, S.
 see Stadnik, R. C.
DeNardo, S. J., Bell, G., DeNardo, G. L., Carretta, R. F., Scheibe, P., Imperato, T. and Jackson, P. Effective hepatic plasma flow, 524*
DeNardo, S. J., DeNardo, G. L.,

AUTHOR INDEX

- Carretta, R. F., Jansholt, A-L.**
Krohn, K. A. and Peek, N. F.
 ^{123}I -fibrinogen for thrombophlebitis detection, 524*
- DeNardo, S. J.**
 see Coates, G.
 see DeNardo, G. L.
 see Rosenthal, S.
 see Stadnik, R. C.
- DePuey, E. G., Thompson, W. L., Alagarsamy, V. and Burdine, J. A.**
 Bone mineral content by functional imaging, 891
- Derenzo, S. E., Zaklad, H. and Budinger, T. F.** Collimators for positron emitters, 524*
- Derenzo, S. E., Zaklad, H. and Budinger, T. F.** Ring detector for transaxial reconstruction tomography, 1166
- Derenzo, S. E.** see Zaklad, H.
- De Roo, M. J. K.** Scintigraphic appearance of necrotic liver metastasis, 250
- De Roo, M. J. K.** ^{75}Se -selenite brain scanning, 331
- Detels, R.** see Taplin, G. V.
- de Tovar, G.** see Bardy, A.
- Deutchman, A. H., Fulmer, L. R., Wise, G. R., Miller, D. W. and Hunter, W. W.** Quantitative regional cerebral circulation determination, 525*
- Deveau, L. A.** see Alpert, N. M.
- Devenney, J. E., Morales, J. O. and Kuhl, D. E.** ^{99m}Tc -Sn-DTPA in obstructive renal disease, 525*
- Dewanjee, M. K.** Autoradiography of ^{99m}Tc -tetracycline in necrotic cells, 315
- Dewanjee, M. K., Kahn, P. C., Dewanjee, U. and Connolly, R. J.** ^{99m}Tc -pyrophosphate and -tetracycline in infarcted myocardium, 525*
- Dewanjee, U.** see Dewanjee, M. K.
- Dhekne, R. D., Nitishin, A. and Burdine, J. A.** Liver/spleen scanning in blunt abdominal trauma, 525*
- Diaz, J. F.** see Skromme-Kadlubik, G.
- DiChiro, G.** see Bacharach, S.
- Dickerman, J. D. and Clements, J. P.** Spleen scan following MOPP therapy for Hodgkin's, 457
- Dierich, H.** see Lentle, B. C.
- Dietholm, A. G.** see Dubovsky, E. V.
- Dietrich, R.** see Sarmiento, A. H.
- Digenis, G. A., Kook, C. S. and Reed, M. F.** Synthesis of ^{18}F -haloperidol, 525*
- Digenis, G. A.** see Theodorakis, M. C.
- Dillon, R. S.** see DeLand, F. H.
- Dillon, W. G. and Glomski, C. A.** Erythrocyte survival in the mongolian gerbil, 682
- Dimitrieva, Z.** see Guarin, U.
- Doehn, M.** see Hupe, W.
- Dolan, K. D.** see Chaudhuri, Tapan K.
- Donabedian, R. K.** see Puri, S.
- Donati, R. M.** Book review: *Nuclear Medicine*, 966
- Donati, R. M.**
 see Fletcher, J. W.
 see George, E. A.
 see Haibach, H.
 see Henry, R. E.
 see Schulz, R. C.
- Donner, M.** see James, A. E.
- Dorais, S.** see Mincey, E.
- Dore, E. K.** see Gates, G. F.
- dos Remedios, L. V.** see Weber, P. M.
- Douglas, M. A.** see Green, M. V.
- Dratz, A. F.** see Hunter, D.
- Driedger, A.** see Peart, R. A.
- Dublin, A. B., Stadnik, R. C., DeNardo, G. L. and Vogel, J. M.** Imaging of a blind-ending ureteral duplication, 208
- Dubovsky, E. V., Logic, J. R., Dietholm, A. G., Balch, C. M. and Tauxe, W. N.** Renal function in the transplanted kidney, 1115
- Dubovsky, E. V.** see Russell, C. D.
- Dubuque, G.** see Ashare, A. B.
- Duknen, H.** see Ikeda, S.
- Dukstein, W. G.** see Prince, J. R.
- Dunn, B.** see Reinke, D. B.
- Dunnick, J. K., McDougall, I. R., Aragon, S., Goris, M. L. and Kriss, J. P.** Vesicle interactions with polyamino acids and antibody, 483
- Dunnick, J. K.** see McDougall, I. R.
- Duxbury, C. E.**
 see Blair, R. J.
 see Subramanian, G.
- Dworkin, H. J., Gutkowski, R. F., Porter, W. and Potter, M.** Number of particles for lung imaging, 526*
- Dworkin, H. J.**
 see Gutkowski, R. F.
 see Roco, R. N.
- Dwyer, R. D.** see Chaudhuri, Tapan K.
- Earl, W. C.** see Sfakianakis, G. N.
- Earll, J. M.** see Burman, K. D.
- Eckelman, W. C., Rzeszotarski, W. J., Siegal, B. A., Kubota, H., Chelliah, M. and Reba, R. C.** Isolated ^{90}Co -bleomycin components, 526*
- Eckelman, W. C., Rzeszotarski, W. J., Siegal, B. A., Kubota, H., Chelliah, M., Stevenson, J. and Reba, R. C.** Isolated radiolabeled bleomycin preparations, 1033
- Eckelman, W. C.**
 see Harbert, J. C.
 see Kubota, H.
 see Poulose, K. P.
- Ectors, M., Abramovici, J. and Jonckheer, M. H.** ^{99m}Tc -citrate-diphosphonate and $^{99m}\text{TcO}_4^-$ brain studies, 526*
- Edelstyn, G. A.** see Gillespie, P. J.
- Edwards, R. Q.** see Kuhl, D. E.
- Eernisse, B.** see Marta, J. B.
- Ege, G. N.** Internal mammary lymphoscintigraphy, 526*
- Eikman, E. A.** see Klingensmith, W. C.
- Elam, D.** see Taplin, G. V.
- Eldridge, J. E. and Capurro, P. U.**
- Nomogram for estimating normal liver weights, 314**
- Ellis, K.** see Aloia, J. F.
- Endow, J. S.** see Tubis, M.
- Eng, R., Hinn, G. M. and Spitznagle, L.** ^{18}F -fluoropregnenolone-3-acetate for adrenal scans, 526*
- English, D. K. and Andersen, B. R.** ^{99m}Tc -S colloid labeling of human phagocytes, 5
- English, D. K., Andersen, B. R. and Akalin, H. E.** ^{99m}Tc -S colloid-leukocytes for inflammatory processes, 527*
- Engstrom, M. A.** see Winstead, M. B.
- Enomoto, K.** see Irie, M.
- Epstein, J., Taylor, A., Alazraki, N. P. and Coel, M.** Pulmonary embolus in transient ventilatory defect, 1017
- Erdal, B. R.** see Grant, P. M.
- Ericksson, L.** see Cho, Z. H.
- Etani, N.** see Goriya, K.
- Evans, P. L.** see Kirch, D. L.
- Evens, R. G.** see Mikhael, M. A.
- Fair, W. R.** see Clark, R. B.
- Fairchild, R.**
 see Atkins, H. L.
 see Lebowitz, E.
- Faith, W. C.** see Loberg, M. D.
- Fajans, S. S.** see Balachandran, S.
- Falk, R.** see Jereb, M.
- Farhat, S. M.** see Klein, E. W.
- Farmelant, M. H., DeMeester, G., Wilson, D. and Barrett, H. H.** Clinical experiences with a Fresnel zone plate imager, 183
- Farrar, P. A.** see Saha, G. B.
- Faunce, H.** see Sy, W. M.
- Favus, M.** see Arnold, J. E.
- Feldstein, B.** see Balachandran, S.
- Feller, P. A. and Sodd, V. J.** Dosimetry of ^{123}Cs , ^{43}K , ^{85}Rb and ^{201}Tl , 527*
- Feller, P. A. and Sodd, V. J.** Dosimetry of ^{43}K , ^{85}Rb , ^{123}Cs and ^{201}Tl for heart imaging, 1070
- Fellows, R. A.** see Sorabella, P. A.
- Fernandez, M.** see Holder, L. E.
- Fernandez-Pol, J. A.** New liquid scintillation vial, 963
- Fernandez-Pol, J. A. and Zaninovich, A. A.** Kinetics of diphenylhydantoin in man, 305
- Finney, C. E., Larson, D. D., Braun, E. J. and Lieberman, D.** Pulse mode display for color code scintiphotos, 527*
- Firnau, G.** see Chan, P.
- Fischer, K. C., McKusick, K. A., Pendergrass, H. P. and Potsaid, M. S.** Brain scan specificity, 705
- Fisher, C. H., Scheffel, U., Tsan, M-F., Rhodes, B. A. and Wagner, H. N.** ^{99m}Tc leukocyte tagging by phagocytosis, 527*
- Fisher, D.** see DeLand, F. H.
- Fisher, H. D.** see Barrett, H. H.
- Fisher, R. S.** see Malmud, L. S.
- Fitzer, P. M.** Nuclide angiography in Paget's disease of the skull, 619
- Fitzer, P. M.** Renal imaging in ^{99m}Tc -polyphosphate bone scanning, 602

- Fitzer, P. M.** 99m Tc-S colloid and 99m TcO₄ studies in hepatic veno-occlusive disease, 1130
- Fitzgerald, J. S.** see Kavula, M. P.
- Flesher, A.** see Spolter, L.
- Fletcher, J. W., Herbig, F. K., Daly, J. L., Donati, R. M. and Walter, K. E.** Left ventricular ejection fraction, 527*
- Fletcher, J. W.**
see Daly, J. L.
see Schulz, R. C.
- Fonroget, F.** see Bok, B. D.
- Fordham, E. W.**
see Cox, R. S.
see Rayudu, G. V. S.
- Forrest, K. V.** see Krishnamurthy, G. T.
- Fortman, D. L.** see Sodd, V. J.
- Fouyé, H.** see Bardy, A.
- Fowler, J.** see Ansari, A. N.
- Francis, M. D.**
see Silberstein, E. B.
see Tofe, A. J.
- Franco, J. A., Kovaleski, B., Vannag, K. and Schreyer, M.** Radionuclide venography, 438
- Franco, J. A.**
see Homesley, J.
see Schreyer, M.
- Frankel, R. S.**
see Levenson, S. M.
see Majd, M.
see Richman, S. D.
- Frazin, L.** see Arnold, J. S.
- Freed, B. R.**
see Tilbury, R. S.
see Woodard, H. Q.
- Freedman, G. S.** see Puri, S.
- Freeman, L. M., Patton, D. D., Rosenthal, L., Taplin, G. V. and Smith, E. M.** Radiation dose estimates for 131 I, 123 I, 130 I, 131 I, and 131 I as sodium rose bengal, 1214
- Freeman, L. M.**
see Atkins, H. L.
see Cloutier, R. J.
see Weiss, M. A.
- Friedman, A. M., Sullivan, J. C., Ruby, S. L., Lindebaum, A., Russell, J. J., Zabransky, B. J. and Rayudu, G. V. S.** Chemical binding of 133 Sm in tumors, 528*
- Friesinger, G.** see Price, R.
- Frisbie, J. H., O'Connell, D. J., Tow, D. E., Sasahara, A. A. and Belko, J. S.** Autologous radio-iodinated fibrinogen, 393
- Frisbie, J. H.** see O'Connell, D. J.
- Frohman, L. A.** see Arnold, J. E.
- Fröhling, J. and Coune, A.** Radio-zinc for prostate, 495
- Fröhling, J.** see Verbist, A.
- Fukunaga, M.** see Hamamoto, K.
- Fulmer, L. R.**
see Deutchman, A. H.
see Sfakianakis, G. N.
- Gach, J.** see Rigo, P.
- Galen, T.** see Burdine, J. A.
- Gallagher, B.** see Ansari, A. N.
- Gallagher, J. A.** see Preston, D. F.
- Gallo, A.** see Salvatore, M.
- Gams, R. A. and Glickson, J. D.** Leukemia cell binding of 67 Ga, 528*
- Gams, R. A., Long, W. K., Alford, C. A. and Glickson, J. D.** 67 Ga binding to hamster embryo cells, 231
- Ganatra, R. D.** see Atmaran, S. H.
- Garcia, D. A., Tow, D. E., Kapur, K. K. and Wells, H.** Resorbing bone uptake of 99m Tc-polyphosphate, 528*
- Garnett, E. S.**
see Bowen, B. M.
see Chan, P.
see Coates, G.
see Nahmias, C.
- Garrett, M.** see Khentigan, A.
- Gates, G. F. and Goris, M. L.** Agents for cardiac shunt determination, 528*
- Gates, G. F., Orme, H. W. and Dore, E. K.** Surgical systemic-pulmonic shunt assessment, 528*
- Gelbard, A. S., McDonald, J. M., Reiman, R. E. and Laughlin, J. S.** Species differences in 15 N-amino acid myocardial uptake, 529*
- Genna, S.** Editorial; 3D transaxial reconstruction, 179
- Genna, S. and Pang, S. C.** Noise propagation in 3-D Fourier convolution reconstruction, 529*
- Genna, S.** see Pang, S. C.
- George, E. A., Henry, R. E., Haibach, H., Codd, J. E., Newton, W. T. and Donati, R. M.** Renal allograft function monitoring, 529*
- George, E. A.** see Henry, R. E.
- George, E. S.** see Haibach, H.
- Gerber, F. H., Goodreau, J. J. and Kirchner, P. T.** 99m Tc-EHDP bone scans in breast carcinoma, 529*
- Geslien, G. E.** 67 Ga uptake in liver lesions, 443
- Ghaed, N.** see McCowen, K. D.
- Giargiana, F. A.** see Siegel, M. E.
- Gilday, D. L.**
see Alderson, P. O.
see Ash, J. M.
- Gill, S. P., Beierwaltes, W. H., Ice, R. D. and Mosley, S. T.** Distribution of 125 I-quinoline analog for tumor, 530*
- Gillespie, P. J., Alexander, J. L. and Edelstyn, G. A.** Changes in 85 Sr concentrations, 191
- Gillespie, P. J. and MacRae, K. D.** Accuracy of liver scintiscanning, 1204
- Gillin, M., Thrall, J. and Johnson, M.** Thyroid fluorescent scanning system, 530*
- Gilson, A. J.** see Serafini, A. N.
- Glassman, A.** Book review: *Nuclear Medicine in Vitro*, 801
- Glaubitt, D. M. H., Schlüter, I. H. and Haberland, K. U. R.** 113 In-citrate bone marrow kinetics, 769
- Gleghorn, B.** see Verma, R. C.
- Glenn, H. J., Ruksawin, N., Konikowski, T. and Haynie, T. P.** 99m Tc-leukocyte labeling, 530*
- Glenn, H. J.** see Haynie, T. P.
- Glickson, J. D.** see Gams, R. A.
- Glomski, C. A.** see Dillon, W. G.
- Gloria, I. V.** see Lathrop, K. A.
- Gobin, R.** see Bardy, A.
- Gobuty, A. H., Barth, R. F. and Robinson, R. G.** Distribution of 99m Tc-autologous lymphocytes, 530*
- Goddard, B. A. and Ackery, D. M.** Radiation dosimetry of 133 Xe, 137 Xe and 131 Xe lung studies, 780
- Goldman, A. B. and Braunstein, P.** Uptake of 99m Tc agents on bone ends, 423
- Goldman, A. B.** see Blum, M.
- Gollan, F.** see Johnson, A. E.
- Goodreau, J. J.** see Gerber, F. H.
- Goodwin, D. A.** see Lin, M. S.
- Goodyear, M.**
see Poulose, K. P.
see Watkins, A. E.
- Gooneratne, N. and Conway, J. J.** Radionuclide angiography for pulmonary sequestration, 530*
- Gooneratne, N.** see Conway, J. J.
- Goossens, C. M. I. C.** see Yap, S. H.
- Gordon, D.** see Citrin, D. L.
- Gordon-Smith, E. C.** see Merrick, M. V.
- Goris, M. L.**
see Dunnick, J. K.
see Gates, G. F.
see McDougall, I. R.
- Goriya, Y., Hoshi, M., Etani, E., Kimura, K., Shichiri, M. and Sigeita, Y.** Scintigraphic study of exocrine function of pancreas, 270
- Gottlieb, S., Groch, M., Kallos, N. and Miale, A.** Mobile dual-probe system, 531*
- Gottlieb, S.** see Campeau, R. J.
- Goyal, Q. R.** see Chervu, L. R.
- d. Graaf, C. N.** see Jambroes, G.
- Graham, G. E.** see Winstead, M. B.
- Graham, K. D.** see Bonte, F. J.
- Graham, L. S. and Poe, N. D.** Collimators for myocardial imaging, 531*
- Graham, L. S.**
see Touya, J. J.
see Verma, R. C.
- Graham, S.** see Cho, Z. H.
- Grames, G. M., Reiswing, R., Jansen, C. and Herber, R.** Consecutive-day Schilling tests, 495
- Grant, P. M., Erdal, B. R. and O'Brien, H. A.** 85 Sr- 85 Rb generator, 300
- Green, M. V., Brody, W. R., Pearlman, A. S., Agress, H., Douglas, M. A., Redwood, D. R., Itscoitz, S. B., Bailey, J. J. and Johnston, G. S.** Left ventricular volume change by ECG-gated angiography, 531*
- Green, M. V., Ostrow, H. G., Douglas, M. A., Myers, R. W., Scott, R. N., Bailey, J. J. and Johnston, G. S.** ECG-gated angiography, 95
- Green, M. V.**
see Agress, H.

AUTHOR INDEX

- see Bacharach, S.
 see Atkins, H. L.
 see Bradley-Moore, P. R.
 see Lebowitz, E.
Greenfield, L. D. see Verma, R. C.
Greenfield, R. see Alazraki, N. P.
Greenleaf, J. F. see Seward, J. B.
Gregg, E. C. Analog image processing in omnidirectional scanning, 685
Groch, M. see Gottlieb, S.
Grossman, L. W., Van Tuinen, R. J., Hoops, R. G. and Lewis, J. T. Bar phantom for Anger camera monitoring, 531*
- Guarin, U., Dimitrieva, Z.** and Ashley, S. J. 99m Tc-S colloid scan of splenogonadal fusion, 922
- Gund, A.** see Deisenhammer, E.
Gutkowski, R. F., Horwitz, N. H. and Dworkin, H. J. A calibrated dose dispenser for 133 Xe gas, 1197
- Gutkowski, R. F.** see Dworkin, H. J.
Haber, K. see O'Mara, R. E.
Haberland, K. U. R. see Glaubitt, D. M. H.
Haden, H. T., Stacy, W. K., Wolf, J. S., Texter, J. H. and Thomas, F. T. Diagnosis of urinary fistula, 612
- Hafkenscheid, J. C. M.** see Yap, S. H.
Hafner, T. V. see DeLand, F. H.
Hagan, P. L., Ayres, P. R., Halpern, S. E. and Chauncey, D. M. 99m Tc-thiomalic acid for renal scanning, 531*
- Hagan, P. L., Chauncey, D., Ayres, P. R.** and Halpern, S. E. Tumor uptake of 210 Pb and 75 Se-selenomethionine, 532*
- Hagan, P. L., Halpern, S. E., Chauncey, D. M.** and Alazraki, N. P. 131 I-tetracycline for tumor scanning, 532*
- Hagan, P. L.**
 see Chauncey, D. M.
 see Hurwitz, S. R.
Haibach, H., George, E. S., Hendershot, L. R. and Donati, R. M. Uptake mechanisms of 99m Tc-S and 198m Au colloids, 532*
- Haibach, H.** see George, E. A.
Haider, B. see Oldewurtel, H. A.
Haines, J. E. see Yeung, W-C.
Hales, C. see Chesler, D. A.
Hall, J. N., Tokars, R. P. and O'Mara, R. E. 32 P-diphosphonate for therapy, 532*
- Hall, J. N.**
 see O'Mara, R. E.
 see Tokars, R. P.
 see Van Antwerp, J. D.
Hall, P. see Wellman, H. N.
Hall, R. C. see Van Heertum, R. L.
Halpern, S. E.
 see Alazraki, N. P.
 see Chauncey, D. M.
 see Hagan, P. L.
 see Taylor, A.
Hamamoto, K., Morita, R., Yamamoto, I., Fukunaga, M., Mori, T., Torizuka, K. and Kodama, H. 99m Tc-phosphorous compound bone imaging in breast cancer, 532*
- Hamamoto, K.** see Mori, T.
Hambright, P., McRae, J., Valk, P. E., Beardon, A. J. and Shipley, B. A. Chemistry of Tc-Sn-gluconate and -diphosphonate, 478
- Hamilton, F.** see Rockett, J. F.
Hammer, B. see Deisenhammer, E.
Hammock, M. K. see Bacharach, S.
Hanc, R. P. see Turner, J. W.
Handmaker, H. and O'Mara, R. E. Gallium imaging in pediatrics, 533*
- Handmaker, H., Young, B. W.** and Lowenstein, J. M. Clinical experience with 99m Tc-DMSA, 28
- Hanelin, L. G.** and Mena, I. Hepatic hemodynamics in metastatic lesions, 533*
- Hansell, J. R.** Book review: *Liquid Scintillation Counting*, 1091
- Hansell, J. R.** see Alexander, J. M.
Harbert, J. C., Eckelman, W. C., Reba, R. C. and Schein, P. S. 57 Co-bleomycin for pancreatic carcinoma, 533*
- Harbert, J. C.** see Cooper, J. F.
Harper, P. V.
 see Brunsden, B.
 see Lathrop, K. A.
 see Pearson, D.
Harrison, D. C. see Berndt, T.
Harrison, J. E., Williams, W. C., Watts, J. and McNeill, K. G. Bone calcium index based on body calcium measurements, 116
- Harrison, K.** see Semenoff, D.
Hartman, A. F. see Alderson, P. O.
Hartman, C. see Robinson, R. G.
Harvey, E. B., Loberg, M. D. and Cooper, M. D. 99m Tc-HIDA for hepatobiliary imaging, 533*
- Harvey, E. B.** see Loberg, M. D.
Harvey, W. C., Podoloff, D. A. and Kopp, D. T. 67 Ga-citrate infection searches, 2
- Harvey, W. J.** see Tofe, A. J.
Harwig, J. F., Alderson, P. O., Priemeau, J. L., Boonvisut, S. and Welch, M. J. Electrolytic preparation of 99m Tc-RBC, 533*
- Harwig, J. F., Coleman, R. E., Harwig, S. S. L., Sherman, L. A., Siegel, B. A.** and Welch, M. J. Highly iodinated fibrinogen, 756
- Harwig, J. F., Harwig, S. L., Wells, L. D.** and Welch, M. J. In vitro studies of 99m Tc-proteins, 534*
- Harwig, J. F.**
 see Coleman, R. E.
 see Harwig, S. S. L.
Harwig, S. S. L., Harwig, J. F., Coleman, R. E. and Welch, M. J. Iodination level effect on radio-iodinated fibrinogen, 534*
- Harwig, S. S. L.**
 see Coleman, R. E.
 see Harwig, J. F.
 see Knight, L. C.
Hashimoto, S. see Ishibashi, A.
Hattner, R. S. Posterior fossa scintangiography, 828
- Hattner, R. S.** Toxicity of 99m Tc-Sn-diphosphonate, 444
- Hattner, R. S. and Kaufman, L.** Algorithm for distribution uniformity, 534*
- Hattner, R. S., Miller, S. W.** and Schimmel, D. Significance of renewal asymmetry in bone scans, 161
- Hattner, R. S.**
 see Clark, E. E.
 see Lim, C. B.
 see Price, C. D.
Hauser, W. Consecutive-day Schilling test, 495
- Hayes, R. L.** see Washburn, L. C.
Haynie, T. P., Konikowski, T. and Glenn, H. J. 99m Tc-Sn-citrate tumor uptake, 534*
- Haynie, T. P.**
 see Glenn, H. J.
 see Konikowski, T.
Heading, R. C. see Tothill, P.
Heal, A. see Ashkar, F. S.
Heerwald, P. see Krejcarek, G. E.
Hégésippe, M. see Bardy, A.
Heindel, N. D., Burns, H. D., Risch, V. R., Honda, T., Brady, L. W. and Micalizzi, M. 131 I-streptozotocin distribution, 535*
- Heindel, N. D.**
 see Honda, T.
 see Risch, V. R.
Heidendal, G. A. K., Roos, P., Thijs, L. G. and Weiner, J. D. 67 Ga-citrate imaging of cold thyroid nodules, 793
- Helson, L.** see Tilbury, R. S.
Heminger, L. see Van Heertum, R. L.
Hendee, W. R. see Moore, M. M.
Hendershott, L. R. see Haibach, H.
Henkin, R. E., Yao, J. S. T., Quinn, J. L. and Bergan, J. J. Radionuclide venography, 438
- Henkin, R. E.** see Martonfly, K.
Henning, H. see Schelbert, H.
Henry, C. A. see Bell, E. G.
Henry, J. E.
 see Alazraki, N. P.
 see Taylor, A.
Henry, R. E., George, E. A., Daly, J. L. and Donati, R. M. 99m Tc-S colloid bone marrow scanning, 535*
- Henry, R. E., George, E. A., and Donati, R. M.** Cellularity and 99m Tc-S colloid bone marrow distribution, 535*
- Henry, R. E.** see George, E. A.
Herber, R. see Grames, G. M.
Herbig, F. K.
 see Daly, J. L.
 see Fletcher, J. W.
Hermann, G. A. Imaging quality control program, 957
- Herrin, W. A.**
 see Preston, D. F.
 see Robinson, R. G.
Hessel, S. J. see McNeil, B. J.
Hetzell, K. R. and Ice, R. D. Radiometric sterility assay, 798
- Hetzell, K. R.**
 see Balachandran, S.

- see Basmadjian, G. P.
see Sarkar, S. D.
- Hevesy, G. see Chievitz, O.
- Hill, J. H., Merz, T. and Wagner, H. N. Fe enhancement of ^{67}Ga uptake in a leukocyte culture, 1183
- Hill, R. L. see Secker-Walker, R. H.
- Hillis, S. see Price, R.
- Hilts, S. V. see Van Antwerp, J. D.
- Hine, G. J. and Paras, P. Performance of scintillation cameras, 1206
- Hines, H. H., Peek, N. F., DeNardo, G. L. and Jansholt, A-L. ^{133}Xe production, 143
- Hinn, G. M.
see Eng, R.
see Lewellen, T. K.
- Hirabashi, S., Koga, Y., Kitahara, T., Hishida, T., Kiga, M. and Iino, S. Inconsistent thyroid nodule images with ^{131}I and $^{99m}\text{TcO}_4^-$, 918
- Hirotani, H. see Mori, T.
- Hisada, K. see Iimori, M.
- Hishida, T. see Hirabayashi, S.
- Hnatowich, D. J. ^{67}Ga -radiopharmaceutical preparation and quality control, 764
- Hnatowich, D. J.
see Chesler, D. A.
see Hoop, B.
- Hochner, G. see Kaplan, E.
- Hofeldt, F. D. see McCowen, K. D.
- Hofer, J. see Bofilas, I.
- Hoffer, P. B., Beck, R. N., Stark, V. and Bekerman, C. Scatter fraction in brain and liver imaging, 535*
- Hoffer, P. B.
see Bekerman, C.
see Metz, C. E.
- Hoffman, E. J.
see Coleman, R. E.
see Phelps, M. E.
- Hohne, K. H. see Hupe, W.
- Holden, J. E. see Nickles, R. J.
- Holder, J. see Serafini, A. N.
- Holder, L. E., Ashare, A. B., Smith, W. and Saenger, E. L. Stimulation of gastric secretion of $^{99m}\text{TcO}_4^-$, 535*
- Holder, L. E., Ashare, A. B., Tomnick, T., Colley, D. P., Fernandez, M., Catz, Z. and Saenger, E. L. The Gamut approach to scintigram interpretation, 1121
- Hollander, C. S. see Shenkman, L.
- Hollifield, J. see Patton, J. A.
- Holly, F. E. Quantitating Anger camera resolution and field uniformity, 536*
- Holman, B. L., Cohn, P. F., See, J. R., Idoine, J. and Adams, D. F. ^{133}Xe measurement of regional myocardial blood flow, 536*
- Holman, B. L. and Zweiman, F. G. $^{99m}\text{Tc}(\text{Sn})$ -tetracycline uptake in myocardial infarct, 1144
- Holman, B. L.
see Davis, M. A.
see See, J. R.
see Zweiman, F. G.
- Holmes, R. A. and Isitman, A. T. $^{99m}\text{Tc-DTPA}$ for brain imaging, 536*
- Holmes, R. A. and Luth, C. N. Glycopyrrolate in $^{99m}\text{TcO}_4^-$ brain imaging, 819
- Holmes, R. A., Manoli, R. S. and Isitman, A. T. ^{99m}Tc -phosphates for breast imaging, 536*
- Holmes, R. A.
see Rosenthal, S.
see Silverstein, E. A.
see Zimmer, A. M.
- Homesley, J., Kovaleski, B., Vanags, K., Schreyer, M. and Franco, J. A. Thermography evaluation of cold thyroid nodules, 536*
- Homesley, J. see Schreyer, M.
- Honda, T., Risch, V. R., Burns, H. D., Micallizi, M., Brady, L. W. and Heindel, N. D. Radioiodinated acetazolamide, 537*
- Honda, T.
see Heindel, N. D.
see Lantieri, R. L.
see Risch, V. R.
- Hoop, B. Naming of scans, 964
- Hoop, B., Hnatowich, D. J., Chesler, D. A., McKusick, K. A., Parker, J. A., Subramanyam, R., Brownell, G. L., Ojemann, R. G. and Taveras, J. M. Positron imaging of cerebral function, 537*
- Hoop, B.
see Budinger, T. F.
see Chesler, D. A.
- Hoops, R. G. see Grossman, L. W.
- Hoory, S. see Levy, L. M.
- Hopkins, G. B., Kan, M. and Mende, C. W. ^{67}Ga scanning of abdominal abscesses, 990
- Hopkins, G. B. and Mende, C. W. ^{67}Ga -citrate abscess imaging, 609
- Horgan, J. D. see Sebern, M. J.
- Horn, N. L., Verma, R. C. and Bennett, L. R. Analysis of normal ^{111}In -bleomycin scans, 537*
- Horn, N. L., Verma, R. C. and Bennett, L. R. ^{111}In -bleomycin scanning of malignant melanoma, 537*
- Horwitz, N. H. see Gutkowski, R. F.
- Hoshi, M. see Goriya, Y.
- Hoskins, P. A. see Klein, E. W.
- Hotte, C. E. see Lamson, M. L.
- Hoving, J., Versluis, A. and Woldring, M. G. ^{203}Pb for skeletal imaging, 170
- Howard, B. Y. and Teates, C. D. Bone scanning time, 958
- Howard, B. Y. see Watson, E. E.
- Hsieh, S. C. see Berndt, T.
- Huang, S-C. see Phelps, M. E.
- Hudson, J. S. see Rockett, J. F.
- Hueboller, R. J. see Krishnamurthy, G. T.
- Hughes, F. A. Liver studies in superior vena caval obstruction, 626
- Hughes, F. G. see Levy, L. M.
- Hughes, F. J. see Marta, J. B.
- Hunter, D., Dratz, A. F., Rohrer, R. H. and Coberly, J. C. Errors in ^{131}I radioassay, 952
- Hunter, G. O. see Selby, J. B.
- Hunter, W. W. see Deutchman, A. H.
- Hupe, W., Montz, R., Doehn, M., Otto, H. F., Höhne, K. H. and Pfeiffer, G. Dual brain and kidney studies with $^{99m}\text{Tc-DTPA}$, 538*
- Hupf, H. B. see Serafini, A. N.
- Hurley, P. J. Blood volume measurements, 962
- Hurley, P. J. Red cell and plasma volumes, 46
- Hurwitz, A. see Robinson, R. G.
- Hurwitz, S. R., Alazraki, N. P., Ramsdell, J., Peters, R., Taylor, A. and Tisi, G. Staging protocol for bronchogenic carcinoma, 538*
- Hurwitz, S. R., Hagan, P. L. and Alazraki, N. P. ^{67}Ga distribution and Na₂EDTA therapy, 280
- Hurwitz, S. R. and Quinto, R. R. Diminished uptake of ^{67}Ga -citrate in pseudoarthrosis, 167
- Hušák, V. see Wiedermann, M.
- Ice, R. D., Wieland, D. M., Beierwaltes, W. H., Lawton, R. G. and Redmond, M. J. Dopamine analog concentration in the adrenal medulla, 1147
- Ice, R. D.
see Anderson, B. G.
see Balachandran, S.
see Basmadjian, G. P.
see Beierwaltes, W. H.
see Gill, S. T.
see Hetzel, K. R.
see Kirschner, A. S.
see Lamson, M. L.
see Ryo, U. Y.
see Sarkar, S. D.
see Seabold, J. E.
see Sturman, M. F.
- Idoine, J.
see Holman, B. L.
see Zweiman, F. G.
- Iimori, M., Hisada, K. and Suzuki, Y. ^{99m}Tc -pyrophosphate bone imaging in trauma, 538*
- Iino, S. see Hirabayashi, S.
- Iio, M.
see Matsui, K.
see Murata, H.
- Ikebe, J. and Nawa, O. A. Isocount scanning and multilevel analysis, 938
- Ikeda, S., Duken, H., Tillmans, H. and Bing, R. J. Coincidence and noncoincidence counting, 658
- Imarisio, J. J. Liver scan showing lung uptake, 188
- Imperato, T. see DeNardo, S. J.
- Ingle, J. N.
see Levenson, S. M.
see Richman, S. D.
- Inoue, K. see Irie, M.
- Irie, M., Enomoto, K., Enomoto, H. and Inoue, K. Serum TSH response to TRH in disease, 538*
- Irwin, G. A. L. see Weinraub, J. M.
- Ishibashi, A., Ishii, K., Hashimoto, S. and Masumi, S. Aseptic necrosis of bone after renal transplant, 538*
- Ishii, K. see Ishibashi, A.
- Ishii, Y., Kawamura, J., Mukai, T., Takahashi, M. and Torizuka, K.

AUTHOR INDEX

- Functional imaging of intrarenal blood flow, 899
Ishii, Y. see Torizuka, K.
Isitman, A. T.
 see Holmes, R. A.
 see Zimmer, A. M.
Ito, T. see Kojima, M.
Itoh, H. see Torizuka, K.
Itscoitz, S. B.
 see Agrest, H.
 see Green, M. V.
Iyer, P. S. see Tripathi, U. B.
Jackson, G. L., Jester, W. A. and Prasad, K. N. ^{99m}Tc for ventilation studies, 539*
Jackson, P. see DeNardo, S. J.
Jahns, M. F. see Konikowski, T.
Jambroes, G., v. Rijk, P. P., v. d. Berg, C. J. M., d. Graaf, C. N. and Zimmerman, A. N. E. ^{201}Tl heart scintigraphy, 539*
James, A. E., McComb, J. G., Christensen, J. and Davson, H. Evaluation of CSF drainage pathway size, 539*
James, A. E., Panigel, M., Natrajan, T. K., Siegel, M. E. and Donner, M. Relative blood flow to the placenta, 539*
Jander, H. P. see Russell, C. D.
Jansen, C.
 see Adelstein, S. J.
 see Grames, G. M.
Jansholt, A-L.
 see DeNardo, S. J.
 see Hines, H. H.
 see Meyers, J.
Jellins, J. see Crocker, E. F.
Jennings, R. B. see Martonfly, K.
Jensen, F. T. see Buhl, M.
Jereb, B. see Jereb, M.
Jereb, M., Falk, R., Jereb, B. and Lindhe, C. Radiation dose from ^{75}Se -selenite, 846
Jester, W. A. see Jackson, G. L.
Johannsen, B. Behavior of ^{99m}Tc -diphosphonate on Sephadex and Bio-gel, 1087
Johns, L. see Pearson, D.
Johnson, A. E. and Collan, F. Properties of ^{111}In -phosphate for cisternography and GFR, 164
Johnson, H. see O'Mara, R. E.
Johnson, M.
 see Gillin, M.
 see Thrall, J.
Johnson, P. M. and Muroff, L. R. Encasement of the spleen, 718
Johnson, P. M.
 see Sorabella, P. A.
 see Winter, P. F.
Johnson, R. P. see Rollo, F. D.
Johnston, A. S., Arnold, J. E. and Pinsky, S. Anger camera dead-time, 539*
Johnston, A. S., Baker, S. I., Arnold, J. E., Colombetti, L. G. and Pinsky, S. M. Impurities and dose calibration of ^{123}I , 540*
Johnston, G. S.
 see Agrest, H.
 see Bacharach, S.
 see Green, M. V.
 see Levenson, S. M.
 see Richman, S. D.
Johnston, R. E. and Staab, E. V. $^{109}\text{Yb-DTPA}$ radiation dose to brain in cisternography, 101
Jonasson, O. M. see Pavel, D. G.
Jonckheer, M. H. see Ectors, M.
Jones, A. E.
 see Levenson, S. M.
 see Richman, S. D.
Jones, A. G. and Davis, M. A. Multidentate phosphonates, 540*
Jones, J. D. see Ryo, U. Y.
Jones, S. E. see O'Mara, R. E.
Jost, R. G. see Alderson, P. O.
Kahan, B. D. see Pavel, D. G.
Kahn, P. C. see Dewanjee, M. K.
Kalbhen, D. A. see Sargent, T.
Kallfelz, F. A. see Subramanian, G.
Kallos, N. see Gottlieb, S.
Kalsbeck, J. see Wellman, H. N.
Kan, M. see Hopkins, G. B.
Kanoor, R. see Rayudu, G. V. S.
Kaplan, E., Hochner, G., Barnes, W. E., Arnold, J. S., Shponka, S., Mayron, L. W. and Frazin, L. Dual-channel ^{99m}Tc radiocardiogram, 789
Kaplan, E. see Arnold, J. S.
Kaplan, E. S. see Rockett, J. F.
Kapur, K. K. see Garcia, D. A.
Karliner, J. see Schelbert, H.
Karran, S. J., Leach, K. G., Wisbey, M. L. and Blumgart, L. H. Colloid uptake in rat liver, 377
Karran, S. J. see Leach, K. G.
Kaufman, L.
 see Hattner, R. S.
 see Lim, C. B.
 see Price, D. C.
Kavula, M. P., Rogge, J. D., Anger, R. T., Wellman, H. N. and Fitzgerald, J. S. Preparation of ^{131}I -rose bengal, 540*
Kawada, T. see Waxman, A. D.
Kawamura, J. see Ishii, Y.
Kay, D. B. and Keyes, J. W. Absorption corrections and resolution compensation in Fourier tomography, 540*
Kaye, M., Silverton S. and Rosenthal, L. ^{99m}Tc -pyrophosphate studies, 40
Kaye, M. see Rosenthal, L.
Kehr, M. D. see Krishnamurthy, G. T.
Kempi, V. see Persson, B. R. R.
Kennedy, T. D., Martin, N. L., Robinson, R. G. and Preston, D. F. ^{67}Ga -citrate scan in infected pancreatic pseudocyst, 1132
Kennedy, T. D. see Preston, D. F.
Kennedy, W. P. see Sarkar, S. D.
Kerejakes, J. G.
 see Ashare, A. B.
 see Saenger, E. L.
Kew, M. C. see Levin, J.
Keyes, J. W. and Rogers, W. L. Improvement of digitized image displays, 541*
Keyes, J. W. see Kay, D. B.
Khaliq, A. see Lentle, B. C.
Khentigan, A., Garrett, M., Lum, D. and Winchell, H. S. ^{99m}Tc -compound distribution post Sn(II) administration, 541*
Khentigan, A. see Winstead, M. B.
Khullar, S. see Schelbert, H.
Khurana, M. see Mishkin, F. S.
Kiga, M. see Hirabayashi, S.
Kim, H.-R., D'Antonio, R., Larson, S. M., Thorell, J. I., Buchanan, J., Morgan, R. D. and Wagner, H. N. Vitamin B_{12} binding by toad-fish serum, 541*
Kimura, K. see Goriya, Y.
Kirch, D. L., Steele, P. P., LeFree, M. T. and Evans, P. L. High count rate imaging system, 541*
Kirchner, P. T.
 see Gerber, F. H.
 see Short, D. B.
Kirschner, A. S. and Ice, R. D. Specific activity effect on distribution and dosimetry, 541*
Kirschner, A. S., Ice, R. D. and Beierwaltes, W. H. Radiation dosimetry of ^{131}I -iodocholesterol, 248
Kirschner, A. S. see Lamson, M. L.
Kitahara, T. see Hirabayashi, S.
Kiuru, A. J. see Nickles, R. J.
Klein, E. W., Farhat, S. M., Hoskins, P. A. and Colvin, J. T. Cerebral blood flow study of an extracranial meningioma, 833
Klein, H. see Sham, R.
Klein, M. S. see Coleman, R. E.
Klingensmith, W. C. Retention of ^{99m}Tc -S colloid in the lungs, 249
Klingensmith, W. C., Eikman, E. A., Maumenee, I. and Wagner, H. N. Radiocolloid distribution in mucopolysaccharidosis, 1002
Klingensmith, W. C., Eikman, E. A., Maumenee, I. and Wagner, H. N. RE cell function in mucopolysaccharidosis, 542*
Klinger, L. Bone scans and ^{32}P in thyroid adenocarcinoma, 964
Knight, L. C., Harwig, S. L. and Welch, M. J. Halogen-SHPP labeling of fibrinogen, 542*
Knoll, G. F. see Koral, K. F.
Knowlton, A. H. see Spencer, R. P.
Kobayashi, M. see Murata, H.
Kodama, H. see Hamamoto, K.
Koenigsberg, M. see Weiss, M. A.
Koga, Y. see Hirabayashi, S.
Kojima, M., Maeda, M., Ogawa, H., Nitta, K. and Ito, T. A new adrenal scanning agent, 542*
Kolodny, G. M. see DeLuca, S. A.
Konikowski, T., Haynie, T. P. and Glenn, H. J. ^{111}In -bleomycin and -chloride kinetics in mice, 738
Konikowski, T., Jahns, M. F., Haynie, T. P. and Glenn, H. J. Comparison of brain tumor agents in animals, 200
Konikowski, T.
 see Glenn, H. J.
 see Haynie, T. P.
Kook, C. S. see Digenis, G. A.
Kopp, D. T. see Harvey, W. C.
Koral, K. F., Rogers, W. L. and

- Knoll, G. F.** Digital tomographic imaging, 402
- Kossoff, G.** see Crocker, E. F.
- Kostenbauder, H. B.** see Tilbury, R. S.
- Kovaleski, B.**
see Franco, J. A.
see Homesley, J.
see Schreyer, M.
- Kral, M.** see Wiedermann, M.
- Krassas, G.** see McHardy-Young, S.
- Krause, J. S., Maxfield, W. S.** and Miale, A. Scan transmission by telephone, 542*
- Krause, J. S.** see Maxfield, W. S.
- Krejcarek, C. E., Tucker, K. L., Nora, J. C.** and Heerwald, P. 99m Tc-minimicrosphere kit, 542*
- Krishnamurthy, G. T., Brickman, A. S., Huebutter, R. J., Cullison, R. C.** and Blahd, W. H. 99m Tc-pyrophosphate imaging in pseudo-hypoparathyroidism, 543*
- Krishnamurthy, G. T., Brickman, A. S., Huebutter, R. J., Forrest, K. V., Tubis, M.** and Blahd, W. H. 99m Tc-pyrophosphate imaging in primary hyperparathyroidism, 543*
- Krishnamurthy, G. T., Huebutter, R. J., Walsh, C. F., Taylor, J. R., Kehr, M. D., Tubis, M.** and Blahd, W. H. Kinetics of 99m Tc-pyrophosphate and polyphosphate, 109
- Krishnamurthy, G. T., Tubis, M.** and Blahd, W. H. Bone scanning time, 958
- Krishnamurthy, G. T., Tubis, M.** and Blahd, W. H. 131 I-rose Bengal and 99m Tc-mercaptoisobutyric acid for hepatobilary studies, 686
- Krishnamurthy, G. T., Tubis, M.** and Blahd, W. H. 99m Tc-polyphosphate and 18 F kinetics, 689
- Krishnamurthy, G. T.** see Tubis, M.
- Kriss, J. P.**
see Dunnick, J. K.
see McDougall, I. R.
- Kristensen, K.** and Pedersen, B. Lung retention of 99m Tc-S colloid, 439
- Krizek, H.**
see Lathrop, K. A.
see Pearson, D.
- Krohn, K. A.**
see DeNardo, G. L.
see DeNardo, S. J.
see Meyers, J.
- Kronenwetter, C.** see Sebern, M. J.
- Kruglik, G. D.** see Conway, J. J.
- Kubota, H., Poulose, K. P., Eckelman, W. C.** and Reba, R. C. 99m Tc-pyridoxylidene-glutamate for gallbladder, 543*
- Kubota, H.** see Eckelman, W. C.
- Kuhl, D. E.** and Edwards, R. Q. Mark IV computerized brain tomography, 543*
- Kuhl, D. E.** see Devenney, J. E.
- Kuhn, G. P.** see Conway, J. J.
- Kurman, D.** see Sagar, V. V.
- Kusubov, N.** see Sargent, T.
- Kutsuzawa, T.** see Uemura, K.
- Kyle, R.** see Corcoran, R. C.
- Kyle, R. A.** see Wahner, H. W.
- Lamb, J. F.** see Winstead, M. B.
- Lambrecht, R. M.** see Packer, S.
- Lamson, M. L., Kirschner, A. S., Hotte, C. E., Lipsitz, E. L.** and Ice, R. D. Carrier in 99m TcO $_4^-$ eluate, 639
- Lamson, M. L., Kirschner, A. S., Hotte, C. E., Lipsitz, E. L.** and Ice, R. D. Specific activity of 99m TcO $_4^-$ generator eluate, 543*
- Lanaro, A. E.** see Sarmiento, A. H.
- Lander, H.** see Ronai, P. M.
- Lantieri, R. L., Honda, T.** and Brady, L. W. Radiolabeled tumor antibody, 544*
- Laor, Y. G.** see Chandra, S.
- Lappin, H.** see Shames, D. M.
- Larson, D. D.** see Finney, C. E.
- Larson, S. M., Chen, M., Charache, P.** and Wagner, H. N. Radiometric identification of streptococcus A in throat cultures, 1085
- Larson, S. M.**
see Camargo, E. E.
see Cummings, D. M.
see Kim, H.-R.
see Oster, Z. H.
see Tran, N.
see Yeung, W.-C.
- Lathrop, K. A., Gloria, I. V.** and Harper, P. V. 99m Tc radiation effects on mouse fetus, 544*
- Lathrop, K. A., Gloria, I. V., Harper, P. V.** and Krizek, H. 208 Pb bone distribution manipulation, 544*
- Lathrop, K. A., Harper, P. V., Battovich, G., Krizek, H.** and Rich, M. Placenta studies with radioindium, 544*
- Lathrop, K. A., Harper, P. V., Gloria, I. V.** and Rich, M. Intestinal localization of 201 Tl, 545*
- Lathrop, K. A.** see Atkins, H. L.
- Laughlin, J. S.**
see Bigler, R. E.
see Gelbard, A. S.
see Tilbury, R. S.
- Lavender, J. P.** see Merrick, L. V.
- Lawton, R. G.** see Ice, R. D.
- Leach, K. G., Karan, S. J., Wisbey, M. L.** and Blumgart, L. H. In vivo assessment of liver size in rat, 380
- Leach, K. G.** see Karan, S. J.
- LeBel, E.**
see Ntundulu, T.
see Tran, N.
- Lebowitz, E.** and Atkins, H. L. 99m Tl radiation dose to the liver, 1090
- Lebowitz, E., Greene, M. W., Ansari, A. N., Steigman, J. MacKenzie, D., Smol, R., Richards, P., Atkins, H. L.** and Solomon, N. A. Xenon compounds for medical use, 545*
- Lebowitz, E., Greene, M. W., Fairchild, R., Bradley-Moore, P. R., Atkins, H. L., Ansari, A. N., Richards, P.** and Belgrave, E. 201 Tl for medical use, 151
- Lebowitz, E.**
see Atkins, H. L.
see Bradley-Moore, P. R.
- Lee, A. W.** see Robinson, G. D.
- Leeper, R. D.** see Yeh, S. D. J.
- LeFree, M. T.** see Kirch, D. L.
- Leh, F. K. V.** and Wolf, W. 106m Pt-bleomycin for tumor imaging, 545*
- Lentle, B. C., Castor, W. R., Khalil, A.** and Dierich, H. Contrast lymphangiography effect on 99m Ga-citrate distribution, 374
- Lentle, B. C., Russell, A. S.** and Percy, J. S. Comparison of techniques for sacro-iliac disease, 545*
- Lentle, B. C.** see Scott, J. R.
- Lerebeller, M. J.** see Blanquet, P.
- Levenson, S. M., Ingle, J. N., Richman, S. D., Frankel, R. S., Torrey, D. C., Jones, A. E.** and Johnston, G. S. Liver scanning in metastatic breast carcinoma, 545*
- Levenson, S. M.** see Richman, S. D.
- Levin, J.** and Kew, M. C. 99m Ga-citrate scanning in primary liver cancer, 949
- Levy, L. M., Baker, J. D., Hughes, F. G.** and Marta, J. B. Refocused gamma system images, 546*
- Levy, L. M., Hoory, S., Moskowitz, G. W.** and Martone, R. J. Scintillation camera dead-time loss compensation, 546*
- Levy, L. M.** see Moskowitz, G. W.
- Lewellen, T. K., Chemut, C. H., Nelp, W. B., Palmer, H. E., Murano, R.** and Hinn, G. M. Excretion of 36 Ar following neutron activation, 672
- Lewis, J. T.**
see Grossman, L. W.
see Nishiyama, H.
see Silberstein, E. B.
- Lewis, S.** see Wellman, H.
- Lewis, S. E.** see Stokeley, E. M.
- Lieberman, D.** see Finney, C. E.
- Lillen, D. L.** see O'Mara, R. E.
- Lim, C. B., Chu, D., Perez-Mendez, V., Kaufman, L., Hattner, R. S., Price, D. C.** and Swann, S. J. Multiwire proportional chamber positron camera, 546*
- Lin, M.S. and Goodwin, D. A.** Aerosol studies in pulmonary obstructive disease, 546*
- Lin, T. H.** see Winstead, M. B.
- Lindberg, D.** see Serafini, A. N.
- Lindebaum, A.** see Friedman, A. M.
- Lindhe, C.** see Jereb, M.
- Lipsitz, E. L.** see Lamson, M. L.
- Lischner, M.** see Matin, P.
- Littenberg, R. L.** Anaphalactoid reactions to HSA microspheres, 236
- Loberg, M. D., Callery, P. S., Harvey, E. B., Faith, W. C.** and Cooper, M. D. Iminodiacetic acid chelating group, 546*
- Loberg, M. D.**
see Harvey, E. B.
see Quinlan, J.
- Logic, J. R.** see Dubovsky, E. V.
- Long, J. M.** see Lull, R. J.

AUTHOR INDEX

- Long, W. K.** see Gams, R. A.
Lowenstein, J. M. see Handmaker, H.
Lowenthal, I. S., Tow, D. E. and Chang, Y. C. 99m Tc-polyphosphate uptake by lung carcinoma, 1021
Lull, R. J., Agee, R. N., Long, J. M., Petroff, P. A. and Andrews, J. W. Inhalation injury in burn patients, 547*
- Lum, D.** see Khentigan, A.
Lunia, S., Parthasarathy, K. L., Bakshi, S. P. and Bender, M. A. Evaluation of 99m Tc-S colloid liver scintiscans, 62
Lusted, L. B. see Metz, C. E.
Luth, C. N. see Holmes, R. A.
Lutzker, L. G. and Perez, L. A. Radioactive embolization from upper extremity thrombophlebitis, 241
Macdonald, B. see Budinger, T. F.
MacDonald, C. S. see Metzger, J. M.
MacDonald, J. M. see Tilbury, R. S.
MacDonald, M. S. see Metzger, J. M.
MacDonald, N. S. see Cho, Z. H.
 see Spolter, L.
MacGregor, R. see Ansari, A. N.
MacKenzie, D. see Lebowitz, E.
Mackenzie, R. see Reese, L.
MacRae, K. D. see Gillespie, P. J.
Macumber, H. H. see Stauffer, J. C.
Maeda, M. see Kojima, M.
Magoun, S. see Simmons, G. H.
Mahon, D. F. see Bell, E. G.
Majd, M. and Frankel, R. S. Pediatric bone imaging in benign disease, 547*
Malamud, H. and Sham, R. Fast interchange of low-energy collimators, 1195
Malamud, L. S., Fisher, R. S., Roberts, G. S., Capuzzi, J. and Bloch, B. Imaging for gastricosophageal reflux, 547*
Malmod, L. S. see Charles, N. D.
Manfredi, O. L. and Ramaden, F. Review of 67 Ga-citrate studies, 547*
Manfredi, O. L., Ramaden, F. and Watson, P. Liver subtraction in 67 Ga tumor imaging, 548*
Manoli, R. S. see Holmes, R. A.
 see Rosenthal, S.
Manothaya, C. see Poshyachinda, M.
Marazano, C. see Comar, D.
Marinsky, J. A. see Owunwanne, A.
Markham, J. see Alderson, P. O.
 see Secker-Walker, R. H.
Marta, J. B., Hughes, F. J., Baker, J. D., Eernisse, B. and Sturgeon, B. Refocused scintillation camera images, 548*
Marta, J. B. see Levy, L. M.
Martin, N. L. see Kennedy, T. D.
Martin, T. R. and Shafer, R. B. Posterior flow study in brain imaging, 548*
Martone, R. J. see Levy, L. M.
Martonfly, K., Reimer, K. A., Henkin, R. E., Jennings, R. B., and Quinn, J. L. 99m Tc-pyrophosphate uptake in myocardial infarcts, 548*
Maruyama, Y. Book review: *Tumors of the Nervous System*, 966
Marzilli, L. see Semenoff, D.
Mason, D. T. see Berman, D. S.
Mason, J. Anatomic landmarks on scintiphotos, 962
Mason, M. M. see Sarkar, S. D.
Masumi, S. see Ishibashi, A.
Matin, P., Bittikofer, F. and Lischner, M. Ventilation imaging in cystic fibrosis, 548*
Matolo, N. see Stadnik, R. C.
Matsui, K., Iio, M., Chiba, K., Yamada, H., Abe, M. and Murata, H. Differential diagnosis of cerebral vascular disease and tumor, 549*
Matsui, K. see Murata, H.
Mattar, A. G. and Prezio, J. A. Visualization of pancreatic pseudocyst, 326
Mattar, A. G. see Steinbach, J. J.
Matuosakal, B. see Poshyachinda, M.
Maughan, E. see Tilbury, R. S.
Maumenee, I. see Klingensmith, W. C.
Maxfield, W. S., Miale, A., and Krause, J. S. Telephone transmission of images, 549*
Maxfield, W. S. see Krause, J. S.
May, L. G. see Chaudhuri, Tapan K.
Maynard, C. D. see Cowan, R. J.
Maynard, W. P. and Mishkin, F. S. Cerebral vascular displacement on radionuclide angiograms, 549*
Mayorga-Cortes, A. see Campeau, R. J.
Mayron, L. W. see Kaplan, E.
Maze, M. and Wood, J. 67 Ga-uptake in liver lesions, 442
Maziere, M. see Comar, D.
McAfee, J. G. see Arnold, R. W.
 see Atkins, H. L.
 see Bell, E. G.
 see Blair, R. J.
 see Blau, M.
 see Chiotellis, E.
 see Cloutier, R. J.
 see Subramanian, G.
 see Van Heertum, R. L.
 see Yeates, M. G.
McCartney, W. H. see Metz, C. E.
McClain, W. J. see DeLand, F. H.
McClelland, R. R. Focal porta hepatis defects, 1007
McComb, J. G. see James, A. E.
McCombs, R. K. and Olson, W. H. 18 F bone scan in osteoid osteoma, 465
McCormack, K. R. see Berman, M.
 see Cloutier, R. J.
McCown, K. D., Hofeldt, F. D., Ghaed, N., Adler, R. A. and Verdon, T. Low dose 131 I thyroid ablation, 549*
McDonald, J. M. see Gelbard, A. S.
McDougall, I. R., Dunnick, J. K., Goris, M. L. and Kriss, J. P. Distribution of radiopharmaceutical loaded vesicles, 488
McDougall, I. R. see Dunnick, J. K.
McGinley, E. see Citrin, D. L.
McHardy-Young, S., Krassas, G. and Ramsay, I. Thyroid studies in pernicious anemia, 549*
McIntyre, P. see Tran, N.
McKnight, R. see Alderson, P. O.
McKusick, K. A. see Fischer, K. C.
 see Hoop, B.
McLaughlin, A. F. 99m Tc-bone agent uptake in metastatic calcification of lung, 322
McLaughlin, A. F. see Crocker, E. F.
McLaughlin, J. see Termini, B.
McNeil, B. J., Hessel, S. J., Branch, W. T., Bjork, L. and Adelstein, S. J. Efficacy and cost-effectiveness of lung scanning, 550*
McNeill, K. G. see Harrison, J. E.
McPherson, T. A. see Scott, J. R.
McRae, J. Effects of tin on 99m TcO₄-distribution, 690
McRae, J. see Hambright, P.
Meade, R. C. see Ruetz, P. P.
 see Sebern, M. J.
 see Yeh, E-L.
Means, J. L. see Winstead, M. B.
Melton, R. E. see Nelson, M. F.
Mena, I. see Hanelin, L. G.
 see Roser, S.
Mende, C. W. see Hopkins, G. B.
Mengeot, P. H. see Rigo, P.
Merrick, M. V., Gordon-Smith, E. C., Lavender, J. P. and Szur, L. Comparison of agents for bone marrow scanning, 66
Merick, M. V., Lavender, J. P. and Gordon-Smith, E. Splenic uptake of 111 In, 1206
Merz, T. see Hill, J. H.
Metager, J. M., MacDonald, N. S., MacDonald, C. S. and Takahashi, J. M. 18 O-hemoglobin myocardial oxygen consumption, 550*
Metz, C. E., Hoffer, P. B., McCartney, W. H. and Lusted, L. B. Carcinoembryonic antigen assay in colonic malignancy diagnosis, 550*
Meyer, S. L. see Parkey, R. W.
Meyers, J., Krohn, K., and DeNardo, G. L. Radioiodinated bleomycin preparation and characterization, 835
Meyers, J., Krohn, K. A., Jansholt, A-L. and DeNardo, G. L. Preparation and characterization of 132 I-bleomycin, 550*
Meyers, J. see DeNardo, G. L.
Meyers, M. see Telfer, N.
Miale, A. see Campeau, R. J.
 see Gottlieb, S.
 see Krause, J. S.
 see Maxfield, W. S.
Micalizzi, M. see Heindel, N. D.
 see Honda, T.
 see Risch, V. R.

- Mikhael, M. A. and Evens, R. G.** Migration and embolization of macrophages to the lung, 22
- Mikhael, M. A. and Evens, R. G.** Phagocytic capability of the kidney, 709
- Miller, C.** see Bronzino, J.
see D'Amato, D.
- Miller, D. W.** see Deutchman, A. H.
- Miller, R. E.** see Spencer, R. P.
- Miller, S. W.** see Hattner, R. S.
- Mincey, E., Bonoguro, E., Dorais, S. and Morrison, R.** Radiometric estimation of serum B_{12} , 551*
- Mishkin, F. S., Niden, A. H., Pick, R. A. and Khurana, M.** "Ga lung imaging for pneumonitis/infarct differentiation, 551*
- Mishkin, F. S.** see Maynard, W. P.
see Reese, I. C.
see Stevens, J. S.
see Wong, D. W.
- Mock, B.** see Pearson, D.
- Mohammedzadeh, A., Colombetti, L. G., Ryo, U. Y. and Pinsky, S. M.** Adrenal and pituitary uptake of ^{14}C -ascorbic acid, 551*
- Mohammedzadeh, A.** see Ryo, U. Y.
- Moinuddin, M.** see Rockett, J. F.
- Moniot, A. L.** Liver-spleen scintigram in kala-azar, 1128
- Monroe, L. A.** see Murphy, P. H.
- Montz, R.** see Hupe, W.
- Moore, D. O.** see Selby, J. B.
- Moore, J. G.** see Bonte, F. J.
- Moore, M. M., Bucher, J. E. and Hendee, W. R.** Quality assurance in nuclear medicine, 550*
- Morales, J. O.** see Devenney, J. E.
- Morgan, R. D.** see Kim, H-R.
- Mori, T., Hamamoto, K., Onoyama, Y. and Torizuka, K.** $^{99\text{m}}\text{Tc}$ -bleomycin tumor imaging, 414
- Mori, T., Odori, T., Yamamoto, I., Sakamoto, T., Morita, R., Hamamoto, K., Torizuka, K. and Hirotani, H.** $^{99\text{m}}\text{Tc}$ -bleomycin imaging in soft tissue lesions, 551*
- Mori, T.** see Hamamoto, K.
- Morin, R. L.** see Brookeman, V. A.
- Morita, R.** see Hamamoto, K.
see Mori, T.
- Morris, J. G.** see Crocker, E. F.
- Morrison, R.** see Mincey, E.
- Mortara, R. H.** see Brooks, W. H.
- Moschos, C. B.** see Oldewurtel, H. A.
- Moses, D. C.** see Balachandran, S.
- Moskowitz, G. W., Levy, L. M. and Sacher, F. J.** Automated ^{133}Xe spirometer system, 551*
- Moskowitz, G. W.** see Levy, L. M.
- Mosley, S. T.** see Balachandran, S.
see Gill, S. P.
see Sarkar, S. D.
- Moyer, R. A., Murphy, P. H. and Burdine, J. A.** Large-field-of-view scintillation camera, 552*
- Moyer, R. A.** see Murphy, P. H.
- Muehllehner, G.** Positron camera with extended counting rate capability, 653
- Mukai, T.** see Ishii, Y.
- Mullani, N. A.** see Phelps, M. E.
- Mundia, A.** see Sham, R.
- Murano, R.** see Lewellen, T. K.
- Murata, H., Kobayashi, M., Iio, M., Yamada, H., Chiba, K., Matsui, K. and Abe, M.** Sensitivity of the Limulus test, 552*
- Murata, H.** see Matsui, K.
- Muroff, L. R.** see Johnson, P. M.
- Murphy, M. P.** see Cowan, R. J.
- Murphy, P. H., Burdine, J. A. and Moyer, R. A.** Converging collimators and a large field of view scintillation camera, 1152
- Murphy, P. H., Monroe, L. A. and Burdine, J. A.** High-efficiency lung imaging, 552*
- Murphy, P. H.** see Burdine, J. A.
see Moyer, R. A.
- Mussa, G. C.** $^{99\text{m}}\text{Tc}$ -gluconate tumor imaging, 552*
- Myers, R. W.** see Agresti, H.
see Green, M. V.
- Myers, W. G.** The first man-made radionuclide study in the life sciences, 1106
- Myerson, P. J.** Pseudotumors in acute hepatitis, 799
- Nahmias, C. and Garnett, E. S.** Blood background in $^{99\text{m}}\text{TcO}_4^-$ brain scans, 553*
- Nahmias, C., Webber, C. E., Banna, M. and Garnett, E. S.** Blood background effect on brain scans, 676
- Nahmias, C.** see Coates, G.
- Natarajan, T. K.** see James, A. E.
- Nawa, O. A.** see Ikebe, J.
- Neifeld, J. P.** see Richman, S. D.
- Neitzschman, H. R.** see Belanger, M. A.
- Nelp, W. B.** see Atkins, H. L.
see Lewellen, T. K.
- Nelson, M. F., Melton, R. E. and Van Wazer, J. R.** Sodium trimetaphosphate for bone imaging, 1043
- Nelson, M. F. and Vorhees, L. C.** Purification and quality control of ^{131}I -cholesterol, 69
- Newton, W. T.** see George, E. A.
- Nickles, R. J., Holden, J. E., Kiuru, A. J. and Polcyn, R. E.** Modular standardization of data acquisition, 553*
- Niden, A. H.** see Mishkin, F. S.
- Nieweg, H. O.** see Beekhuis, H.
- Nishiyama, H., Lewis, J. T., Ashare, A. B. and Saenger, E. L.** Interpretation of liver images, 11
- Nishiyama, H., Sodd, V. J., Adolph, R. J., Lewis, J. T. and Saenger, E. L.** Comparison of myocardial imaging agents, 553*
- Nishiyama, R. H.** see Anderson, B. G.
- Nissen, A. W.** see Sy, W. M.
- Nitishin, A.** see Dhekne, R. D.
- Nitta, K.** see Kojima, M.
- Nohara, N. and Tanaka, E.** Analog image processing in omnidirectional scanning, 685
- Nolan, N. G.** Computer assisted ventilation/perfusion in pulmonary embolism, 553*
- Nolan, N. G.** see Berquist, T. H.
see Seward, J. B.
- Nora, J. C.** see Krejcerek, G. E.
- Ntundulu, T., Tran, N. and LeBel, E.** Continuous $^{14}\text{CO}_2$ breath analysis in vitamin B_{12} deficiency, 553*
- Ntundulu, T.** see Tran, N.
- Nusynowitz, M. L. and Benedetto, A. R.** Determination of MTF for the scintillation camera, 1200
- Nusynowitz, M. L. and Benedetto, A. R.** Thyroxine binding globulin capacity, 1076
- Nusynowitz, M. L.** see Pick, R. O.
- Nuttall, F. Q.** see Shafer, R. B.
- O'Brien, H. A.** see Grant, P. M.
- O'Connell, D. J., Stein, M. E., Tow, D. E., Frisbie, J. H., Sasahara, A. A. and Belko, J. S.** Radioiodinated autologous fibrinogen kit, 554*
- O'Connell, D. J.** see Frisbie, J. H.
- Oddie, T. H.** see Berman, M.
- Odori, T.** see Mori, T.
- Ogawa, H.** see Kojima, M.
- Ojemann, R. G.** see Hoop, B.
- O'Keefe, A.** see Zweiman, F. G.
- Oldendorf, W. H.** Photon spectra of ^{125}I and ^{131}I , 246
- Oldewurtel, H. A., Rao, D. V., Moschos, C. B., Haider, B. and Regan, T. J.** ^{113}Er imaging of early myocardial infarct, 554*
- Ollodart, R.** see Quinlan, J.
- Olson, W. H.** see McCombs, R. K.
- O'Mara, R. E., Capps, S. J. and Hall, J. N.** Autoradiography of kidney distribution, 554*
- O'Mara, R. E., Haber, K., Corrigan, J., Johnson, H. and Lilien, D. L.** ^{113}In -bleomycin tumor scanning in pediatrics, 554*
- O'Mara, R. E., Scheeter, J. P., Jones, S. E. and Woolfenden, J. M.** Bone scanning in lymphoma, 555*
- O'Mara, R. E., Witte, M., Witte, C. L., Corrigan, J., Woolfenden, J. M. and Ovitt, T. W.** Liver-splenic perfusion studies, 555*
- O'Mara, R. E.** see Hall, J. N.
see Handmaker, H.
see Tokars, R. P.
see Van Antwerp, J. D.
- Onoyama, Y.** see Mori, T.
- Oppenheim, B. E.** Transaxial reconstruction by iterative techniques, 555*
- Orme, H. W.** see Gates, G. F.
- O'Rourke, J.** see Bronzino, J.
see D'Amato, D.
- O'Rourke, R.** see Schelbert, H.

AUTHOR INDEX

- Oster, Z. H., Larson, S. M., Strauss, H. W. and Wagner, H. N. Analysis of liver scanning, 450
- Ostrom, B. see Shapiro, B.
- Ostrow, H. G. see Green, M. V.
- Otto, H. F. see Hupe, W.
- Ovitt, T. W. see O'Mara, R. E.
- Owunwanne, A., Marinsky, J. A. and Blau, M. Valence state of Sn(II) reduced Tc, 555*
- Pabst, H. W. see Bofilia, I.
- Packer, S., Lambrecht, R. M., Wolf, A. P. and Atkins, H. L. ^{203}Pb -Tris for melanoma, 556*
- Padikal, T. see Ashare, A. B.
- Palmer, H. E. see Lewellen, T. K.
- Palser, R. F. see Billinghurst, M. W.
- Pang, S. C. and Genna, S. Fourier convolution fan-geometry reconstruction, 556*
- Pang, S. C. see Genna, S.
- Panigel, M. see James, A. E.
- Pannecière, C. see Bardy, A.
- Paras, P. see Hine, G. J.
- Parker, J. A. see Hoop, B.
- Parker, R., Wilson, B. and Dance, D. Digital techniques for a zone-plate aperture, 556*
- Parkey, R. W., Bonte, F. J., Stokeley, E. M., Meyer, S. L. and Willerson, J. T. ^{99m}Tc -pyrophosphate myocardial imaging, 556*
- Parkey, R. W.
see Bonte, F. J.
see Stokeley, E. M.
- Parmley, W. see Shames, D. M.
- Parthasarathy, K. L.
see Adler, S.
see Lunia, S.
- Patel, D. see Sy, W. M.
- Patel, S. R. see Balachandran, S.
- Patterson, V. N. see Pavel, D. G.
- Patton, D. D. Posterior fossa brain scans, 556*
- Patton, D. D.
see Atkins, H. L.
see Cloutier, R. J.
see Freeman, L. M.
see Patton, J. A.
- Patton, J. A., Hollifield, J., Patton, D. D. and Brill, A. B. Quantitative fluorescent thyroid scanning, 557*
- Pavel, D. G., Jonasson, O. M., Anderson, O., Patterson, V. N. and Kahan, B. D. Diagnosis of post renal transplant collecting system, 557*
- Pearlman, A. S.
see Agress, H.
see Green, M. V.
- Pearson, D., Harper, P. V., Brown, F., Mock, B., Krizek, H., Johns, L. and Rich, M. Effect of compression on the cerebral blood pool, 557*
- Pearl, R. A. and Driedger, A. A. Obstructed mediastinal return effect on cerebral angiography, 622
- Pedersen, B. see Kristensen, K.
- Peek, N. F.
- see DeNardo, S. J.
see Hines, H. H.
- Pendergrass, H. P. see Fischer, K. C.
- Percy, J. S. see Lentle, B. C.
- Perez, L. A. see Lutzker, L. G.
- Perez-Mendez, V. see Lim, C. B.
- Persson, B. R. R. and Kempf, V. ^{99m}Tc -streptokinase for thrombus imaging, 557*
- Persson, B. R. R. and Kempf, V. ^{99m}Tc -streptokinase labeling and testing, 475
- Peters, R. see Hurwitz, S. R.
- Petrocelli, R. D. and Wetzel, R. A. Detection of a pheochromocytoma, 234
- Petroff, P. A. see Lull, R. J.
- Pfeiffer, G. see Hupe, W.
- Phelps, M. E., Hoffman, E. J., Huang, S-C., and Ter-Pogossian, M. M. Effect of positron range on spatial resolution, 649
- Phelps, M. E., Hoffman, E. J., Mullani, N. A. and Ter-Pogossian, M. M. Transaxial reconstruction tomography, 210
- Phelps, M. E., Ter-Pogossian, M. M. Hoffman, E. J., Mullani, N. A. and Coble, C. S. Computerized transaxial tomograph, 558*
- Phelps, M. E. see Coleman, R. E.
- Philips, C. see Charles, N. D.
- Piccone, J. see Sagar, V. V.
- Pick, R. A. see Mishkin, F. S.
- Pick, R. O., Daniels, D., Waliszewski, J. A. and Nusynowitz, M. L. Comparison of T₁ kits, 558*
- Pierson, R. N. see Price, D. C.
- Pinsky, S. see Thrall, J.
- Pinsky, S. M.
see Arnold, J. E.
see Johnston, A. S.
see Mohammedzadeh, A.
see Ryo, U. Y.
- Pircher, F. J. Book review: *Nuclear Medicine—Brief and to the Point*, 1091
- Pitt, B.
see Rossman, D. J.
see Semenoff, D.
- Pitt, M. J. see Van Antwerp, J. D.
- Pizer, S. M. see Alpert, N. M.
- Platzter, H. see Bofilia, I.
- Podoloff, D. A. see Harvey, W. C.
- Poe, N. D., Robinson, G. D. and Tillisch, J. H. Blood flow effect on myocardial infarct uptake, 558*
- Poe, N. D. see Graham, L. S.
- Pohlmann, G. P. see Yeh, E-L.
- Polcyn, R. E. see Nickles, R. J.
- Polin, S. G. see Ryo, U. Y.
- Pongpatirojana, A. see Bacharach, S.
- Porter, W. see Dworkin, H. J.
- Poshyachinda, M., Maturosakul, B. and Manothaya, C. Liver scanning in pseudocyst, 825
- Potsaid, M. S. see Fischer, K. C.
- Potter, M. see Dworkin, H. J.
- Poulouse, K. P., Watkins, A. E., Reba, R. C., Eckelman, W. C. and Goodyear, M. Cobalt labeled bleomycin, 839
- Poulouse, K. P., Watkins, A. E.,
- Reba, R. C., Eckelman, W. C. and Goodyear, M. Comparison of ^{90}Co -bleomycin and ^{67}Ga -citrate tumor scanning, 558*
- Poulouse, K. P.
see Kubota, H.
see Watkins, A. E.
- Pozderac, R. V. see Skinner, R. W. S.
- Prakash, S. see Sturman, M. F.
- Prasad, K. N. see Jackson, G. L.
- Preston, D. F., Servoss, W. C., Kennedy, T. D., Herrin, W. A., Gallagher, J. A., Wegst, A. V. and Riley, R. C. Sequential smoothing of scintillation camera images, 558*
- Preston, D. F. see Kennedy, T. D.
- Prezio, J. A. see Mattar, A. G.
- Price, D. C. and Hattner, R. S. Comparison of bone and bone marrow imaging, 559*
- Price, D. C., Kaufman, L. and Persson, R. N. Bromide space by fluorescent excitation analysis, 814
- Price, D. C. see Lim, C. B.
- Price, R., Hillis, S., Friesinger, G. and Brill, A. B. Analytical techniques for image superposition, 559*
- Primeau, J. L. see Harwig, J. F.
- Prince, J. R., Dukstein, W. G. and White, W. E. Systems analysis of a computer for radioimmunoassay, 559*
- Pritchard, J. H., Ackerman, M. J., Tubis, M. and Blahd, W. H. ^{111}In -chelates-antibodies, 559*
- Profio, A. E. and Cho, Z. H. Semiconductor camera for small tumor detection, 53
- Puri, S., Belliveau, R. E., Spencer, R. P. and Bachur, N. R. Prostaglandins in mice with neuroblastoma, 83
- Puri, S., Freedman, G. S., Donabedian, R. K., Wolfson, S. and Zaret, B. L. ^{99m}Tc -pyrophosphate uptake and CPK depletion in myocardial infarct, 559*
- Quenelle, D. J. see Silberstein, E. B.
- Quinlan, J., Loberg, M. D., Olloidart, R. and Cooper, M. D. ^{131}I -autologous fibrinogen studies in kidney transplant rejection, 555*
- Quinn, J. L.
see Henkin, R. E.
see Martonfly, K.
- Quinto, R. R. see Hurwitz, S. R.
- Ramachandran, P. C. see Rayudu, G. V. S.
- Ramaden, F. see Manfredi, O. L.
- Ramanna, L.
see Atmaran, S. H.
see Taplin, G. V.
- Ramsay, I. see McHardy-Young, S.
- Ramsdell, J. see Hurwitz, S. R.
- Ramsey, P. see Sagar, V. V.
- Rao, D. V. see Oldewurtel, H. A.
- Rasker, J. J., van de Poll, M. A. C. P., Beekhuis, H., Woltring, M. G. and Nieweg, H. O. ^{90}Co -bleomycin for tumor studies, 1058
- Rauf, C. G. see Ashare, A. B.
- Raventos, A. see Stadnik, R. C.

- Raynaud, C.**
see Comar, D.
see Soussaline, F.
- Rayudu, G. V. S., Kanoor, R., Ramachandran, P. C., Ali, A., Turner, D. A. and Fordham, E. W.** Distribution of labeled serum proteins in tumor bearing mice, 560*
- Rayudu, G. V. S., Kanoor, R., Ramachandran, P. C., Ali, A., Turner, D. A. and Fordham, E. W.** Tumor uptake of ^{67}Ga - and ^{197}Hg -adriamycin, ^{197}Hg -acetate and ^{197}Ga -chloride, 560*
- Rayudu, G. V. S.** see Friedman, A. M.
- Reba, R. C.**
see Eckelman, W. C.
see Harbert, J. C.
see Kubota, H.
see Poulose, K. P.
see Watkins, A. E.
- Redmond, M. J.**
see Balachandran, S.
see Ice, R. D.
- Redwood, D. R.**
see Agrest, H.
see Green, M. V.
- Reed, M. F.** Abstracts of current literature, 501, 502, 503
- Reed, M. F.** see Digenis, G. A.
- Reese, I. C. and Mishkin, F. S.** Cardiac motion images, 368
- Reese, I. C. and Mishkin, F. S.** Recording scans on 4 \times 5 inch film, 560*
- Reese, L. and Mackenzie, R.** Normal range of ^{131}I thyroid uptakes, 560*
- Reeve, J.** see Wooten, R.
- Regan, T. J.** see Oldewurtel, H. A.
- Reilly, B. J.** see Ash, J. M.
- Reiman, R. E.** see Gelbard, A. S.
- Reimer, K. A.** see Martonfly, K.
- Reinke, D. B., Damm, D. W., Dunn, B. and Shafer, R. B.** Data storage and retrieval system, 275
- Reinke, D. B.** see Shook, D. R.
- Reiswing, R.** see Grames, G. M.
- Resnick, D.** see Alazraki, N. P.
- Rhodes, B. A.**
see Chen, M.
see Fisher, C. H.
see Semenoff, D.
- Riccobono, X. J.** see Sfakianakis, G. N.
- Rich, M.**
see Lathrop, K. A.
see Pearson, D.
- Richards, A. G.** Metastatic calcification and bone scanning, 1087
- Richards, P.**
see Ansari, A. N.
see Lebowitz, E.
see Smith, T. D.
- Richman, S. D., Brodey, P. A., Frankel, R. S., de Moss, E. V., Tormey, D. C. and Johnston, G. S.** Breast scintigraphy with $^{99m}\text{TcO}_4^-$ and ^{67}Ga -citrate, 293
- Richman, S. D., Ingle, J. N., Levenson, S. M., Neifeld, J. P., Tor-** mey, D. C., Jones, A. E. and Johnston, G. S. ^{67}Ga studies in breast carcinoma, 996
- Richman, S. D., Ingle, J. N., Levenson, S. M., Tormey, D. C., Jones, A. E. and Johnston, G. S.** ^{67}Ga detection of metastatic breast carcinoma, 560*
- Richman, S. D.** see Levenson, S. M.
- Rigo, P., Gach, J., and Mengoet, P. H.** Myocardial and blood pool scans in left ventricular aneurysm, 1024
- Rigo, P.** see Schelbert, H.
- v. Rijk, P.** see Jambroes, G.
- Riley, R. C.**
see Preston, D. F.
see Wegst, A. V.
- Risch, V. R., Burns, H. D., Honda, T., Micalizzi, M., Brady, L. W. and Heindel, N. D.** ^{99m}Tc -sulfonylurea preparation and animal distribution, 561*
- Risch, V. R.**
see Heindel, N. D.
- Ristroph, D.** see Cummings, D. M.
- Roberts, B. R.** see See, J. R.
- Roberts, G. S.** see Malmud, L. S.
- Roberts, R.** see Coleman, R. E.
- Robertson, J.** see Rockett, J. F.
- Robinson, G. D.** High specific activity ^{18}F -fluoroethanol, 561*
- Robinson, G. D. and Lee, A. W.** ^{123}I -iodoantipyrine kit, 561*
- Robinson, G. D. and Lee, A. W.** Radioiodinated fatty acids for heart imaging, 17
- Robinson, G. D., Uzler, J. M. and Bennett, L. R.** Brain dynamics of lipophilic radiopharmaceuticals, 561*
- Robinson, G. D.** see Poe, N. D.
- Robinson, R. G., Hurwitz, A., Skibba, R., Herrin, W. A. and Hartman, C.** Effects of antacids on gastric emptying, 562*
- Robinson, R. G.**
see Gobuty, A. H.
see Kennedy, T. D.
see Wegst, A. V.
- Rockett, J. F., Hamilton, F., Robertson, J. and Moinuddin, M.** Bifrontal epidural hematoma image, 908
- Rockett, J. F., Kaplan, E. S., Hudson, J. S. and Moinuddin, M.** Intracerebral hemorrhage on $^{99m}\text{TcO}_4^-$ angiogram, 459
- Roco, R. N. and Dworkin, H. J.** ^{123}I thyroid uptakes, 562*
- Rodden, A. F.** see DeGrazia, J. A.
- Rogers, W. L. and Wainstock, M. A.** An ultrasound guided gamma-ray probe, 562*
- Rogers, W. L.**
see Keyes, J. W.
see Koral, K. F.
- Rogge, J. D.** see Kavula, M. P.
- Rohrer, R. H.**
see Berman, M.
see Blau, M.
see Hunter, D.
- Rollo, F. D. and Johnson, R. F.** Imaging properties of ^{85}Rb and ^{41}K , 562*
- Ronai, P. M., Baker, R. J., Bellen, J. C., Collins, P. J., Anderson, P. J. and Lander, H.** ^{99m}Tc -pyridoxylidene-glutamate hepatobiliary studies, 728
- Ronai, P. M.** see Baker, R. J.
- Roos, P.** see Heidendal, G. A. K.
- Rosenberg, R.** see Weinraub, J. M.
- Rosenstreich, M.** see Subramanian, G.
- Rosenthal, S., Ashkar, F. S., Denardo, G. L., Holmes, R. A., Serafini, A. N., Manoli, R. S., DeNardo, S. J. and Caretta, R. F.** Safety of ^{131}I -fibrinogen, 562*
- Rosenthal, L. and Kaye, M.** ^{99m}Tc -pyrophosphate kinetics, 33
- Rosenthal, L.**
see Cloutier, R. J.
see Freeman, L. M.
see Kaye, M.
- Roser, S. and Mena, I.** ^{99m}Tc -diphosphonate bone graft imaging, 563*
- Rose, D. A.** see DeLand, F. H.
- Rossman, D. J., Rouleau, J., Strauss, H. W. and Pitt, B.** ^{99m}Tc -glucoheptonate for myocardial infarct characterization, 980
- Rossman, D. J., Rouleau, J., Strauss, H. W. and Pitt, B.** ^{99m}Tc -glucoheptonate imaging of myocardial infarct, 563*
- Rossman, D. J., Strauss, H. W., Siegel, M. E. and Pitt, B.** ^{99m}Tc -glucoheptonate uptake in myocardial infarct, 875
- Rouleau, J.** see Rossman, D. J.
- Ruby, S. L.** see Friedman, A. M.
- Ruetz, P. P., Meade, R. C., Yeh, E.-L. and Balint, R.** Diagnosis of biliary pancreatic disease, 563*
- Ruetz, P. P.** see Sebern, M. J.
- Ruksawin, N.** see Glenn, H. J.
- Russ, G. A.** see Bigler, R. E.
- Russ, G. R.**
see Tilbury, R. S.
see Woodard, H. Q.
- Russell, A. S.** see Lentle, B. C.
- Russell, C. D., Jander, H. P. and Dubovsky, E. V.** Perfusion imaging of a chemodectoma, 472
- Russell, J. J.** see Friedman, A. M.
- Ryo, U. Y.** Artifact simulation of spleen infarct, 99
- Ryo, U. Y., Arnold, J. E. and Pinsky, S. M.** Thyroid image sensitivity, 563*
- Ryo, U. Y., Colombetti, L. G., Polin, S. G. and Pinsky, S. M.** Radionuclide venography, 563*
- Ryo, U. Y., Ice, R. D., Jones, J. D. and Beierwaltes, W. H.** Distribution of labeled bleomycin in rats, 127
- Ryo, U. Y., Mohammedzadeh, A., Colombetti, L. G., Siddiqui, A. and Pinsky, S. M.** Evaluation of ^{99m}Tc -RBC, 564*
- Ryo, U. Y., Siddiqui, A. and Pinsky, S. M.** Nonvascular cranial tumor on cerebral flow study, 462

AUTHOR INDEX

- Ryo, U. Y.**
 see Arnold, J. E.
 see Balachandran, S.
 see Beierwaltes, W. H.
 see Mohammedzadeh, A.
- Rzeszotarski, W. J.** see Eckelman, W. C.
- Sacher, F. J.** see Moskowitz, G. W.
- Sachura, M.** see Arnold, J. E.
- Sade, R.** see Treves, S.
- Saenger, E. L., Sodd, V. J., Kereiakes, J. G. and Van Tuinen, R. J.** Scintillation camera quality control, 564*
- Saenger, E. L.**
 see Holder, L. E.
 see Nishiyama, H.
 see Smith, W.
- Safi, N.** see Blanquet, P.
- Sagar, V. V., Ramsey, P., Kurman, D. and Piccone, J.** Femoral head changes in cup-arthroplasty, 564*
- Saha, G. B., Schell, E. T. and Farrar, P. A.** Lymphocyte labeling with ⁶⁷Ga, ¹¹¹In, and ^{199m}Hg, 564*
- Saito, H.** see Yamada, H.
- Sakamoto, T.**
 see Mori, T.
 see Torizuka, K.
- Sakimura, I. T., Waxman, A. D. and Siemsen, J. K.** Comparison of ^{99m}Tc-DTPA and ^{99m}TcO₄ brain images, 564*
- Salel, A. F.** see Berman, D. S.
- Salvatore, M. and Gallo, A.** Accessory thyroid in the anterior mediastinum, 1135
- Sansi, P. K.** see Verma, R. C.
- Saparoff, G. R.** see Chaudhuri, Tapan K.
- Sargent, T., Kalbhen, D. A., Shulgin, A. T., Stauffer, H. and Kusubov, N.** ⁷⁵Br-dimethoxyphenylisopropylamine for brain scanning, 243
- Sarkar, S. D., Beierwaltes, W. H., Ice, R. D., Basmadjian, G. P., Hetzel, K. R., Kennedy, W. P. and Mason, M. M.** NP-59 for adrenal studies, 1038
- Sarkar, S. D., Ice, R. D., Beierwaltes, W. H., Basmadjian, G. P., Hetzel, K. R. and Kennedy, W. P.** ¹³¹I-cholesterol analog for adrenal gland, 565*
- Sarkar, S. D., Ice, R. D., Beierwaltes, W. H., Basmadjian, G. P., Kennedy, W. P. and Mosley, S. T.** ⁷⁵Se-selenocholesterol for adrenal imaging, 565*
- Sarmiento, A. H., Alba, J., Lanaro, A. E. and Dietrich, R.** ^{99m}Tc-pyrophosphate soft tissue scan in dermatomyositis, 467
- Sasahara, A. A.**
 see Frisbie, J. H.
 see O'Connell, D. J.
- Searchilli, J.** see Yeates, M. G.
- Schauwecker, D.** see Wellman, H. N.
- Scheeter, J. P.** see O'Mara, R. E.
- Scheffel, U.** see Fisher, C. H.
- Schein, P. S.** see Harbert, J. C.
- Schelbert, H., Henning, H., Chauncey, D. M., Khullar, S., O'Rourke, R. and Ashburn, W.** ²⁰¹Tl distribution and myocardial imaging, 565*
- Schell, E. T.** see Saha, G. B.
- Scherlis, L.** see Termini, B.
- Schimmel, D.** see Hattner, R. S.
- Schlüter, I. H.** see Glaubitt, D. M. H.
- Schneider, A.** see Arnold, J. E.
- Schreyer, M., Kovaleski, B., Vanags, K., Homesley, J. and Franco, J. A.** Thermography for peripheral venous thrombosis, 566*
- Schreyer, M.**
 see Franco, J. A.
 see Homesley, J.
- Schroeder, E. T.** see Blair, R. J.
- Schteingart, D. E.** see Seabold, J. E.
- Schuck, L. D.** see Chandler, W. M.
- Schulz, R. C., Shields, J. B., Fletcher, J. W. and Donati, R. M.** Liver scanning and the intrahepatic gallbladder, 1029
- Scott, J. R., Lentle, B. C. and McPherson, T. A.** ^{99m}Tc-granulocyte preparation and uptake by inflammation, 566*
- Scott, R. N.** see Green, M. V.
- Seabold, J. E., Beierwaltes, W. H., Zaken, J. F., Wieland, D. M. and Ice, R. D.** ³H-aminoglutethimide adrenal localization, 566*
- Seabold, J. E. and Schteingart, D. E.** Adrenal imaging with ¹³¹I-iodocholesterol, 566*
- Sebern, M. J., Horgan, J. D., Meade, R. C., Kronenwetter, C., Ruetz, P. P. and Yeh, E.-L.** Minicomputer enhancement of scintillation camera images, 566*
- Secker-Walker, R. H., Alderson, P. O., Hill, R. L. and Markham, J.** Regional ventilation in chronic obstructive lung disease, 567*
- See, J. R., Cohn, P. F., Holman, B. L., Roberts, B. R. and Adams, D. F.** Regional myocardial blood flow in coronary artery disease, 567*
- See, J. R.** see Holman, B. L.
- Seibert, J. J.** See Conway, J. J.
- Selby, J. B., Hunter, G. O. and Moore, D. O.** The pancreas scan as a functional study, 1090
- Semenoff, D., Marzilli, L., Strauss, H. W., Harrison, K., Rhodes, B. A. and Pitt, B.** ²⁰¹Pb- and ²⁰¹Tl-ionophores, 567*
- Serafini, A. N., Hupf, H. B., Lindberg, D., Smoak, W. M. and Gilson, A. J.** ¹²³I-rose bengal in jaundice, 567*
- Serafini, A. N., Smoak, W. M., Hupf, H. B., Beaver, J. E., Holder, J. and Gilson, A. J.** ¹²³I-rose bengal for hepatobiliary imaging, 629
- Serafini, A. N.** see Rosenthal, S.
- Servoss, W. C.** see Preston, D. F.
- Seward, J. B., Greenleaf, J. F., Nolan, N. G. and Tancredi, R. G.** Myocardial tomography, 568*
- Sfakianakis, G. N., Damoulaki-Sfakianaki, E., Bass, J. C., Earl, W. C. and Riccobono, X. J.** ^{99m}Tc-pyrophosphate scanning in calcinosis universalis of dermatomyositis, 568*
- Sfakianakis, G. N., Fulmer, L. R. and Riccobono, X. J.** Pancreas scanning analysis, 568*
- Shafer, P. B.** see Custer, J. R.
- Shafer, R. B. and Nuttall, F. Q.** Thyroid function following ¹³¹I therapy, 568*
- Shafer, R. B.**
 see Martin, T. R.
 see Reinke, D. B.
- Sham, R., Cortes, E. P., Mundia, A., Klein, H., Azueta, V. and Silver, L.** ^{99m}Tc-diphosphonate chest imaging, 568*
- Sham, R.** see Malamud, H.
- Shambu, M.** see Theodorakis, M. C.
- Shames, D. M., Botvinick, E., Lapin, H., Townsend, R., Tyberg, J. and Parmley, W.** ^{99m}Tc-pyrophosphate imaging and CPK depletion in myocardial infarct, 569*
- Shani, J.** see Wolf, W.
- Shapiro, B., Stein, I., Cantor, R. E. and Ostrom, B.** ^{99m}Tc-EHDP and ¹⁸F scanning in Paget's disease, 569*
- Shapiro, S. H., Castronovo, F. P., Callahan, R. J. and Athanasoulis, C. A.** ^{113m}In detection of gastrointestinal bleeding, 569*
- Share, A. B.** see Smith, W.
- Sharma, S. M.** see Atmaran, S. H.
- Shaw, M. J.** see Beierwaltes, W. H.
- Shenkan, L. and Hollander, C. S.** Effective thyroid ratio in pediatrics, 955
- Sherman, L. A.**
 see Coleman, R. E.
 see Harwig, J. F.
- Shichiri, M.** see Goriya, Y.
- Shields, J. B.** see Schulz, R. C.
- Shigeta, Y.** see Goriya, Y.
- Shih, W.-J.** Imaging in delayed traumatic splenic rupture, 912
- Shih, W.-J.** ^{113m}In perfusion study and thyroid nodule, 1187
- Shipley, B. A.** see Hambright, P.
- Shoop, D. R. and Reinke, D. B.** ^{99m}Tc-S colloid uptake in vertebral compression fractures, 92
- Shoop, J. D.** see Stahly, T. L.
- Short, D. B. and Kirchner, P. T.** Detection of spinal fluid leak, 616
- Shponka, S.** see Kaplan, E.
- Shulgin, A. T.** see Sargent, T.
- Siddiqui, A.** see Ryo, U. Y.
- Siegel, B. A.**
 see Coleman, R. E.
 see Eckelman, W. C.
 see Harwig, J. F.
 see Welch, D. M.
- Siegel, M. E., Giargiana, F. A. and**

- Wagner, H. N.** Arteriovenous shunting in a hypernephroma, 569*
- Siegel, M. E., Walker, W. J. and Campbell, J. J.** 99m Tc-diphosphonate uptake by malignant pleural effusions, 883
- Siegel, M. E., Williams, G. M., Giaragna, F. A. and Wagner, H. N.** Vascular perfusion studies of ischemic ulcers, 993
- Siegel, M. E.** see James, A. E.
see Rossman, D. J.
- Siemsen, J. K.** see Sakimura, I. T.
see Waxman, A. D.
see Wolfenden, J. M.
- Silberstein, E. B., Francis, M. D., Tofe, A. J. and Slough, C. L.** Distribution of 99m Tc-diphosphonate and 99m TcO $_4^-$, 58
- Silberstein, E. B., Lewis, J. T. and Quenelle, D. J.** Physiologic relationship of upper and lower airways, 570*
- Silver, L.** see Sham, R.
- Silverstein, E. A., Zimmer, A. M. and Holmes, R. A.** Quench correction for 3 H radioimmunoassays, 570*
- Silverstein, M. J.** see Verma, R. C.
- Silverton, S.** see Kaye, M.
- Simmons, G. H.** Abstracts of current literature, 500
- Simmons, G. H.** Book review: *Computer Processing of Dynamic Images from an Anger Scintillation Camera*, 498
- Simmons, G. H., DeLand, F. H., Magoun, S. and Beihn, R. M.** Linear total body scanner, 570*
- Simon, G.** see Conway, J. J.
- Simpson, R. G.** see Barrett, H. H.
- Singh, M.** see Cho, Z. H.
- Singla, O.** see Barth, R. F.
- Singleton, R.** see Termini, B.
- Sisson, J. C.** see Balachandran, S.
- Skibba, R.** see Robinson, R. G.
- Skinner, R. W. S., Pozderac, R. V., Counsell, R. E. and Weinhold, P. A.** Steroidal prostate agents, 570*
- Skromme-Kadlubik, G., Diaz, J. F. and Celis, C.** Basal ganglia scans, 787
- Slough, C. L.** see Silberstein, E. B.
- Slovits, T. L.** see Sorabella, P. A.
- Smith, E. M.** see Atkins, H. L.
see Berman, M.
see Blau, M.
see Cloutier, R. J.
see Freeman, L. M.
- Smith, T. D., Steimers, J. R. and Richards, P.** 99m Tc carrier effect on 99m Tc labeled agents, 570*
- Smith, T. D.** see Ansari, A. N.
- Smith, W., Share, A. B. and Saenger, E. L.** Hepatic artery aneurysm, 1027
- Smith, W.** see Holder, L. E.
- Smoak, W. M.** see Serafini, A. N.
- Smol, R.** see Lebowitz, E.
- Snow, R. M. and Weber, D. A.** Time-dependent image quality with 99m Tc-pyrophosphate, 879
- Snow, R. M. and Wilson, G. A.** Scanning of multiple pulmonary arteriovenous fistulas, 328
- Snyder, W. S.** see Blau, M.
- Sobel, B. E.** see Coleman, R. E.
- Sodd, V. J. and Fortman, D. L.** ^{89}Sr contamination in 99m Mo- 99m Tc generators, 571*
- Sodd, V. J.** see Feller, P. A.
see Nishiyama, H.
see Saenger, E. L.
- Soin, J. S., Burdine, J. A. and Beal, W.** Myocardial uptake of 99m Tc-pyrophosphate, 944
- Solomon, N. A.** see Lebowitz, E.
see Steigman, J.
- Sorabella, P. A., Slovis, T. L., Fellows, R. A. and Johnson, P. M.** Gastric fundus simulation of suprarenal mass, 947
- Sorenson, J. A.** Deadtime characteristics of Anger cameras, 284
- Soucek, C. D.** Foramen of Morgagni hernia, 261
- Soucek, C. D.** Sinusitis demonstrated by brain scanning, 89
- Soussaline, F., Todd-Pokropek, A. and Raynaud, C.** Multi-isotope study equipment, 571*
- Spencer, R. P.** Artifact simulation of spleen infarct, 100
- Spencer, R. P.** Compartmental model for hepatoma uptake of 99m TcO $_4^-$, 571*
- Spencer, R. P.** The small spleen, 571*
- Spencer, R. P. and Caride, V. J.** Low dose ^{131}I therapy for hyperthyroidism, 572*
- Spencer, R. P., and Knowlton, A. H.** Splenic response to external radiation, 123
- Spencer, R. P. and Miller, R. E.** Distribution of iodo-folate, 573*
- Spencer, R. P. and Miller, R. E.** Mercury adducts of unsaturated fatty acid esters, 573*
- Spenceer, R. P.** see Puri, S.
see Sziklas, J. J.
see Wittek, J. T.
- Spies, S. M., Swift, T. R. and Brown, M.** Muscle uptake of 99m Tc-polyphosphate in polymyositis, 1125
- Spitznagle, L.** see Eng, R.
- Spolter, L., Chang, C. C., Bobinet, D., Cohen, M. B., MacDonald, N. S., Flesher, A. and Takahashi, J. M.** Chemical and enzymatic synthesis of ^{14}C -acetyl phosphate, 572*
- Staab, E. V.** see Johnston, R. E.
- Stacy, W. K.** see Haden, H. T.
- Stadalmik, R. C., DeNardo, G. L. and Matolo, N.** Quantitative hepatic blood flow, 573*
- Stadalmik, R. C., DeNardo, S. J., DeNardo, G. L. and Raventos, A.** Evaluation of blood flow studies in liver tumor, 595
- Stadalmik, R. C.** see Dublin, A. B.
- Stahly, T. L. and Shoop, J. D.** Plague and the gallium scan, 1031
- Stark, V.** see Hoffer, P. B.
- Stauffer H.** see Sargent, T.
- Stauffer, J. C., Macumber, H. H. and Brown, M. J.** EMI brain scanning, 573*
- Stavchansky, S.** see Tilbury, R. S.
- Stebner, F. C.** Steroid effect on brain scan in cerebral metastases, 320
- Steele, P. P.** see Kirch, D. L.
- Steigman, J., Williams, H. P. and Solomon, N. A.** Protein sulfhydryl group in 99m Tc-HSA preparation, 573*
- Steigman, J.** see Lebowitz, E.
- Steimers, J. R.** see Smith, T. D.
- Stein, I.** see Shapiro, B.
- Stein, M. E.** see O'Connell, D. J.
- Steinbach, J. J. and Mattar, A. G.** Anomalous venous drainage effects on cerebral blood flow study, 573*
- Steinhaeusl, H.** see Deisenhammer, E.
- Stephens, D. H.** see Berquist, T. H.
- Stevens, J. S. and Mishkin, F. S.** Brain studies in seizure, 573*
- Stevens, J. S. and Mishkin, F. S.** Persistent left superior vena cava, 569
- Stevenson, J.** see Eckelman, W. C.
- Stokeley, E. M., Lewis, S. E., Buja, L. M., Parkey, R. W., Bonte, F. J. and Willerson, J. T.** Myocardial size estimation with 99m Tc-pyrophosphate, 573*
- Stokeley, E. M.** see Parkey, R. W.
- Stratman, M. G., and Welch, M. J.** Labeling proteins with ^{14}C , 425
- Strauss, A. W.** see Alderson, P. O.
- Strauss, H. W.** see Oster, Z. H.
see Rossman, D. J.
see Semenoff, D.
- Surgeon, B.** see Marta, J. B.
- Sturman, M. F., Beierwaltes, W. H., Ice, R. D. and Prakash, S.** Adrenal uptake of 3 H-estradiol, 77
- Stutzman, L.** see Adler, S.
- Subramanian, G., McAfee, J. G., Blair, R. J., Kallfelz, F. A. and Thomas, F. D.** 99m Tc-methylene diphosphonate for bone imaging, 744
- Subramanian, G., McAfee, J. G., Blair, R. J., Rosenstreich, M., Coco, M. and Duxbury, C. E.** 99m Tc-Sn-imidodiphosphate for bone scanning, 1137
- Subramanian, G., McAfee, J. G., Rosenstreich, M. and Coco, M.** ^{113m}In -polyfunctional phosphonates for bone imaging, 1080
- Subramanian, G., McAfee, J. G., Rosenstreich, M. and Coco, M.** 99m Tc-imidodiphosphate for bone imaging, 574*
- Subramanian, G.**

AUTHOR INDEX

- see Arnold, R. W.
 see Chiotellis, E.
 see Van Heertum, R. L.
Subramanyam, R. see Hoop, B.
Sullivan, J. C. see Friedman, A. M.
Sullivan, J. P. see Brahmeyer, S. M.
Sun, T. T. see Washburn, L. C.
Sunderland, M. L. Radiochromatographic quality control, 225
Suzuki, T. see Torizuka, K.
Suzuki, Y. see Iimori, M.
Swann, S. J. see Lim, C. B.
Swanson, L. A. see Uzler, J. M.
Swift, T. R. see Spies, S. M.
Sy, W. M. and Nissen, A. W. Radionuclide studies in hemangioendotheliomatosis, 915
Sy, W. M., Patel, D. and Faunce, H. Kidney sign on bone scan, 454
Sy, W. M., Westring, D. W. and Weinberger, G. Cold lesions on bone imaging, 1013
Syed, I. B. see Turner, J. W.
Sziklas, J. J. and Spencer, R. P. Hepatic artery-portal vein fistula, 910
Szur, L. see Merrick, L. V.
Takahashi, J. M.
 see Metzger, J. M.
 see Spalter, L.
Takahashi, M. see Ishii, Y.
Tanacescu, D. see Waxman, A. D.
Tancredi, R. G. see Seward, J. B.
Taplin, G. V., Tashkin, D. P., Anselmi, O. E., Elam, D. and Detels, R. Inhalation imaging in obstructive airways disease, 574*
Taplin, G. V., Tashkin, D. P., Ramanna, L., Detels, R. and Anselmi, O. E. Radioaerosol imaging in obstructive airways disease, 574*
Taplin, G. V. see Freeman, L. M.
Tashkin, D. P. see Taplin, G. V.
Tauxe, W. N. see Dubovsky, E. V.
Taveras, J. M. see Hoop, B.
Taylor, A., Baily, N. A., Halpern, S. A. and Ashburn, W. L. Localization for intracavitary ^{90}Y -phosphate therapy, 318
Taylor, A., Henry, J. E. and Alazraki, N. P. $^{99m}\text{TcO}_4^-$ secretion into isolated loops of rat bowel, 574*
Taylor, A.
 see Alazraki, N. P.
 see Epstein, J.
 see Hurwitz, S. R.
Taylor, J. R. see Krishnamurthy, G. T.
Teates, C. D.
 see Howard, B. Y.
 see Weiner, M. J.
Telfer, N. and Meyers, M. Avascular necrosis, degenerative joint disease differentiation, 574*
Tepper, B. S. see Camargo, E. E.
Teresi, J. D. see DeGrazia, J. A.
Termini, B., Cooper, M. D., Scherlis, L., Singleton, R. and McLaughlin, J. ^{43}K myocardial scan in coronary artery disease, 575*
Ter-Pogossian, M. M.
- see Coleman, R. E.
 see Phelps, M. E.
Texter, J. H. see Haden, H. T.
Theodorakis, M. C., Beihn, R. M., Digenis, G. A., DeLand, F. H., Shambu, M. and Wilson, L. C. ^{99m}Tc -polystyrene-TETA for gastric emptying, 575*
Thijs, L. G. see Heidendaal, G. A. K.
Thomas, F. D.
 see Arnold, R. W.
 see Subramanian, G.
 see Van Heertum, R. L.
Thomas, F. T. see Haden, H. T.
Thomas, R. see Alazraki, N. P.
Thompson, W. L. see DePuey, E. G.
Thorell, J. I. see Kim, H.-R.
Thoreson, E. see Blanquet, P.
Thrall, J., Pinsky, S., Corcoran, R. C. and Johnson, M. Computer records system, 575*
Thrall, J.
 see Corcoran, R. C.
 see Gillin, M.
Tilbury, R. S., Stavchansky, S., Ting, C. T., MacDonald, J. M., Maughan, E., Freed, B. R., Russ, G. R., Nelson, L., Benua, R. S., Kostenbauder, H. B. and Laughlin, J. S. ^{13}C -diphenylhydantoin for tumor, 575*
Tillisch, J. H. see Poe, N. D.
Tilmans, H. see Ikeda, S.
Ting, C. T. see Tilbury, R. S.
Tisi, G. see Hurwitz, S. R.
Todd-Pokropek, A. see Soussaline, A.
Tofe, A. J. and Francis, M. D. Toxicity of ^{99m}Tc -Sn-diphosphonate, 444
Tofe, A. J., Francis, M. D. and Harvey, W. J. ^{99m}Tc -diphosphonate bone scans in metastatic disease, 986
Tofe, A. J. see Silberstein, E. B.
Tokars, R. P., Hall, J. N. and O'Mara, R. E. Computer determination of specific scan boundary, 576*
Tokars, R. P. see Hall, J. N.
Tomsick, T. see Holder, L. E.
Tonaka, E. see Nohara, N.
Torizuka, K., Itoh, H., Ishii, Y., Suzuki, T. and Sakamoto, T. Imaging bronchogenic carcinoma of the hilum, 576*
Torizuka, K.
 see Hamamoto, K.
 see Ishii, Y.
 see Mori, T.
Tormey, D. C.
 see Levenson, S. M.
 see Richman, S. D.
Tothill, P. and Heading, R. C. ^{75}Se -amino acids, 933
Touya, J. J., Graham, L. S. and Bennett, L. R. Kidney phantom for dynamic studies, 576*
Tow, D. E.
 see Frisbie, J. H.
 see Garcia, D. A.
 see Lowenthal, I. S.
 see O'Connell, D. J.
Townsend, R. see Shames, D. M.
Tran, N., Chen, M., McIntyre, P., Larson, S. M. and Wagner, H. N. Lymphocyte carbohydrate metabolism assay, 576*
Tran, N., Ntundulu, T. and LeBel, E. Antirheumatoid drug effect on SH groups in blood, 576*
Tran, N. see Ntundulu, T.
Treves, S., Sade, R., Williams, R. and Castenada, A. Lung function in pulmonary artery band, 577*
Tripathi, U. B. and Iyer, P. S. Computation of specific absorbed fraction, 492
Troy, F. A. see Coates, G.
Tsan, M.-F. see Fisher, C. H.
Tubis, M., Krishnamurthy, G. T. and Endow, J. S. ^{123}I , ^{131}I -chlorpropamide for pancreas studies, 577*
Tubis, M.
 see Krishnamurthy, G. T.
 see Pritchard, J. H.
Tucker, K. L. see Krejcarek, G. E.
Turcotte, R. E. see Bell, E. G.
Turner, D. A.
 see Cox, R. S.
 see Rayudu, G. V. S.
Turner, J. W., Syed, I. B. and Hane, R. P. Retention of ^{99m}Tc -S colloid in the lungs, 249
Turner, T. see Ashkar, F. S.
Tyberg, J. see Shames, D. M.
Uemura, K., Yamaguchi, K., and Kutsuzawa, T. Cerebral blood flow in subarachnoid hemorrhage, 577*
Uren, R. F. see Crocker, E. F.
Uzler, J. M. and Swanson, L. A. Focal nodular hyperplasia of the liver, 831
Uzler, J. M. see Robinson, G. D.
Valk, P. E. see Hambright, P.
Vanags, K.
 see Franco, J. A.
 see Homesley, J.
 see Schreyer, M.
Van Antwerp, J. D., Hall, J. N., O'Mara, R. E. and Hilts, S. V. In vivo interaction of ^{99m}Tc -diphosphonate with Fe-dextran, 577*
Van Antwerp, J. D., O'Mara, R. E., Pitt, M. J. and Walsh, S. ^{99m}Tc -diphosphonate accumulation in amyloid, 238
van de Poll, M. A. C. P. see Rasker, J. J.
Van Dyke, D.
 see Berndt, T.
 see Weber, P. M.
Van Heertum, R. L., Subramanian, G., Thomas, F. D., McAfee, J. G., Hall, R. C., Heminger, L. and Vescio, P. D. ^{99m}Tc -hepatobiliary agents, 577*
Van Tongeren, J. H. M. see Yap, S. H.
Van Tuinen, R. J.
 see Grossman, L. W.
 see Saenger, E. L.
Van Wazer, J. R. see Nelson, M. F.

- Verba, J. W.**
see Alazraki, N. P.
see Schelbert, H.
- Verbist, A., Capon, A. and Frühling, J.** Rapid evaluation of ^{133}Xe regional cerebral blood flow, 264
- Verdon, T.** see McCowen, K. D.
- Verma, R. C., Silverstein, M. J., Graham, L. S. and Bennett, L. R.** Tumor/nontumor ratio concept, 578*
- Verma, R. C., Silverstein, M. J., Greenfield, L. D. and Bennett, L. R.** ^{113}In -bleomycin breast mass scanning, 578*
- Verma, R. C., Silverstein, M. J., Greenfield, L. D. and Bennett, L. R.** ^{113}In -bleomycin breast scanning and mammography, 578*
- Verma, R. C., Webber, M. M., Sansi, P. K. and Gleghorn, B.** In vivo thrombosis model, 578*
- Verma, R. C.** see Horn, N. L.
- Versluis, A.** see Hoving, J.
- Vescio, P. D.**
see Van Heertum, R. L.
see Yeates, M. G.
- Vider, M.** ^{32}P -chromic phosphate synovectomy, 100
- Vieras, F.** Splenic uptake of ^{113}In , 1205
- Vieras, F. and Boyd, C. M.** Kidney image on ^{99m}Tc -phosphate compound bone images, 1109
- Vogel, J. M.** see Dublin, A. B.
- Vorhees, L. C.** see Nelson, M. F.
- Wagner, H. N.**
see Adelstein, S. J.
see Camargo, E. E.
see Chen, M.
see Cummings, D. M.
see Fisher, C. H.
see Hill, J. H.
see Kim, H. R.
see Klingensmith, W. C.
see Larson, S. M.
see Oster, Z. H.
see Siegel, M. E.
see Tran, N.
- Wahner, H. W., Kyle, R. A. and Beabout, J. W.** ^{99m}Tc -diphosphonate myeloma imaging, 579*
- Wainstock, M. A.** see Rogers, W. L.
- Waliszewski, J. A.** see Pick, R. O.
- Walker, A. G.** Effect of ^{99m}Tc -Sn agents on subsequent $^{99m}\text{TcO}_4^-$ brain scan, 579*
- Walker, W. J.** see Siegel, M. E.
- Walsh, C. F.** see Krishnamurthy, G. T.
- Walsh, S.** see Van Antwerp, J. D.
- Walter, K. E.** see Fletcher, J. W.
- Walz, D. R.** see DeGrazia, J. A.
- Wang, Y.** Comparison of methods for breast carcinoma metastases evaluation, 579*
- Wang, Y.** Radionuclide venogram combined with lung imaging, 579*
- Wartofsky, L.** see Burman, K. D.
- Washburn, L. C., Sun, T. T., Wieland, B. W. and Hayes, R. L.** Synthesis and purification of ^{11}C -amino acids, 579*
- Waschnich, R.** see Berndt, T.
- Watkins, A. E., Poulose, K. P., Goodyear, M. and Reba, R. C.** $^{99m}\text{Tc-HSA}$ arthroscintigraphy in popliteal cyst, 581*
- Watkins, A. E.** see Poulose, K. P.
- Watson, E. E. and Coffey, J. L.** ^{201}Tl radiation dose to the liver, 1089
- Watson, E. E., Howard, B. Y. and Cloutier, R. J.** ^{133}Xe radiation dose to lungs, 580*
- Watson, P.** see Manfredi, O. L.
- Watte, J.** see Harrison, J. E.
- Waxman, A. D., Kawada, T., Siemsen, J. K. and Wolf, W.** Comparison of ^{67}Ga -citrate preparations, 580*
- Waxman, A. D. and Siemsen, J. K.** ^{67}Ga -citrate gallbladder scanning, 148
- Waxman, A. D. and Siemsen, J. K.** ^{67}Ga scanning of cranial and intrascanning, 580*
- Waxman, A. D., Tanacescu, D., Siemsen, J. K. and Wolfstein, R. S.** ^{99m}Tc -glucoheptonate brain scanning, 580*
- Waxman, A. D.**
see Sakimura, I. T.
see Woolfenden, J. M.
- Webber, C. E.** see Nahmias, C.
- Webber, M. M.** see Verma, R. C.
- Weber, D. A.** see Snow, R. M.
- Weber, P. M., Van Dyke, D., dos Remedios, L. V. and Anger, H. O.** Tomographic scanning in myocardial infarct, 581*
- Wegst, A. V., Robinson, R. G. and Riley, R. C.** Transplacental transfer of ^{67}Ga , 581*
- Wegst, A. V.** see Preston, D. F.
- Weinberger, G.** see Sy, W. M.
- Weiner, M. J. and Teates, C. D.** Brain scanning in metastatic disease, 960
- Weinhold, P. A.** see Skinner, R. W. S.
- Weinraub, J. M., Buzzi, K. W. and Irwin, G. A. L.** Voltage fluctuation in camera image degradation, 581*
- Weinraub, J. M., Rosenberg, R. and Irwin, G. A. L.** ^{99m}Tc -polyphosphate in breast mass diagnosis, 581*
- Weiss, M. A., Koenigsberg, M. and Freeman, L. M.** Pulmonary arteriovenous malformation, 180
- Welch, D. M., Coleman, R. E. and Siegel, B. A.** Cisternographic imaging patterns, 267
- Welch, M. J.**
see Coleman, R. E.
see Harwig, J. F.
see Harwig, S. L.
see Knight, L. C.
see Straatman, M. G.
- Wellman, H. N., Hall, P., Kalsbeck, J. and Lewis, S.** $^{99m}\text{Tc-HSA}$ studies in hydroxyrimmelia, 581*
- Wellman, H. N. and Schauwecker, D.** $^{99m}\text{Tc-DMSA}$ myocardial infarct imaging, 582*
- Wellman, H. N.**
see Berman, M.
see Kavula, M. P.
- Wells, H.** see Garcia, D. A.
- Wells, L. D.** see Harwig, J. F.
- Westring, D. W.** see Sy, W. M.
- Wetzel, R. A.** see Petrocelli, R. D.
- White, W.** see Bell, E. G.
- White, W. E.** see Prince, J. R.
- Widner, P. J.** see Winstead, M. B.
- Wiedermann, M., Hušák, V. and Král, M.** Radiation synovectomy with ^{32}P -chromic phosphate, 442
- Wieland, B. W.** see Washburn, L.C.
- Wieland, D. M.**
see Ice, R. D.
see Seabold, J. E.
- Wiener, J. D.** see Heidendal, G. A. K.
- Wieseler, D. L. and Zimmerman, A. S.** Scintillation camera whole-body scanning system, 582*
- Wilkie, A.** see Alderson, P. O.
- Willerson, J. T.**
see Parkey, R. W.
see Stokeley, E. M.
- Williams, G. M.** see Siegel, M. E.
- Williams, H. P.** see Steigman, J.
- Williams, R.** see Treves, S.
- Williams, W. C.** see Harrison, J. E.
- Wilson, B.** see Parker, R.
- Wilson, D.** see Farmelant, M. H.
- Wilson, G. A.** see Snow, R. M.
- Wilson, L. C.** see Theodorakis, M. C.
- Winchell, H. S.** ^{99m}Tc -mercaptoisobutyric acid for hepatobiliary studies, 687
- Winchell, H. S.**
see Khentigan, A.
see Winstead, M. B.
- Winstead, M. B., Widner, P. J., Means, J. L., Engstrom, M. A., Graham, G. E., Khentigan, A., Lin, T. H., Lamb, J. F. and Winchell, H. S.** ^{13}C -aminonitriles, 582*
- Winstead, M. B., Widner, P. J., Means, J. L., Engstrom, M. A., Graham, G. E., Khentigan, A., Lin, T. H., Lamb, J. F. and Winchell, H. S.** Distribution patterns of ^{13}C -aminonitriles, 1049
- Winston, M. A.** ^{32}P -chromic phosphate synovectomy, 442
- Winston, M. A.** Pseudotumors in acute hepatitis, 799
- Winter, P. F. and Johnson, P. M.** Kidney uptake of ^{99m}Tc -diphosphonate in Paget's disease, 582*
- Wisbey, M. L.**
see Karan, S. J.
see Leach, K. G.
- Wise, G. R.** see Deutchman, A. H.
- Witek, J. T. and Spencer, R. P.** Clinical correlation of hepatic flow studies, 71
- Witte, M.** see O'Mara, R. E.
- Woldring, M. G.**
see Beekhuis, H.
see Hoving, J.
- Wolf, A. P.**
see Ansari, A. N.
see Packer, S.
- Wolf, J. S.** see Haden, H. T.
- Wolf, W., Berman, J. A. and Shani,**

SUBJECT INDEX

- J. Kinetics of ^{113}C -fluorouracil, 582*
- Wolf, W.**
see Leh, F. K. V.
see Waxman, A. D.
- Wolff, J. R.** see Bell, E. G.
- Wolfson, S.** see Puri, S.
- Wolfstein, R. S.**
see Waxman, A. D.
see Woolfenden, J. M.
- Wong, D. W.** and Mishkin, F. S.
 ^{99m}Tc -human fibrinogen, 343
- Wood, J.** see Maze, M.
- Woodard, H. Q.**, Bigler, R. E., Freed, B. R. and Russ, G. R. Expression of tissue isotope distribution, 958
- Woolfenden, J. M.**, Waxman, A. D., Wolfstein, R. S. and Siemsen, J. K. Imaging liver metastases of thyroid carcinoma, 669
- Woolfenden, J. M.** see O'Mara, R. E.
- Wooten, R.** and Reeve, J. ^{99m}Tc -polyphosphate and ^{18}F kinetics, 688
- Wright, F. D.** see Burman, K. D.
- Yamada, H.** and Saito, H. Radioassay of total iron-binding capacity of serum, 583*
- Yamada, H.**
see Matsui, K.
see Murata, H.
- Yamaguchi, K.** see Uemura, K.
- Yamamoto, I.**
see Hamamoto, K.
see Mori, T.
- Yano, Y.**
see Budinger, T. F.
see Cho, Z. H.
- Yao, J. S. T.** see Henkin, R. E.
- Yap, S. H.**, Hafkenscheid, J. C. M., Goossens, C. M. I. C., Buys, W. C. A. M., Binkhorst, R. A. and Van Tongeren, J. H. M. Radiation dose and effects from ^{113}C -albumin synthesis studies, 642
- Yeates, M. G.**, Scarchilli, J., Vescio, P. D., Blair, R. J. and McAfee, J. G. Leukocyte labeling for abscess detection, 583*
- Yeh, E.-L.**, Pohlmann, G. P. and Meade, R. C. Liver-heart imaging in hepatic focal defect, 896
- Yeh, E.-L.**
see Ruetz, P. P.
see Sebern, M. J.
- Yeh, S. D. J.**, Leeper, R. D., and Benua, R. S. Liver and spleen filling defects in cancer, 583*
- Yeung, W.-C.**, Larson, S. M. and Haines, J. E. Zero extrapolation in plasma volume determination, 1207
- Young, B. W.** see Handmaker, H.
- Zabransky, B. J.** see Friedman, A. M.
- Zakem, J. F.** see Seabold, J. E.
- Zaklad, H.**, Derenz, S. E. and Budinger, T. High resolution optimal collimators, 583*
- Zaklad, H.** see Derenz, S. E.
- Zaninovich, A. A.** see Fernandez-Pol, J. A.
- Zanzi, I.** see Aloia, J. F.
- Zaret, B. L.** see Puri, S.
- Zimmer, A. M.** and Holmes, R. A. ^{99m}Tc -diphosphonate kit evaluation, 584*
- Zimmer, A. M.**, Isitman, A. T. and Holmes, P. A. Enzymatic inhibition of diphosphonate uptake, 352
- Zimmer, A. M.** see Silverstein, E. A.
- Zimmerman, A. N. E.** see Jambroes, G.
- Zimmerman, A. S.** see Wieseler, D. L.
- Zu'bi, S. M.** see Brahmeyer, S. M.
- Zwas, S. T.** and Czerniak, P. Head and brain scans in rhinocerebral mucormycosis, 925
- Zweiman, F. G.**, Holman, B. L., O'Keefe, A. and Idoine, J. Myocardial infarct uptake of ^{99m}Tc -complexes and ^{67}Ga , 975
- Zweiman, F. G.** see Holman, B. L.

1975 SUBJECT INDEX

Asterisk indicates abstract

Abdomen

- see also specific organ
liver image subtraction in ^{67}Ga -citrate scanning, 548*
trauma, liver-spleen imaging, in children, 525*

Abscess

- abdominal, ^{67}Ga -citrate imaging, 990
brain, ^{67}Ga -citrate scanning, 580*
 ^{67}Ga -citrate scanning, 2
 ^{67}Ga -citrate uptake, effect of EDTA, in rats, 280
imaging, ^{67}Ga - ^{113}In -leukocytes, in rabbits, 583*
liver, ^{67}Ga -citrate, colloid imaging, 250
subphrenic, ^{67}Ga -citrate imaging, 609
subphrenic, lung-spleen interface, 822
 ^{99m}Tc -microsphere-leukocyte uptake, in animals, 527*
 ^{99m}Tc -S-colloid-leukocyte uptake, in dogs, 527*

Adrenal glands

- aminoglutethimide distribution, in rats, 566*
 ^{14}C -ascorbic acid uptake, in dogs, 551*
 ^{14}C -dopamine analogs, distribution, in rats, 1147
carcinoma, ^{131}I -iodocholesterol imaging, distribution, 566*
 ^{3}H -estradiol uptake, in dogs, 77
 ^{18}F -pregnenolone acetate uptake, in rats, 526*
 ^{125}I - ^{131}I -iodomethylnorcholesterol, preparation, distribution, in animals, 542*, 565*, 666, 1038
 ^{131}I -cholesterol analog preparation, 514*
 ^{131}I -iodocholesterol therapy doses in hyperplasia, in dogs, 928
pheochromocytoma, ^{99m}Tc -DTPA kidney angiogram, 234
 ^{75}Se -selenocholesterol uptake, in animals, 565*

Adverse reaction

- anaphylactoid, ^{99m}Tc -microspheres, 236
aseptic meningitis, cisternography agents, 809
 ^{75}Co -bleomycin, 1058

Aerosol

- lung ventilation in obstructive airways disease, 574*
 Tc , In-colloids, inhalation imaging in obstructive disease, 546*

Albumin

- see also Carbon-11; Iodine-125; Iodine-131, albumin; Technetium-99m, albumin; Technetium-99m, macro-aggregated albumin
synthesis studies, ^{14}C , radiation dose, 642

Alpha-fetoprotein

- immunodiffusion, primary liver cancer, 949
levels in cystic fibrosis, 968*
lung cancer metastatic to liver, 1094*

American Board of Nuclear Medicine

Americium-241

- anatomic landmark, 962
source, fluorescent scanner, 530*
source, photon absorptiometry, 891

Amino acids

- ^{14}C , preparation, purification, 579*
 ^{15}N , myocardial uptake, species differences, 529*
 ^{75}Se , for pancreas imaging, 933
 ^{99m}Tc -pyridoxyl-, preparation, hepatobiliary imaging, in animals, 520*
 ^{99m}Tc -pyridoxylidene-glutamate, gallbladder imaging, 728

- ^{99m}Tc-pyridoxylidene glutamate, preparation, gallbladder studies, in animals, 720
^{99m}Tc-vesicles, survival, in mice, 483
- Anger camera** see *Camera, scintillation*
- Animals**
see also Models
 species differences, myocardial uptake, 529*
- Antibiotics**
see also Technetium-99m, tetracycline
 adriamycin, ¹⁹Hg-, ⁶⁷Ga, tumor uptake in mice, 560*
 assays of gentamicin, 968*
³H-tetracycline, myocardial infarct uptake mechanism, 525*
¹³¹I-streptozotocin analogs, tumor uptake, in hamsters, 535*
¹³¹I-tetracycline for tumor, preparation, 519*; tumor uptake, in animals, 520*, 532*
^{99m}Tc-penicillamine, kidney uptake, in rats, 531*
^{99m}Tc-penicillamine, myocardial infarct uptake, in rats, 523*
- Antibodies** see *Immunology; Radioimmunoassay*
- Antigens** see *Immunology; Radioimmunoassay*
- Argon-37**
 whole-body Ca by neutron activation analysis, 672
- Arthritis**
^{99m}Tc-polyphosphate bone scan, 510*
- Artifact**
 anatomic, spleen image, 99, 100
 collimator hole pattern elimination, 517*
- Aseptic meningitis** see *Adverse reactions*
- Autoradiography**
 kidney agent distribution, in rabbits, 554*
 liver, ¹⁹⁸Au, ^{99m}Tc-S colloid, in rat, 532*
 mammalian cell, ^{99m}Tc-tetracycline, 315
¹²⁵Sr in mouse tumor, 528*
^{99m}Tc-microsphere-leukocytes, 527*
- Bacteria**
see also Infection
¹⁴C-substrate metabolism, continuous measurement, 517*
M. lepraeumurium metabolism, radiometric detection, 518*
M. tuberculosis metabolism, radiometric detection, 518*, 1189
³⁵S-cyclamate metabolism, in rats, 970*
streptococcus Group A, radiometric identification, 1085
- Basal ganglia**
 imaging, ⁶⁷Cu-complex, 787
- Bile** see *Gallbladder*
- Bismuth-204, citrate**
 radiation dosimetry, nuclear parameters, 515*
- Bismuth-206, citrate**
 radiation dosimetry, nuclear parameters, 515*
- Bleomycin**
see also Cobalt-57; Indium-111, bleomycin; Iodine-123; Iodine-131; Platinum-195m; Technetium-99m
⁶⁴Cu-, ³H-, ^{99m}Tc-, tumor uptake, in rats, 127
 properties of fractions, 526*
 radioiodinated, preparation, characterization, 835
- Blocking dose**
 glycycryptrolate, ^{99m}TcO₄⁻ brain imaging, 819
 meralluride, ¹⁹Hg-, ²⁰³Hg-chlormerodrin, radiation dosimetry, 1095
- Blood**
see also Leukocytes; Lymphocytes; Red blood cells; Technetium-99m, red blood cells
 clot, see *Thrombus*
 leukemic cell binding of ⁶⁷Ga, 528*
 plasma volume, ¹³¹I-HSA, 1207
 red cell and plasma volumes, normal, 46, 961, 962
 serum binding capacity, Fe, 583*
 SH group, effect of antirheumatoid drugs, 576*
- Blood flow** see *specific organ; Vascular system*
- Blood pool**
see also specific organ
- ^{Sn(II)} content effects, in animals, 541*
^{99m}Tc-iminodiacetic acid complexes, 546*
¹³³Xe-compounds, 545*
- Blood vessels** see *specific organ; Vascular system*
- Bone**
 blood flow, 520*; compartmental model, 519*
 blood supply, effect on uptake, in rats, 40
 Ca content, neutron activation analysis, 116, 196, 672
 ends, ^{99m}Tc-polyphosphate, -diphosphonate uptake, osteosarcoma, 423
 effect of ^{99m}Tc on ^{99m}Tc-diphosphonate distribution, in rats, 478
 grafts, ^{99m}Tc-diphosphonate imaging, in dogs, 563*
^{113m}In-polyfunctional phosphonates, preparation, distribution, in rabbits, 1080
 kinetics of ^{99m}Tc-pyrophosphate, -polyphosphate, 109, 958
 lymphoma, ⁶⁷Ga-citrate scanning, 255
 mineral content, photon absorption, 196, 891
 osteomyelitis, cranium, ⁶⁷Ga-citrate scan, 580*
 Paget's disease of skull, on brain image, ^{99m}TcO₄⁻, 619
²⁰³Pb-chloride imaging, distribution, in rats, 171
²⁰³Pb-compounds, distribution, in mice, 544*
 radiation dosimetry, 502*
 radiation therapy effect on ^{99m}Tc-polyphosphate uptake, 501*
 resorbing, ^{99m}Tc-polyphosphate uptake, in rats, 528*
 rickets, uptake kinetics, in rats, 40
^{99m}Tc-agents, current literature, 502*
^{99m}Tc-Cu-HEDSPA, preparation, distribution, in animals, 520*
^{99m}Tc-diphosphonate uptake mechanism, enzymatic, 352
^{99m}Tc-imidodiphosphate, preparation, distribution, in animals, 574*
^{99m}Tc-multidentate phosphates, distribution, in animals, 540*
^{99m}Tc-trimetaphosphate distribution, in animals, 1043
 therapy, ³²P-diphosphonate distribution, in rats, 532*
 tomography, camera, coded aperture, in rat, 402
 tumor, parathormone and ³²P therapy, 519*
 uptake mechanisms, in rats, 40
 uptake parameters, 520*
- Bone imaging**
 comparison of agents, 744, 803*
¹⁸F, avascular necrosis, 969*
¹⁸F, osteoid osteoma of the carpal scaphoid bone, 969*
 femoral metaphyseal irregularities, in children, 521*
 Fresnel zone-plate, ^{99m}Tc-polyphosphate, 183
 hip disorders, in children, 512*
 jaw lesions, ^{99m}Tc-polyphosphate, -diphosphonate, 511*
 kidney abnormalities, 1092*
 kidney failure, muscle uptake of agent, 515*
 kidney sign, ^{99m}Tc-polyphosphate, 602
 kidney studies on ^{99m}Tc-phosphate images, 1109
 kidney transplant effects, ^{99m}Tc-diphosphonate, 538*
 large-field-of-view scintillation camera, 1158
 parathyroid disease, ^{99m}Tc-pyrophosphate, hyper-, 33, 543*; pseudohyper-, 543*
 refocused images, 546*, 548*
 rhinocerebral mucormycosis, ^{99m}Tc-diphosphonate, 925
 sacro-iliac disease, ^{99m}Tc-pyrophosphate, 545*
^{99m}Sr, metastases response to chemotherapy, 191
^{99m}Tc-diphosphonate kinetics, 886
^{99m}Tc-imidodiphosphate, 1137
^{99m}Tc-pyrophosphate kinetics, metabolic disease, 33
 tumors, current literature, 502*
 tumor, metastatic, ^{99m}Tc-diphosphonate, 986
- Bone scanning**
 cold lesions, ^{99m}Tc-polyphosphate, 1013
 compared to bone marrow scanning, in malignancy, 559*
 dermatomyositis, soft-tissue uptake, 467
 femoral head, avascular necrosis, degenerative joint disease differentiation, 574*
 hip displacement, ¹⁸F, ^{99m}Tc-diphosphonate, 522*

SUBJECT INDEX

- in breast cancer, ^{99m}Tc -phosphorous compounds, 529*
532*
- in cup-arthroplasty, ^{99m}Tc -polyphosphate, 564*
- in lymphoma, ^{99m}Tc -phosphate compounds, 555*
- in melanoma and prostate cancer, ^{99m}Tc -diphosphonate, 579*
- in Paget's disease, ^{99m}Tc -diphosphonate, ^{18}F , 569*
- interpretation, Gamut approach, 1121
- kidney activity, Paget's disease, ^{99m}Tc -diphosphonate, 582*
- kidney asymmetry, ^{18}F , ^{99m}Tc -pyrophosphate, 161
- kidney sign, ^{99m}Tc -polyphosphate, 454
- lung carcinoma staging, 538*
- muscle uptake of ^{99m}Tc -polyphosphate in polymyositis, 1125
- osteogenic sarcoma, 1211*
- osteoid osteoma, ^{18}F , 465
- osteomyelitis, cellulitis, bone infarct differentiation, in children, 547*
- principles, techniques, interpretations, 969*
- serous fluid content, ^{97}Sr , ^{99m}Tc -polyphosphate, 1208
- solitary lesion, ^{99m}Tc -polyphosphate, -diphosphonate, 522*
- time of study, optimal, ^{99m}Tc -pyrophosphate, 879
- trauma, ^{99m}Tc -pyrophosphate, 538*
- tumor, metastatic, ^{99m}Tc -polyphosphate, -pyrophosphate, 1211*
- Bone marrow**
- biopsy, Hodgkin's disease, 852*
- function in mucopolysaccharidoses, 541*
- imaging, ^{113}In -citrate, 769
- imaging, vertebral compression fracture, ^{99m}Tc -S colloid, 92
- red, radiation dosimetry, ^{198}Au , MIRD, 173
- red, radiation dosimetry, ^{197}Hg -, ^{203}Hg -chlormerodrin, MIRD, 1095
- red, radiation dosimetry, radioiodides, MIRD, 857
- red, radiation dosimetry, ^{99m}Tc -S colloid, MIRD, 108A
- scanning, comparison of ^{113}In -chloride, ^{99m}Tc and ^{99m}Tc -S colloid, 66
- scanning, effect of cellularity, ^{99m}Tc -S colloid, 535*
- scanning, nonhematologic disease, ^{99m}Tc -S colloid, 535*
- scanning, ^{99m}Tc -S colloid, compared to bone scanning in malignancy, 559*
- Book Reviews**
- Atlas of Cerebral Angiography*, 801
- Cardiovascular Nuclear Medicine*, 966
- Computer Processing of Dynamic Images from an Anger Scintillation Camera*, 498
- Liquid Scintillation Counting*, 1091
- New Techniques in Tumor Localization and Radioimmunoassay*, 498
- Nuclear Medicine*, 966
- Nuclear Medicine—Brief and to the Point*, 1091
- Nuclear Medicine in Vitro*, 801
- PDR for Radiology and Nuclear Medicine*, 499
- Tumors of the Nervous System*, 966
- Brain**
- blood flow, *see following listing* Brain, blood flow
- blood volume, ^{11}CO tomography, 521*
- blood volume, 3D reconstruction technique, 1092*
- Book Review, *Atlas of Cerebral Angiography*, 801
- ^{75}Br - and ^{99m}Tc -dimethoxyphenylisopropylamine, preparation, distribution, 243
- ^{113}C -aminonitriles, distribution, in dogs, 582*
- ^{113}C -ethanol distribution, in animals, 561*
- ^{113}C -psychoactive drug uptake, 521*
- cerebral death combined with kidney studies, ^{99m}Tc -DTPA, 538
- ^{18}F -fluoro-DOPA, distribution, in animals, 518*
- ^{18}F -fluoroethanol preparation, 561*; distribution, in animals, 561*
- ^{18}F -haloperidol, preparation, distribution, in rats, 525*
- ^{123}I -iodoantipyrine kit, 561* distribution, in animals, 561*
- imaging, *see following listing*, Brain imaging
- intracranial lesions, screening, 851*
- lesion, computer diagnosis method, 805*
- lipophilic agents, distribution, in animals, 561*
- posterior fossa lesion imaging, 556*
- radiation dose, ^{103}Yb -DTPA cisternography, 101
- scanning, *see following listing*, Brain scanning
- subdural hematoma uptake, compartmental model, $^{99m}\text{TcO}_4^-$, 571*
- tomography, axial, 1210*
- tomography system, 543*
- tumor agents, comparison, in mice, 200
- tumor, ^{99m}Tc -Sn-citrate uptake, in mice, 534*
- Brain, blood flow**
- acute cerebral infarct, ^{133}Xe in saline, 853*; in baboons, 852*
- ^{113}C -aminonitriles, preparation, distribution, in dogs, 1049
- cerebral infarct, ^{133}Xe washout, in monkeys, 514*
- computer-camera system, ^{133}Xe , 264
- data processing system, ^{133}Xe , 386
- effect of anomalous venous return, 573*, 622
- effect of seizures, $^{99m}\text{TcO}_4^-$, 573*
- extracranial meningioma, $^{99m}\text{TcO}_4^-$, 833
- hemorrhage, intracerebral, $^{99m}\text{TcO}_4^-$, 459
- hemorrhage, subarachnoid, acute, ^{133}Xe , 577*
- in hemangioblastomatosis, $^{99m}\text{TcO}_4^-$, 915
- in neonates, 1210*
- in trauma, ^{133}Xe in saline, 803*
- posterior flow study, 548*
- quantitative regional circulation, $^{99m}\text{TcO}_4^-$, 525*
- regional, ^{133}Xe inhalation, 1093*
- scalp flow elimination, $^{99m}\text{TcO}_4^-$, 679
- ^{99m}Tc -RBC, 512*
- tumor and cerebrovascular disease, $^{99m}\text{TcO}_4^-$, 854*
- tumor, nonvascular cranial, 462
- vascular displacement, 86, 549*
- Brain imaging**
- basal ganglia, ^{64}Cu -complex, 787
- cerebral infarct, $^{99m}\text{TcO}_4^-$, 1210*
- comparison of ^{99m}Tc -citrate, -diphosphonate, $^{99m}\text{TcO}_4^-$, 526*
- compression effects, ^{11}CO , in monkeys, 557*
- computer image correction, $^{99m}\text{TcO}_4^-$, 523*
- delayed, $^{99m}\text{TcO}_4^-$, ^{99m}Tc -DTPA, 564*
- "doughnut" sign, $^{99m}\text{TcO}_4^-$, 432
- dynamic/static, neonates, 1210*
- EMI, 573*
- hematoma, bifrontal epidural, 908
- in hemangioblastomatosis, $^{99m}\text{TcO}_4^-$, 915
- in medulloblastoma, 520*
- in proven recanalized cerebral infarct, 852*
- in rhinocerebral mucormycosis, $^{99m}\text{TcO}_4^-$, 925
- large-field-of-view scintillation camera, 1158
- positron camera, $^{15}\text{NH}_3$, ^{67}Ga -chelates, $^{18}\text{O}_2$, 537*
- posterior fossa uptake, ^{99m}Tc -DTPA, in von Hippel-Lindau syndrome, 828
- rapid sequence, ^{99m}Tc , in children, 511*
- refocused images, 546*, 548*
- scatter fraction measurement, ^{99m}Tc , 535*
- ^{99m}Tc -DTPA, 536*; effect of steroid medication, 320
- ^{99m}Tc -glucoheptonate, 580*
- ^{99m}Tc -gluconate, in children, 552*
- $^{99m}\text{TcO}_4^-$, effect of previously administered Sn(II), 518, 579*, 690
- $^{99m}\text{TcO}_4^-$, glycopyrrolate blocking dose, 819
- $^{99m}\text{TcO}_4^-$, ^{99m}Tc -diphosphonate, comparison, 705
- ^{99m}Tc -RBC, 512*
- tumor, ^{133}Co -bleomycin, 1058
- tumor, CVD differentiation, $^{99m}\text{TcO}_4^-$, -pyrophosphate, 549*
- Brain scanning**
- blood activity levels, $^{99m}\text{TcO}_4^-$, ^{99m}Tc -RBC, 553*, 676
- cerebral vascular disease, 852*
- encephalitis, current literature, 502*
- extracranial meningioma, $^{99m}\text{TcO}_4^-$, 833

- Hodgkin's disease,** ^{87m}Sr , ^{99m}Tc -polyphosphate, 852*
- infection,** ^{67}Ga -citrate, 580*
- interpretation,** Gamut approach, 1121
- lung carcinoma staging,** 538*
- metastatic adenocarcinoma,** $^{99m}\text{TcO}_4^-$, 960, 961
- ^{75}Se -selenite, 331
- sinusitis,** $^{99m}\text{TcO}_4^-$ concentration, 89
- $^{99m}\text{TcO}_4^-$, effect of previously administered ^{99m}Tc -Sn bone agents, 518, 579*, 690
- tumor, blood activity contribution,** $^{99m}\text{TcO}_4^-$, 553*
- tumor, chemotherapy response,** 1210*
- Breast**
- cancer, bone scanning,** ^{99m}Tc -phosphorous compounds, 529*, 532*, 1158
 - cancer, ^{67}Ga -citrate scanning,** 560*
 - carcinoma, ^{67}Ga -citrate whole-body scanning,** 996
 - carcinoma, ^{113}In -bleomycin scanning,** 578*
 - carcinoma, liver scanning,** 545*, 802*
 - carcinoma, metastatic, CEA radioimmunoassay,** 579*
 - imaging,** $^{99m}\text{TcO}_4^-$, ^{67}Ga -citrate, 293
 - lesion uptake of ^{99m}Tc -diphosphonate, -polyphosphate,** 536*
 - lymph node drainage,** ^{99m}Tc -Sb colloid, 526*
 - mass, differential diagnosis,** ^{99m}Tc -polyphosphate imaging, 581*; ^{113}In -bleomycin scanning, 578*
- Bromine-77**
- dimethoxyphenylisopropylamine for brain, preparation, distribution,** 243
 - fibrinogen, preparation, comparison to other labels,** 542*
- Bromine-82**
- bromide space, fluorescent excitation analysis,** 814
 - dimethoxyphenylisopropylamine for brain- preparation, distribution,** 243
- Cadmium-109**
- source, fluorescent excitation analysis,** 814
- Calcium**
- partial-body, neutron activation analysis,** 116
 - whole-body, ^{36}Ar excretion following neutron activation,** 672
 - whole-body, in osteoporosis, neutron activation analysis,** 196
- Calcium-45**
- bone uptake mechanisms, in rats,** 40
 - myocardial infarct uptake mechanism,** 525*
 - radiation dosimetry,** 502*
- Camera, image intensifier**
- operating characteristics,** 541*
- Camera, multiwire liquid xenon**
- high-resolution collimator,** 583*
- Camera, positron**
- brain imaging,** $^{15}\text{NH}_3$, $^{18}\text{O}_2$, ^{67}Ga -chelates, 537*
 - extended counting rate,** 653
 - multiwire proportional chamber,** 546*, 804*
 - ^{85}Rb , $^{15}\text{NH}_3$, heart imaging, in dogs, 429
 - transverse section 3D image reconstruction,** 80
- Camera, scintillation**
- anatomic landmark,** 962
 - bar phantom,** 441, 531*
 - chromatographic imaging,** 553*
 - coded aperture tomography,** 402
 - collimator changing system,** 1195
 - collimator hole pattern elimination,** 517*
 - color code images,** 527*
 - computer system, see Computer**
 - data processing, annular coded apertures,** 514*
 - data processing, spatial filtering,** 516*
 - deadtime,** 284; correction, 539*, 546*
 - deconvolution analysis, renogram,** 1212*
 - ^{103}Er myocardial infarct imaging, in dogs, 554*
 - field flood uniformity,** 513*, 534*, 536*
 - field of view, large,** 518*, 552*, 1152, 1158
 - Fresnel zone plate image reconstruction,** 309
 - image processing, Fourier transforms,** 566*
 - image superposition,** 559*
- modules for data unification,** 553*
- MTF determination,** 1200
- performance characteristics,** 1206
- portable,** 515*
- positron imaging,** 653
- quality control,** 564*
- refocused images,** 546*, 548*
- resolution indices,** ^{99m}Tc , 228
- sequential image smoothing,** 558*
- software, multi-isotope studies,** 571*
- specific image boundary determination,** 576*
- ^{99m}Tc scatter fraction measurement, 535*
- voltage fluctuation effects, 581*
- whole-body imaging,** 582*
- Camera, semiconductor**
- small tumor detection,** 53
- Carbon-11**
- acetyl phosphate, preparation, distribution, in animals,** 572*
 - albumin, preparation,** 425
 - aliphatic amines, lung uptake, in animals,** 511*
 - amino acids, preparation, purification,** 579*
 - aminonitriles, preparation, distribution, in dogs,** 582*, 1049
 - ^{13}CO , brain blood volume, tomography, 521*
 - ^{13}CO , compression effects on brain image, in monkeys, 557*
 - ^{13}CO , myocardial blood pool tomography, 521*
 - ^{13}CO , transaxial tomography, 210
 - diphenylhydantoin, -hydroxydiphenylhydantoin, tumor scanning,** 575*
 - ethanol, distribution, in animals,** 561*
 - ethanol, liver imaging, in cats,** 73
 - fibrinogen, preparation,** 425
 - LSF,** 649
 - norepinephrine for myocardial imaging,** 151
 - positron range,** 1174
 - psychoactive drugs, preparation, distribution,** 521*
 - putrescine for prostate, distribution, in rats,** 337
- Carbon-14**
- acetate, -glycerol, M. lepraeumurium metabolism,** 518*
 - ascorbic acid, adrenal and pituitary uptake, in dogs,** 551*
 - bile salts, kinetics, colonic injection,** 805*
 - carbohydrates, radiometric assay of lymphocyte metabolism,** 576*
 - chromatogram imaging, modular system,** 553*
 - ^{14}CO , breath analysis, metabolism in vitamin B₁₂ deficiency, in rats, 553*
 - dextran, CSF drainage, in rabbits,** 539*
 - diphenylhydantoin for pancreas, distribution,** 775
 - diphosphonate, bone uptake mechanisms, in rats,** 40
 - DOPA, blood metabolism, drug effects, radiometric assay,** 576*
 - dopamine analogs for adrenals, distribution, in rats,** 1147
 - fluorouracil, distribution, tumor uptake, in mice,** 582*
 - formaldehyde, -propionate metabolism, in vitamin B₁₂ deficiency, in rats,** 553*
 - formate, M. tuberculosis metabolism,** 518*
 - glycerol, -acetate, M. tuberculosis metabolism,** 1189
 - inulin, GFR, in dogs,** 510*
 - oleic acid, myocardial uptake, in animals,** 842
 - radiation dose, albumin synthesis studies,** 642
 - radiation dosimetry, current literature,** 502*
 - radiometric sterility assay,** 798
 - substrate metabolism, continuous measurement system,** 517*
 - sugars, radiometric identification of streptococcus Group A,** 1085
- Carcinoembryonic antigen**
- comparison of radioimmunoassays,** 1094*
 - diagnosis of colon malignancy,** 550*
 - radioimmunoassay, breast carcinoma metastases,** 579*
 - radioimmunoassay, ulcerative proctocolitis,** 1094*

- Cardiac** *see Heart*
Cardiopulmonary *see Heart, blood flow; Lungs, blood flow*
Carrier
 - 99m Tc in 99m Tc-gluconate and -diphosphonate distribution, in rats, 478
 - 99m Tc in 99m TcO₄⁻, 570*, 639
- Cartilage**
 - 99m Tc-diphosphonate uptake, in rats, 58
- CEA** *see Carcinoembryonic antigen*
- Central nervous system** *see Brain; Cisternography*
- Cerebral** *see Brain*
- Cerebrospinal fluid**
 - see also Cisternography*
 - drainage, pathway size, in rabbits, 539*
 - formation rate, 123 I-HSA, blue dextran, in monkeys, 1093*
 - 99m Tc-HSA ventriculography, hydronephrosis, 581*
- Cerenkov effect**
 - 32 P eye tumor imaging, 516*
- Cerium-141**
 - scatter subtraction and image contrast, 102
- Cerium-144**
 - particles, lung clearance, in dogs, 851*
- Cesium-129**
 - characteristics for myocardial imaging, 151
 - radiation dosimetry, 527*, 1070
- Cesium-131**
 - characteristics for myocardial imaging, 151
 - chloride, thyroid scanning, 522*
 - myocardial scan, left ventricular aneurysm, 1024
- Cesium-134m**
 - characteristics for myocardial imaging, 151
- Cesium-137**
 - specific absorbed fraction computation, 492
- Cesium-149**
 - myocardial imaging, in dogs, 553*
- Chelates**
 - see also Cobalt-57; Indium-111; Indium-113m; Technetium-99m, DTPA; Ytterbium-169*
 - DTPA agents for cisternography, radiation dosimetry, 1177
 - EDTA effect on 67 Ga-citrate distribution, in rats, 280
- Chemotherapy**
 - antirheumatoid, effect on SH blood group, 576*
 - central nervous system, monitoring, 522*
 - cyclical, breast to bone metastases, 90 Sr monitoring, 191
 - dexamethasone, brain tumor scanning, 1210*
 - MOPP, Hodgkin's disease, spleen scan, 457
 - steroid, effect on brain image of metastases, 320
- Chlormerodrin**
 - see also Mercury-197; Mercury-203*
 - myocardial infarct uptake, in rats, 523*
- Cholesterol** *see Iodine-131; Selenium-75*
- Chromatography**
 - 14 C, 32 P imaging, modular system, 553*
 - 97 Co-bleomycin fractions, 1033
 - 97 Ga-citrate preparations, 580*
 - gel scanning, 99m Tc-diphosphonate, 1087, 1088
 - 131 I-cholesterol purification, 69
 - liquid, bleomycin fraction separation, 526*
 - paper, strip counter, 225
 - 99m Tc-diphosphonate, 584*
- Chromium-51**
 - DTPA, radiation dosimetry, cisternography, 1177
 - RBC, preparation, survival, in gerbils, 682
 - red cell volume, normal, 46, 961, 962
 - thymocytes, distribution, in mice, 633
- Cisternography**
 - agents, Limulus test, 809
 - DTPA agents, radiation dosimetry, 1177
 - evaluation of chemotherapy, 522*
 - faulty injection effects, 267
 - 131 I-HSA current literature, 502*
 - in achondroplastic children, 969*
 - 111 In-DTPA, residual 99m Tc artifact, 434
- in hydrocephalus, 500*
- 111 In-phosphate**, in dogs, 164
- spinal fluid leak, 99m Tc-DTPA, 616
- unilateral ventricular reflux, 131 I-HSA, 716
- 166 Yb-DTPA, radiation dose to brain, 101
- 166 Yb-DTPA retention, 570*
- Clinical evaluation**
 - bone imaging in sacro-iliac disease, 99m Tc-pyrophosphate, 55 cases, 545*
 - bone imaging, metastases, 99m Tc-diphosphonate, 1355 cases, 986
 - bone marrow scanning, 99m Tc-S colloid, 196 cases, 535*; 101 cases, 535*; 60 cases, 559*
 - bone scanning in breast cancer, 115 cases, 529*; 86 cases, 532*
 - bone scanning in malignancy, 60 cases, 559*; 124 cases, 579*
 - bone scanning in trauma, 99m Tc-pyrophosphate, 182 cases, 538*
 - bone scanning in metastases, 99m Tc-polyphosphate, -pyrophosphate, 60 cases, 1211*
 - bone scanning, solitary lesion, 99m Tc-diphosphonate, -polyphosphate, 142 cases, 522*
 - brain blood flow in tumor and cerebrovascular disease, 99m TcO₄⁻, 89 cases, 854*
 - brain imaging, rapid sequence, 500 children, 511*
 - brain imaging, 99m Tc-DTPA, 904 cases, 536*
 - brain scanning, cerebral infarct, 99m TcO₄⁻, 84 cases, 1210*
 - brain screening for intracranial lesions, 147 cases, 851*
 - brain studies in cerebral vascular disease, 162 cases, 852*
 - breast uptake of 99m Tc-diphosphonate, -pyrophosphate, 271 cases, 536*
 - CEA radioimmunoassay, metastatic breast carcinoma, 75 cases, 579*
 - CEA radioimmunoassay, ulcerative proctocolitis, 59 cases, 1094*
 - cisternography, extra-arachnoid injection effects, 54 cases, 267
 - 77 Co-bleomycin imaging, 132 cases, 1058
 - 77 Co-bleomycin tumor scanning, 50 cases, 839; 50 cases, 558*
 - effective thyroxine ratio ranges, in pediatrics, 89 cases, 955
 - 67 Ga-citrate imaging, 2000 cases, 547*
 - 67 Ga-citrate imaging, infection, 60 cases, 990
 - 67 Ga-citrate scanning for infection, 68 cases, 2
 - 67 Ga citrate scanning in breast cancer, 84 cases, 560*; 125 cases, 996
 - 67 Ga-citrate staging of lymphoma, 111 cases, 255
 - 67 Ga-citrate, thyroid imaging, cold nodules, 134 cases, 793
 - 67 Ga citrate tumor scanning, 50 cases, 558*
 - gastrin radioimmunoassay, 298 cases, 805*
 - gastrointestinal tract imaging, 99m TcO₄⁻, 100 cases, 515*
 - hip imaging, in children, 176 cases, 512*
 - 123 I-fibrinogen from single donor, 129 cases, 562*
 - 111 In-bleomycin scanning, malignant melanoma, 51 cases, 537*
 - 111 In-bleomycin tumor imaging, 65 cases, 854*
 - iron, total serum binding capacity, 550 radioassays, 583*
 - kidney images on bone scans, 247 cases, 1092*; 119 cases, 1109
 - kidney imaging, 99m Tc-DMSA, 65 cases, 28
 - kidney transplant evaluation, 99m Tc-DTPA, 131 I-Hippuran, 86 cases, 1115
 - kidney transplant evaluation, 99m Tc-S colloid, 99m TcO₄⁻, 54 cases, 529*
 - large-field-of-view scintillation camera, 636 studies, 518*
 - left ventricular ejection fraction, 99m Tc and echocardiography, 77 cases, 565*
 - liver and spleen focal defects, multiradionuclide studies, 125 cases, 583*
 - liver blood flow, 99m Tc-S colloid, 100 cases, 71; 92 cases, 595

- liver imaging in abdominal tumor, ^{99m}Tc -S colloid, 70 cases, 853*
 liver imaging, ^{99m}Tc -S colloid, 1115 cases, 62, 1204; 125 cases, 450
 liver scanning in breast cancer, 86 cases, 545*; 100 cases, 802*
 liver scanning, negative focal uptake ^{99m}Tc -S colloid, porta hepatis region, 80 cases, 1007
 lung imaging, cost-effectiveness, 97 cases, 550*
 lung ventilation in obstructive airways disease, 60 cases, 574*
 lung ventilation/perfusion, Xe, wide-field-of-view scintillation camera, 140 cases, 552*
 lung washout, ^{133}Xe in saline, 154 burn patients, 547*
 myocardial imaging, ^{99m}Tc -pyrophosphate, 242 cases, 556*
 myocardial infarct tomography, 92 cases, 581*
 pancreas scanning, 526 cases, 568*
 pancreas scanning and ultrasound, 600 cases, 563*
 portable scintillation camera, 2000 cases, 515*
 posterior fossa lesion imaging, 49 cases, 556*
 red cell and plasma volume, normal, 784 cases, 46, 961, 962
 serum TSH response to TRH, in thyroid disease, 101 cases, 538*
 spleen scanning in Hodgkin's disease, 68 cases, 1212*
 ^{99m}Tc -bleomycin, ^{99m}Ga -citrate tumor imaging, 142 cases, 414
 telephone image transmission, 50 cases, 549*
 thyroid, autonomously functioning lesions, 164 cases, 1092*
 thyroid imaging, ^{131}I and $^{99m}\text{TcO}_4^-$, 65 cases, 512*
 thyroid imaging, nodules, $^{99m}\text{TcO}_4^-$, 87 cases, 563*
 thyroid, nonfunctioning nodule, ^{131}Cs scans and echography, 110 cases, 522*
 thyroid therapy, low-dose ^{131}I , 62 cases, 549*
 thyroid uptake, ^{131}I , 400 cases, 562*
 thyroid uptake, ^{131}I , normal range, 275 cases, 560*
 tomography, computerized axial, 750 cases, 1210*
 vascular perfusion, peripheral ischemic ulcer, ^{99m}Tc -microspheres, 60 cases, 993
 venography combined with lung scanning, ^{131}I -MAA, ^{99m}Tc -microspheres, 108 cases, 579*
 vesicoureteral reflux, ^{131}I -Hippuran imaging, 136 cases, 968*
 vesicoureteral reflux, radionuclide cystography, 90 children, 522*
 x-ray therapy, long-range effects, thyroid imaging, $^{99m}\text{TcO}_4^-$, 1500 cases, 512*
Cobalt-57
 -EDTA, -HSA, competitive binding with bleomycin, in vitro, 1033
 refocused scintillation camera images, 546*
Cobalt-57, bleomycin
 fractions, characterization, distribution, tumor uptake, in rats, 1033
 melanoma uptake, in animals, 556*
 pancreas tumor imaging, 533*
 preparation, distribution, tumor imaging, 1058
 properties of fractions, 526*
 radiation dosimetry, 550*
 tumor imaging, compared to ^{99m}Tc -gluconate, 552*
 tumor scanning, 839; compared to ^{99m}Ga -citrate, 558*
Cobalt-60
 specific absorbed fraction computation, 492
Collimator
see also Fresnel zone plate
 changing system, 1195
 converging, large-field-of-view scintillation camera, 518*, 552*, 1152
 diverging, low-energy, 970*
 diverging, scintillation camera, Xe lung studies, 552*
 diverging, scintillation camera, Xe phantom resolution, 143
 high-resolution, left ventricular blood flow, ^{99m}Tc , 865
 hole pattern elimination, 517*
 multiwire liquid xenon camera, 583*
 optimum, ^{131}I , ^{99m}Tc , ^{131}I , ^{43}K for myocardial imaging, 531*
 pinhole, hip imaging, in children, 512*
 pinhole, ^{131}I thyroid imaging, 512*
 pinhole, $^{99m}\text{TcO}_4^-$ thyroid imaging, 512*
 positron imaging, 524*
 resolution indices, ^{99m}Tc , 228
 scanner, ^4K and ^{85}Rb heart studies, 562*
 septal penetration, computer correction, 523*
 spatial resolution, positron range effect, 649
 ^{131}I , 513*
 whole-body scintillation camera imaging, 582*
Colloid *see specific radionuclide*
Communications
 computer-telephone transmission, 523*, 542*, 549*
Compton *see Scatter*
Computer
see also: Data processing
 analog, image processing, omnidirectional scanner, 685
 axial tomography, 1093*, 1210*
 brain lesion characterization method, 805*
 -camera, book review, 498
 -camera, cardiac shunt evaluation, in children, 511*
 -camera, coded aperture tomography, 402
 -camera, dual-channel $^{99m}\text{TcO}_4^-$ angiogram, 789
 -camera, early thyroid kinetics of I and $^{99m}\text{TcO}_4^-$, 517*
 -camera, ECG gated left-ventricular ejection fraction, 527*, 531*, 865
 -camera, ECG gated left-ventricular volume change, 531*
 -camera, ECG gated myocardial studies, 95, 368, 510*
 camera image correction, 523*, 558*
 camera image processing, book review, 498
 -camera, intrarenal blood flow, ^{133}Xe , 899
 -camera, liver size estimation, in rats, 380
 -camera, multi-isotope studies, 571*
 -camera, regional cerebral blood flow, ^{133}Xe , 264
 -camera, ventilation/perfusion in tetralogy of Fallot, 510*
 code for collimator design, 524*
 deconvolution analysis of scintillation camera renogram, 1212*
 digital techniques for Fresnel zone plate imaging, 556*
 digitized display improvement, 541*
 Fourier convolution fan-geometry reconstruction algorithm, 556*
 Fourier transform image processing, 566*
 Fresnel zone plate image reconstruction, 309
 image superposition, 559*
 interhospital image transmission, 523*, 542*, 549*
 isocount scanning and multilevel analysis, 938
 lung ventilation/perfusion, ^{133}Xe , ^{99m}Tc crossover subtraction, 553*
 on-line processing system, 386
 program for thyroxine-binding globulin capacity, 1076
 pulse mode display for color images, 527*
 radioreceptor assay data, 559*
 record system, 275, 575*
 refocused scintillation images, 546*, 548*
 regional cerebral blood flow, ^{133}Xe gas, 1093*
 scintillation camera flood field uniformity, 534*
 specific image boundary determination, 576*
 system for dynamic eye studies, 523*
 technique for cardiac blood flow, 500*
 whole-body scanner, 570*
Concentration, tissue
 data presentation, 247, 958
Contrast media
 effect on ^{99m}Ga -citrate distribution, 374
 effect on regional myocardial blood flow, 536*
 ^{131}I thyroid uptake depression, 802*

SUBJECT INDEX

- Copper-64**
-bleomycin, tumor uptake, compared to ³H- and ^{99m}Tc-bleomycin, in rats, 127
-complex, basal ganglia imaging, 787
detection efficiency, single and annihilation photon systems, 210
LSF, 649
- Cost**
relative weights, 348
effectiveness, lung imaging, 550*
- Cows** *see Generators*
- Creatinine phosphokinase**
levels in myocardial infarct, 521*, 559*, 569*
- Crystal**
NaI(Tl), ¹²³I radioassay, 952
NaI(Tl), scatter subtraction effects, 102
- CSF** *see Cerebrospinal fluid; Cisternography*
- Cyclotron**
¹³³Xe production, 143
- Cystic fibrosis**
alpha-fetoprotein levels, 968*
- Data processing**
see also Computer
analog, omnidirectional scanning, 685
annular coded apertures, 514*
coherent optical spatial filtering, 516*
deconvolution analysis, scintillation camera renogram, 1212*
isocount scanning and multilevel analysis, 938
on-line, 386
pulmonary arteriovenous malformation study, ^{99m}TcO₄-, 180
specific image boundary determination, 576*
tomography, unfocused plane subtraction, 517*
transaxial reconstruction by iterative techniques, 555*
3D image reconstruction, 80, 529*
- Data storage and retrieval** *see Computer; Record Keeping*
- Deadtime**
image intensifier camera, 541*
ring detector transaxial tomography, 1166
scintillation camera, 284, 539*, 546*
- Detector**
see also Collimator; Fresnel zone plate
crystal uniformity, computer correction, 523*
multiwire proportional chamber positron camera, 546*, 804*
NaI(Tl), scatter subtraction effects, 102
ring, transaxial reconstruction tomography, 1166
semiconductor, small tumor imaging, 53
unidirectional whole-body scanner, 516*
- Dextran**
blue, CSF formation rate, in monkeys, 1093*
Fe-, effect on ^{99m}Tc-diphosphonate uptake, 577*
³H-, CSF drainage, in rabbits, 539*
- Diaphragm**
foramen of Morgagni hernia, ^{99m}Tc-S colloid liver scan, 261
- Digoxin**
radioimmunoassay, 559*
radioimmunoassay, postmortem, 1212*
- Diphosphonate** *see Carbon-14; Phosphorous-32; Technetium-99m, diphosphonate*
- Display**
color code, computer generated, 527*
digitized, improvement, 541*
scan, 4 × 5-in. film, 560*
telephone image transmission, 523*, 542*, 549*
- DOPA**
¹⁴C-, blood metabolism, radiometric assay, drug effects, 576*
¹⁸F-fluoro-, for brain scanning, 518*
- Dopamine**
-analogs, ¹⁴C-, ³⁵S-, ¹²³I-, for adrenal gland, distribution, in rats, 1147
- Dose calibrator**
¹²³I assay, 540*
- Dosimetry** *see Radiation dosimetry*
- Drugs**
see also Chemotherapy
¹¹C-psychoactive, preparation, distribution, 521*
DTPA *see Chromium-51; Gallium-67; Indium-111; Indium-113m; Indium-114m; Lead-203; Technetium-99m, DTPA; Ytterbium-169*
- Dyes**
blue dextran, CSF formation rate, monkeys, 1093*
trypan blue, india ink, phagocytic action of kidney, in animals, 709
- Echography** *see Ultrasound*
- EDTA** *see Cobalt-57; Technetium-99m*
- Electrolysis**
^{99m}Tc-albumin, -fibrinogen, preparation, 534*
^{99m}Tc-autologous fibrinogen preparation, 343
^{99m}Tc-RBC preparation, 533*
- EMI**
brain scanning, 573*
- Energy**
photopeak and backscatter dual windows, ^{99m}Tc imaging, 513*
positron ranges, ¹¹C, ¹³N, ¹⁵O, ¹⁸F, ⁶⁶Ga, ⁸²Rb, 1174
resolution, ring detector transaxial tomograph, 1166
- Enzyme**
assay, continuous ¹⁴CO₂ measurement, 517*
assay of gentamicin, 968*
CPK levels in myocardial infarct, 521*, 559*, 569*
diphosphonate inhibition, 352
folate reductase, ¹²³I-folate displacement by methotrexate, in dogs, 572*
inhibitor for adrenal gland imaging, 566*
lactoperoxidase, radioiodination of bleomycin, 835
mucopolysaccharidoses, RES function, 542*, 1002
pancreatic, drug response in diabetes mellitus, 270
synthesis of ¹¹C-acetyl phosphate, 572*
- Erbium-165**
myocardial infarct imaging, in dogs, 554*
- Extremities**
see also Joints
perfusion, ischemic ulcers, ^{99m}Tc-microspheres, 993
perfusion, occlusive disease, ¹³³Xe, 1211*
thermography in thrombosis, 438, 566*
thrombophlebitis, cyst differentiation, ^{99m}Tc-HSA, 580*
thrombosis, ^{99m}Tc-streptokinase imaging, 474
venography, ¹²³I-MAA, ^{99m}Tc-microspheres, 579*
venography, ^{99m}Tc-MAA, in dogs, 563*
- Eye**
dynamic studies, computer system, 523*
lacrimal drainage, contrast and ^{99m}TcO₄-, 605
melanoma, ²⁰³Pb-Tris, ⁶⁷Co-bleomycin uptake, in hamsters, 556*
microvasculature function, ¹²³I-HSA, ¹³³Xe, 517*
tumor, ¹²³I-chloroquine, probe system, 562*
tumor imaging, ³²P Cerenkov effect, 516*
- Fatty acids**
¹⁴C- and ¹⁸I-oleic, ¹⁸I-linoleic, myocardial uptake, in animals, 842
esters, ²⁰³Hg-, preparation, distribution, in animals, 572*
¹²³I- and ¹³¹I-, characteristics for myocardial imaging, 151
¹²³I- and ¹³¹I-, preparation, 17
- Fetus**
cell binding, ⁶⁷Ga-citrate, hamster, in vitro, 231
congenital nephrosis, alpha-fetoprotein radioimmunoassay, 805*
effects of ^{99m}Tc radiation, in mice, 544*
placental blood flow, ¹³³Xe, 968*
placental transfer, ⁶⁷Ga-citrate, in animals, 581*
- Fibrin**
radioiodo-, thrombus uptake, in dogs, 521*

Fibrinogen

see also Iodine-123; Iodine-125, fibrinogen; Iodine-131, fibrinogen; Technetium-99m
 autologous, radioiodinated, kit, 554*
¹¹³C-, preparation, 425
 highly iodinated, preparation, characterization, 756
¹²³I-, ¹³¹I-, ⁷⁵Br-, preparation, distribution, in animals, 542*
 radioiodo-, effect of iodination levels, 534*

Film

4 × 5 in., scans, 560*

Filter

see also Fresnel zone plate
 spatial, data processing, 516*

Fluorescein

radioiodinated mercurihydroxy-, myocardial infarct uptake, in rats, 523*

Fluorescence

scanning, thyroid, 530*, 557*
 x-ray, iothalamate, for GFR, in dogs, 510*

Fluorescent excitation analysis

bromide space, 814

Fluorine-18

bone imaging, 969*
 bone scanning, 465, 522*, 559*, 569*, 574*
 bone uptake, compartmental model, 519*
 bone uptake parameters, 520*
 -fluoro-DOPA for brain scanning, 518*
 -fluoroethanol, preparation, 561*; distribution, in animals, 561*
 -haloperidol, preparation, distribution, in rats, 525*
 kinetics, compared to ^{99m}Tc-polyphosphate, 688, 689
 myocardial infarct tomography, 581*
 myocardial infarct uptake, in dogs, 132
 positron range, 1174
 -pregnenolone acetate, adrenal uptake, in rats, 526*
 radiation dosimetry, 502*
 renal asymmetry, whole-body bone scan, 161

Fluorouracil

¹⁴C-, distribution, tumor uptake, in mice, 582*

Fourier

convolution fan-geometry reconstruction algorithm, 556*
 tomography, internal absorption corrections, 540*
 transforms, image processing, 566*
 transforms, tomography, unfocused plane subtraction, 517*
 3D convolution reconstruction, noise, 529*

Fresnel zone plate

clinical studies, 183
 digital image reconstruction, 309
 digital techniques, 556*

FWHM

collimator for multiwire liquid xenon camera, 583*
 image intensifier and scintillation camera, ^{99m}Tc, 541*
 multiwire proportional chamber positron camera, 546*
 positron collimator, 524*
 positron range effect, 649
 ring detector, transaxial tomography, 1166
 scintillation camera, 1206
 transaxial positron tomography, 210

Gallbladder

bile leakage on ¹⁹⁶Au liver scan, 825
¹¹³C-aminonitriles, distribution, in dogs, 582*
¹¹³C-bile salts, kinetics, colonic injection, 805*
 comparison of agents, in baboons, 577*
 ectopic, ¹²³I-rose bengal, ^{99m}Tc-S colloid imaging, 1029
⁶⁷Ga-citrate scanning in cholecystitis, 148
¹²³I-rose bengal imaging, in rabbits, 540*
¹²³I-rose bengal, jaundice evaluation, 567*
¹²³I-rose bengal, preparation, imaging, 629
¹²³I-folate in bile, 572*
 pancreas and liver scanning in obstructive jaundice, 853*
 radiation dosimetry, ¹²³I-, ¹²⁴I-, ¹²⁶I-, ¹³¹I-¹³¹I-rose bengal, MIRD, 1214

^{99m}Tc-iminodiacetic acid analog, distribution, in animals, 533*

^{99m}Tc-mercaptopropionic acid, ¹³¹I-rose bengal comparison, 686, 687

^{99m}Tc-pyridoxylideneglutamate imaging, 543*, 728

^{99m}Tc-pyridoxylideneglutamate, preparation, distribution, imaging, in animals, 720

Gallium-67

-adriamycin, tumor uptake, in mice, 560*
 -chloride, -Fe-DTPA, -lactate, brain tumor uptake, radiation dosimetry, in mice, 200
 -DTPA, radiation dosimetry, cisternography, 1177
 leukemic cell binding, serum inhibition, 528*
 -leukocytes, abscess detection, in rabbits, 583*
 -lymphocyte, labeling, 564*

Gallium-67, citrate

abscess imaging, 250, 443, 609, 990
 benign process uptake, 414, 470
 bone tumor imaging, 503*
 brain tumor uptake, radiation dosimetry, in mice, 200
 breast carcinoma, whole-body scanning, 996
 breast imaging, 293
 bronchogenic carcinoma staging, 538*
 contrast media effect on whole-body scan, 374
 decreased uptake in pseudoarthrosis, 167
 distribution, Na₂EDTA therapy effects, in rats, 280
 gallbladder scanning in cholecystitis, 148
 hamster embryo cell binding, in vitro, 231
 infection scanning, 2
 infection uptake, 443, 580*
 leukocyte culture uptake, Fe effects, 1183
 liver and spleen scanning, focal defects, 583*
 lymphoma staging, 255
 multi-isotope lung studies, ^{99m}Tc-microspheres, ¹⁹⁷Hg, 571*
 myocardial infarct uptake, in dogs, 975
 pancreatic pseudocyst scan, 1132
 placental transfer, in animals, 581*
 preparations, comparison of solutions, 580*
 pulmonary infarct/pneumonitis differentiation, 551*
 rectilinear scanner modification, 1192
 salivary gland uptake, postradiation therapy, 514*
 scan in plague, 1031
 spleen image in kala-azar, 1128
 thyroid imaging, cold nodules, 793
 tumor detection, ^{99m}Tc-compound subtraction technique, 523*

tumor imaging, 1212*

tumor imaging, compared to ^{99m}Tc-bleomycin and ^{99m}Tc-phosphate compounds, 551*; compared to ^{99m}Tc-glucanate, 552*

tumor imaging, primary liver cancer, 949

tumor imaging, with ^{99m}Tc-bleomycin, 414

tumor scanning, compared to ^{99m}Co-bleomycin, 558*

tumor scanning, hilar tumors, 576*

tumor scanning in breast cancer, 560*

tumor scanning, in children, 533*

tumor scanning, liver image subtraction, 548*

tumor uptake, compared to ⁶⁷Ga-, ¹⁹⁷Hg-adriamycin, in mice, 560*

tumor uptake, compared to labeled bleomycins, 525*

tumor uptake, viability, in rats, 532*

whole-body imaging, usefulness, 547*

Gallium-68

-adenosine triphosphate, -citrate, preparation, 764

-chelates, brain imaging, positron camera, 537*

-microspheres, lung transverse section imaging, in dogs, 80

-microspheres, 3D lung imaging, in dogs, 386

positron range, 1174

Gastrointestinal tract

bleeding, ^{113m}In-chloride detection, 569*

distended gastric fundus on kidney image, 947

emptying, antacid effects, ^{113m}In, 562*

⁶⁷Ga-citrate content, effect of Na₂EDTA, in rats, 280

- gastric emptying, ^{99m}Tc -polystyrene-TETA, 575*
 gastrin radioimmunoassay, 805*
 gastro-esophageal reflux, ^{99m}Tc -S colloid, 547*
 Meckel's diverticulum diagnosis, $^{99m}\text{TcO}_4^-$, 515*
 radiation dosimetry model, 853*
 radiation dosimetry, radioiodides, MIRD, 857
 $^{99m}\text{TcO}_4^-$ secretion, effect of pentagastrin, in dogs, 535*
 $^{99m}\text{TcO}_4^-$ secretion into isolated loops, in rats, 574*
 $^{99m}\text{TcO}_4^-$ secretion site, 1204
 ^{201}Ti concentration, 545*
Gating *see Heart, blood flow*
Generator
 $^{66}\text{Ge}-^{66}\text{Ga}$, 764
 $^{98}\text{Mo}-^{99m}\text{Tc}$, ^{89}Sr , ^{90}Sr contamination, 571*
 $^{98}\text{Mo}-^{99m}\text{Tc}$, ^{99m}Tc content in eluate, 639
 $^{89}\text{Sr}-^{89}\text{Rb}$, 300, 429
Glomerular filtration rate *see Kidney*
Gold-198
 effective hepatic plasma flow, 524*
 liver scan, bile leakage, 825
 liver uptake mechanism, in rats, 532*
 radiation dose estimates in liver disease, MIRD, 173
 specific absorbed fraction computation, 492
 synovium therapy, 100
Granulocyte *see Leukocyte*
Health physics *see Quality Control; Radiation Dosimetry; Radiation safety*
Heart
 ^{11}C -aminonitriles, distribution, in dogs, 582*
 ^{11}C -diazepam uptake, 521*
 cardiac silhouette, wide, on lung image, 324
 ^{127}I , ^{131}I -fatty acid preparation, 17
 Inter-Society Commission for Heart Disease report, 959
 left ventricular volume change, ECG gated, 531*
 myocardial infarct, CPK levels, 521*; in dogs, 559*, 569*
 myocardial infarct, ^{43}K , ^{99m}Tc -pyrophosphate uptake, in dogs, 559*
 myocardial infarct, ^{99m}Tc -complexes, ^{67}Ga -citrate, uptake, in dogs, 975
 myocardial infarct, ^{99m}Tc -glucoheptonate uptake, in animals, 865, 975
 myocardial infarct, ^{99m}Tc -phosphates and ^{18}F , uptake, in dogs, 132
 myocardial infarct, ^{99m}Tc -pyrophosphate, -tetracycline uptake mechanism, 525*
 myocardial infarct, ^{99m}Tc -pyrophosphate uptake, 512*; in dogs, 548*, 559*
 myocardial infarct, ^{99m}Tc -tetracycline uptake rate, 1144
 myocardial infarct uptake, effect of blood flow, ^{43}K , ^{99m}Tc -tetracycline, -pyrophosphate, in dogs, 558*
 myocardial infarct uptake, effects of molecular structure, in rats, 523*
 myocardial uptake of ^{14}C - and ^{131}I -oleic acid, ^{131}I -linoleic acid, in animals, 842
 myocardial uptake of ^{15}N -compound, species differences, 529*
 myocardial uptake of ^{15}O -hemoglobin, in dogs, 550*
 myocardial uptake of ^{208}Pb - and ^{201}Ti -ionophores, in mice, 567*
 myocardial uptake of ^{99m}Tc -pyrophosphate, 944
 radiation dosimetry, ^{125}Cs , ^{43}K , ^{89}Rb , ^{201}Ti , 527*, 1070
 scanning, ^{43}K , in coronary artery disease, 575*
 scanning, left ventricular aneurysm, ^{131}Cs , ^{113m}In , 1024
 ^{201}Ti , distribution, in animals, 156
 tomography, myocardial infarct, ^{99m}Tc -diphosphonate, -pyrophosphate, -glucoheptonate, ^{18}F , 581*
 tomography, ^{99m}Tc -microspheres, in dogs, 568*
 tomography, transaxial, ^{11}CO , $^{15}\text{NH}_3$, 521*: in dogs, 210
Heart, blood flow
 cardiac ejection fraction, ^{99m}Tc -RBC, 512*
 data processing system, 386
 dual channel, dual color subtraction technique, $^{99m}\text{TcO}_4^-$, 789
 during stress, 510*, 514*, 851*
- ECG gated, 553*; ^{99m}Tc -HSA, 95, 368, 527*, 865
 left ventricular ejection fraction, cardiac output, portable probe, 289
 left ventricular ejection fraction, ECG gated, 531*; ^{99m}Tc -HSA, 527*; ^{99m}Tc -RBC, 865
 left ventricular ejection fraction, ^{99m}Tc , echocardiography, 565*
 ^{113m}In , current literature, 500*
 ^{113m}In , ^{99m}Tc -MAA, stress-induced ischemia, 851*
 large-field-of-view scintillation camera, 1158
 myocardial, during stress, ^{85}Rb , 514*
 myocardial infarct, Fresnel zone plate, ^{99m}Tc -MAA, in dogs, 183
 myocardial infarct, ^{99m}Tc -polyphosphate, 851*
 persistent left superior vena cava, $^{99m}\text{TcO}_4^-$, 469
 regional myocardial, contrast hyperemia, ^{133}Xe , 536*
 regional myocardial, ^{133}Xe in saline, in coronary artery disease, 567*
 shunt evaluation, $^{99m}\text{TcO}_4^-$, in children, 511*
 shunt evaluation, ^{99m}Tc -microspheres, -MAA, ^{113m}In -Fe(OH)₃, 528*
 ^{201}Ti , ^{43}K , ^{89}Rb , ^{99m}Tc -microspheres, in animals, 851*
- Heart, imaging**
 coincidence and noncoincidence, ^{43}K , ^{89}Rb , in dogs, 658
 collimator choice, 531*
 comparison of ^{125}Cs , ^{43}K , ^{201}Ti , ^{89}Rb , in dogs, 553*
 comparison of ^{89}Rb and ^{43}K , 562*
 coronary artery thrombosis, ^{123}I -fibrinogen, 804*
 evaluation of focal hepatic defect, ^{99m}Tc -S colloid, 896
 myocardial infarct, ^{165}Er , in dogs, 554*
 myocardial infarct quantification, ^{99m}Tc -pyrophosphate, in dogs, 569*, 573*
 myocardial infarct, ^{99m}Tc -compounds, in dogs, 582*
 myocardial infarct, ^{99m}Tc -glucoheptonate, 563*, 975
 myocardial infarct, ^{99m}Tc -polyphosphate, -pyrophosphate, 518*, 521*, 851*
 myocardial infarct, ^{201}Ti , 539*, 565*
 properties of imaging agents, 151
 ^{89}Rb , $^{15}\text{NH}_3$, in dogs, 429
 ^{99m}Tc -MAA, -HSA, pericardial effusion, 969*
 ^{99m}Tc -pyrophosphate, 518*, 521*, 556*, 851*
 ^{201}Ti , 513*, 539*, 565*; in animals, 151, 553*
- Hepatic** *see Liver*
Hepatitis
 B, radioimmunoassay, 513*
Hippuran *see Iodine-123; Iodine-131, Hippuran*
Hormones
 estrogen, effect on ^{131}I -diphenylhydantoin kinetics, 305
 estrogen radioimmunoassay, 500*
 estrogen, RES stimulation, in animals, 22
 ^{3}H -estradiol, adrenal uptake, in dogs, 77
 human chorionic gonadotrophin radioassay, 500*, 501*
 testosterone analogs for prostate, in rats, 570*
Human serum albumin *see Carbon-11; Iodine-125; Iodine-131, albumin; Technetium-99m, albumin; Technetium-99, macroaggregated albumin*
Hydrogen-3
 β -bleomycin, tumor uptake, compared to ^{99m}Tc - and ^{64}Cu -bleomycin, in rats, 127
 -dextran, CSF drainage, in rabbits, 539*
 -dihydrotestosterone, uptake inhibition, in rats, 570*
 -estradiol, adrenal uptake, in dogs, 77
 -prostaglandin E, A and -arachidonic acid for tumor, in mice, 83
 -putrescine for prostate, distribution, in rats, 337
 radioimmunoassays, quench correction, 570*
 -tetracycline, myocardial infarct uptake mechanism, 525*
Imaging *see Camera; specific organ*
Immunology
 CEA assay in colonic malignancy, 550*
 CEA radioimmunoassay, 579*, 1094*
 hepatitis B, 513*
 ^{131}I -tumor antibody, distribution, in animals, 544*
 ^{113m}In -chelate-antibodies, preparation, 559*

- motilin, radioimmunoassay, 1094***
thyroid antibodies in pernicious anemia, 549*
trichinosis diagnosis, ^{123}I -antitrichinosis, 501*
vesicle interactions, 483
- Indium-111**
 -chelate-antibodies, preparation, 559*
 -chloride, bone marrow scanning, compared to ^{59}Fe , $^{99m}\text{Tc-S}$ colloid, 66, 1204, 1205
 chloride, brain tumor uptake, compared to other agents, in mice, 200
 -chloride, kinetics, in mice, 738
 -chloride, radiation dosimetry, 200
 -citrate, kinetics, bone marrow imaging, 769
 -citrate, uptake in pudendal region, 769
 -DTPA, cisternography, 267, 434; aseptic meningitis, 809
 -leukocytes, abscess detection, in rabbits, 583*
 lymphocyte labeling, 564*
 -phosphate, for cisternography, preparation, distribution, 164
 placenta uptake, in animals, 544*
- Indium-111, bleomycin**
 brain tumor uptake, radiation dosimetry, in mice, 200
 breast carcinoma scanning, 578*
 distribution, radiation dosimetry, 854*
 kinetics, in mice, 738
 liver and spleen scanning, focal defects, 583*
 normal scans, 537*
 radiation dosimetry, 200, 550*, 854*
 tumor imaging, 537*, 854*; in children, 554*
 tumor/nontumor ratio relevance, 578*
 tumor uptake, compared to ^{67}Ga -citrate, 524*
 tumor uptake, compared to other labeled bleomycins, 524*
- Indium-113m**
 aerosol, lung ventilation in obstructive airways disease, 574*
 cardiac blood flow, 500*
 -chloride, gastric emptying, antacid effect, 562*
 -chloride, gastrointestinal bleeding detection, 569*
 -chloride, hepatic blood flow, in metastases, 533*
 -chloride, liver and spleen scanning, focal defects, 583*
 -DTPA, brain tumor uptake, radiation dosimetry, in mice, 200
 -DTPA, CSF drainage, in rabbits, 539*
 -DTPA, radiation dosimetry, cisternography, 1177
 - Fe(OH)_3 , cardiac shunt determination, 528*
 left ventricular ejection fraction, cardiac output, portable probe, 289
 -MAA, myocardial perfusion, 851*
 myocardial scan, left ventricular aneurysm, 1024
 -polyfunctional phosphonates for bone, preparation, distribution, in rabbits, 1080
 thyroid perfusion, cold nodule, 1187
- Indium-114m**
 -DTPA, distribution, kidney uptake, in rabbits, 357
- Infection**
see also Abscess; Bacteria
 bubonic plague, ^{67}Ga -citrate scan, 1031
 ^{67}Ga -citrate scanning, 2, 580*
 mucormycosis, kidney transplant, 925
 pancreatic pseudocyst, ^{67}Ga -citrate scan, 1132
 streptococcus Group A, radiometric identification, 1085
- Inflammation**
 ^{99m}Tc -microsphere-leukocyte uptake, in animals, 527*
 $^{99m}\text{Tc-S}$ colloid-leukocyte uptake, 566*; in dogs, 527*
- Injection**
 effects in cisternography, 267
 eye microvasculature studies, 517*
 intrasplenic, intramesenteric, effect on liver uptake of $^{99m}\text{Tc-S}$ colloid, in rats, 377
 site, Fe-dextran, ^{99m}Tc -diphosphonate uptake, 577*
- Iodine**
 early thyroid kinetics, 517*
 radio-, iodination level effects on fibrinogen, 534*
- Iodine-123**
 -bleomycin, preparation, characterization, 550*
 -bleomycin, radiation dosimetry, 550*
 -bleomycin, tumor imaging, 524*
 collimator for myocardial imaging, 531*
 -estradiol, radiation dosimetry, 541*
 -fatty acids, characteristics for myocardial imaging, 151
 -fatty acids, preparation, 17
 -fibrin for thrombus, 521*
 fibrinogen, thrombus detection, 524*
 -Hippuran, renogram, 1212*
 impurities, 540*
 radiation dosimetry, MIRD, 857
 -rose bengal, evaluation of jaundice, 567*
 -rose bengal, hepatobiliary imaging, 629
 -rose bengal, preparation, 540*
 -rose bengal, radiation dosimetry, MIRD, 1214
 -streptokinase, preparation, kinetics, in animals, 136
 thyroid imaging, compared to $^{99m}\text{TcO}_4^-$, 512*
 thyroid imaging, Fresnel zone plate, 183
- Iodine-124**
 radiation dosimetry, MIRD, 857
 -rose bengal, radiation dosimetry, MIRD, 1214
- Iodine-125**
 -albumin, CSF formation rate, in monkeys, 1093*
 -albumin, eye humor flow, 517*
 antitrichinosis, assay, 501*
 -chloroquine, eye tumor, 562*
 -diphenylhydantoin for pancreas, distribution, imaging, 775
 -dopamine analogs for adrenal glands, distribution, in rats, 1147
 -folate, displacement by methotrexate, in dogs, 572*
 hepatitis B radioimmunoassay, 513*
 -immunoglobulin, vesicle survival, in mice, 483
 -iododeoxyuridine, tumor therapy, in mice, 516*
 -iodomethylnorcholesterol, preparation, distribution, in mice, 666
 -microspheres, blood flow, skin flap, in dogs, 1212*
 -motilin, radioimmunoassay, 1094*
 photon spectrum, 246
 -plasminogen, distribution, tumor uptake, in mice, 560*
 -quinoline analog, for melanoma, distribution, in mice, 530*
 radiation dosimetry, MIRD, 857
 radioassay of small samples, 952
 source, photon absorptiometry, bone mineral content, 196
 -streptokinase, preparation, kinetics, in animals, 136
 thyroid uptake, 562*
 T_3 radioimmunoassay, 514*
- Iodine-125, fibrinogen**
 -autologous, preparation, 393
 compared to other labels, 542*
 distribution, tumor uptake, in mice, 560*
 high specific activity, preparation, characterization, 756
 single donor, safety, 562*
 thrombus uptake, in dogs, 370
- Iodine-126**
 radiation dosimetry, MIRD, 857
 -rose bengal, radiation dosimetry, MIRD, 1214
- Iodine-129**
 photon spectrum, 246
- Iodine-130**
 radiation dosimetry, MIRD, 857
 -rose bengal, radiation dosimetry, MIRD, 1214
- Iodine-131**
 -acetazolamide, preparation, distribution, in animals, 537*
 -bleomycin, tumor uptake, in animals, 524*
 -bromsulphalein, bile leakage, liver pseudocyst, 825
 -chlorpropamide for pancreas, distribution, in animals, 577*
 -cholesterol, adrenal carcinoma, 566*
 -cholesterol, preparation, purification, 69

- cholesterol, radiation dosimetry, 247, 248
- cholesterol, therapy for adrenal cortical hyperplasia, in dogs, 928
- diphenylhydantoin for pancreas, distribution, imaging, 775
- diphenylhydantoin, kinetics, effects of carrier and estrogen, 305
- fatty acids, characteristics for myocardial imaging, 151
- fatty acids, preparation, 17
- hepatographic patterns in disease, rectal administration, 802*
- iodoantipyrine, distribution, in animals, 561*
- iodoantipyrine, kit, 561*
- iodoethanol, distribution, in animals, 561*
- iodomethylnorcholesterol, preparation, distribution, in animals, 514*, 666, 1038
- iodomethylnorcholesterol, uptake by adrenals, in rats, 542*, 565*
- liver imaging, metastatic thyroid carcinoma, 669, 919
- lysozyme, -ribonuclease, for kidney, distribution, in animals, 357
- oleic, -linoleic acid, myocardial uptake, in animals, 842
- radiation dosimetry, MIRD, 857
- rose bengal, compared to ^{99m}Tc agents, in baboons, 577*
- rose bengal, compared to ^{99m}Tc-mercaptoisobutyric acid, 686, 687
- rose bengal, gallbladder imaging, 543*, 1029
- rose bengal, radiation dosimetry, MIRD, 1214
- streptokinase, preparation, kinetics, in animals, 136
- streptozotocin analogs, tumor uptake, in hamsters, 535*
- tetracycline, preparation, stability, 519*
- tetracycline, tumor uptake, compared to other agents, in rats, 532*
- tetracycline, tumor uptake, in animals, 520*
- thyroid imaging, with ^{99m}TcO₄⁻, 918
- thyroid scan, accessory thyroid, 1135
- thyroid scan, cold nodule, 713
- thyroid therapy, effect on red blood cells, 963, 964
- thyroid therapy, effect on thyroid function, 568*
- thyroid therapy, low dose, 549*, 572*
- thyroid uptake, depression by contrast media, 802*
- thyroid uptake, normal range, 560*
- thyroid uptake suppression test, 538*
- tumor antibody, preparation, distribution, in animals, 544*
- Iodine-131, albumin**
 - bone kinetics, in rats, 40
 - brain tumor uptake, radiation dosimetry, in mice, 200
 - cisternography, 267, 502*; aseptic meningitis, 809
 - MAA, myocardial perfusion during stress, 510*
 - MAA, venography, 579*
 - plasma volume determination, 1207; normal range, 46, 961, 962
 - tumor imaging, 1212*
 - unilateral ventricular reflux, 716
- Iodine-131, fibrinogen**
 - autologous, kidney transplant rejection, 555*
 - autologous, preparation, 393
 - coronary artery thrombus image, 804*
 - high specific activity, preparation, characterization, 756
 - preparation, comparison to other labels, 542*
 - thrombus uptake, in dogs, 370
- Iodine-131, Hippuran**
 - blind-ending ureteral duplication image, 208
 - collecting system evaluation in renal transplant, 557*
 - kidney transplant evaluation, 557*, 1092*, 1115
 - renogram for urinary tract obstruction in pregnancy, 803*
 - renogram in hemangioendotheliomatosis, 915
 - ureteral fistula imaging, 612
 - vesicoureteral reflux imaging, 968*
- Iodine-132**
 - radiation dosimetry, MIRD, 857
- Iothalamate**
 - GFR by x-ray fluorescence, in dogs, 510*
- Iron**
 - total serum binding capacity, 583*
- Iron-52**
 - bone marrow scanning, compared to ¹¹¹In, ^{99m}Tc-S colloid, 66
- Iron-59**
 - RBC, bone kinetics, in rats, 40
- Joints**
 - see also Extremities*
 - knee, ^{99m}Tc-polyphosphate scan in arthritis, 510*
 - ³²P-chromic phosphate synovectomy, 442
 - popliteal cyst, thrombosis differentiation, ^{99m}Tc-HSA, 580*
 - sacro-iliac disease, ^{99m}Tc-pyrophosphate imaging, 545*
 - synovium, ¹⁹⁸Au-therapy, 100
 - ^{99m}TcO₄⁻ imaging in periarthritis nodosa, 804*
- Kidney**
 - autoradiography of uptake, ^{99m}Tc agents, 554*
 - disease, effect on bone uptake of ^{99m}Tc-pyrophosphate, 33
 - disease, effect on ^{99m}Tc-bleomycin tumor imaging, 1058
 - failure, effect on soft-tissue uptake of ^{99m}Tc-phosphates, 1087
 - failure, rhabdomyolysis, muscle uptake of bone agents, 515*
 - function tests, combined with cerebral death studies, ^{99m}Tc-DTPA, 538*
 - GFR, ¹⁸F, ^{99m}Tc-polyphosphate, 688, 689
 - GFR, x-ray fluorescence of iothalamate, in dogs, 510*
 - glomerular filtration, ¹¹¹In-phosphate, in animals, 164
 - ¹³I-acetazolamide distribution, in animals, 537*
 - ¹¹¹In-bleomycin uptake on normal scan, 537*
 - multi-isotope studies, ¹⁹⁷Hg-chloride, ^{99m}Tc-DMSA, 571*
 - phagocytic capability, in animals, 709
 - phantom, blood background and mean transit studies, 576*
 - renogram, deconvolution analysis, scintillation camera, 1212*
 - renogram in hemangioendotheliomatosis, ¹³¹I-Hippuran, 915
 - renogram, transplant evaluation, ¹³¹I-Hippuran, 612, 1092*, 1115
 - renogram, urinary tract obstruction in pregnancy, 803*
 - ^{99m}Tc effect on ^{99m}Tc-gluconate distribution, in rats, 478
 - ^{99m}Tc-diphosphonate uptake in Paget's disease, 582*
 - ^{99m}Tc-thiomalic acid, preparation, distribution, in rats, 531*
 - uptake of ^{99m}Tc kidney agents, in rats, 531*
 - uptake on bone scans, 1092*, 1109; ^{99m}Tc-polyphosphate, 454, 602; ¹⁸F and ^{99m}Tc-pyrophosphate, 161
- Kidney, blood flow**
 - carcinoma detection, ^{99m}Tc-MAA, 472
 - ERPF, transplant, ^{99m}Tc-DTPA, 1115
 - hypernephroma, arteriovenous shunting, ^{99m}Tc-microspheres, 569*
 - intra-, camera-computer system, ¹³³Xe in saline, 899
 - pheochromocytoma detection, ^{99m}Tc-DTPA, 234
- Kidney imaging**
 - effect of distended gastric fundus, ^{99m}Tc-DTPA, 947
 - in hemangioendotheliomatosis, ¹⁹⁷Hg-chlormerodrin, 915
 - large-field-of-view scintillation camera, 1158
 - multi-isotope studies, ¹⁹⁷Hg-chloride, ^{99m}Tc-DMSA, 571*
 - radiation dosimetry, ¹⁹⁷Hg-, ^{99m}Hg-chlormerodrin, 1095
 - refocused images, 548*
 - ^{99m}Tc-complexes, 357
 - ^{99m}Tc-DMSA, 28
 - ^{99m}Tc-DTPA imaging in obstructive disease, 525*
 - ^{99m}Tc-phosphate bone scans, 161, 454, 602, 1092*, 1109
 - vesicoureteral reflux, ¹³¹I-Hippuran, 968*
- Kidney transplant**
 - bone imaging, 538*
 - collecting system evaluation, ^{99m}Tc, ¹³¹I-Hippuran, 557*
 - ERPF, ^{99m}Tc-DTPA, 1115
 - monitoring, ^{99m}Tc-S colloid, ^{99m}TcO₄⁻, 529
 - mucormycosis infection, head and brain imaging, 925

- rejection, ^{131}I -autologous fibrinogen studies, 555*
- renograms, 1092*, 1115
- ureteral fistula imaging, ^{99m}Tc -DTPA, ^{131}I -Hippuran, 612
- Kit**
- ^{123}I -iodoantipyrine, 561*
 - radioiodinated autologous fibrinogen, 554*
 - ^{99m}Tc -diphosphonate, chromatography, 584*
 - ^{99m}Tc -minimicrospheres, 542*
 - ^{99m}Tc -RBC, 512*, 570*
 - T₁ radioimmunoassay, 514*; evaluation, 558*
- Krypton-79**
- nuclear parameters, radiation dosimetry, 143
- Krypton-81m**
- see also Rubidium-81m*
 - characteristics for myocardial imaging, 151
- Krypton-85**
- nuclear parameters, radiation dosimetry, 143
- Krypton-85m**
- for lung ventilation, 539*
 - nuclear parameters, radiation dosimetry, 143
- Lacrimal gland**
- drainage, contrast and $^{99m}\text{TcO}_4^-$, 605
- LD₅₀** *see Toxicity*
- Lead-203**
- chloride, -acetate, -EDTA, -polyphosphate, -diphosphate, distribution, in mice, 544*
 - chloride, for bone, distribution, in rats, 170
 - DTPA, radiation dosimetry, cisternography, 1177
 - ionophores, for heart imaging, distribution, in mice, 567*
 - Tris, melanoma uptake, in hamsters, 556*
 - tumor uptake and viability, in rats, 532*
- Lesion** *see also Abscess; Inflammation; Tumor*
- benign, ^{99m}Tc -bleomycin, ^{67}Ga -citrate uptake, 414
- Leukocytes**
- ^{14}C -substrate metabolism, continuous measurement, 517*
 - culture, Fe enhancement of ^{67}Ga -citrate uptake, 1183
 - ^{67}Ga -, ^{113}In -, abscess detection, in rabbits, 583*
 - leukemic, ^{99m}Tc uptake, 530*
 - ^{99m}Tc labeling, 530*
 - ^{99m}Tc -microsphere-, preparation, abscess, inflammation uptake, in animals, 527*
 - ^{99m}Tc -S colloid labeling, uptake in inflammation, 566*; in dogs, 527*
- Licensing**
- compliance tests and radiation safety procedures, 517*
- Limulus amoebocyte lysate test**
- cisternography agents, 809
 - test sensitivity, 552*
- Line spread function**
- determination, scintillation camera, 1200
 - high-count-rate positron imaging, 653
 - positron range effects, 649
 - transaxial positron tomography, 210
- Liquid scintillation counting**
- book review, 1091
 - continuous measurement of ^{14}C -substrate metabolism, 517*
 - ^3H , quench correction, 570*
 - vial design, 963
- Liver**
- ^{75}Br - and ^{85}Br -dimethoxyphenylisopropylamine, preparation, distribution, 243
 - ^{11}C -aminonitriles, distribution, in dogs, 582*
 - ^{14}C , albumin synthesis rate, radiation dose, 642
 - comparison of hepato-biliary agents, in baboons, 577*
 - disease, radiation dose estimates, MIRD, ^{198}Au , 173
 - hepatographic patterns in disease, rectal administration of ^{131}I , 802*
 - ^{123}I -rose bengal jaundice evaluation, 567*
 - ^{123}I -rose bengal, preparation, imaging, 629
 - lesion, ^{67}Ga -citrate uptake, 443
 - metastases from lung, alpha-fetoprotein levels, 1094*
 - normal, weight estimation, 314
 - radiation dose, ^{197}Hg -, ^{203}Hg -chlormerodrin, 1095
 - radiation dosimetry, radioiodides, MIRD, 857
 - radiation dosimetry, ^{201}Tl , 1089, 1090
 - size estimation, in rats, 381
 - subtraction from ^{67}Ga -citrate scans, 548*
 - ^{99m}Tc -iminodiacetic acid analog, distribution, in animals, 533*
 - ^{99m}Tc -minimicrosphere kit, 542*
 - ^{99m}Tc -S colloid, 108A
 - ^{99m}Tc -S colloid uptake, effect of injection site, in rats, 377
 - ^{99m}Tc -Schiff's bases, preparation, imaging, in animals, 520*
 - to-spleen ratio of ^{99m}Tc -S colloid, in cirrhosis, 802*
 - uptake, ^{131}I -diphenylhydantoin, effects of carrier, estrogen, 305
 - uptake mechanism, ^{99m}Tc -S colloid, ^{198}Au , in rats, 532*
- Liver, blood flow**
- effect of metastases, ^{113m}In -chloride, 533*
 - effective plasma flow, disease differentiation, 524*
 - hepatic artery-portal vein fistula, ^{99m}Tc -S colloid, 910
 - in hypersplenism, ^{99m}Tc -S colloid, 555*
 - neoplastic tumors, ^{99m}Tc -S colloid, 595
 - quantitative, ^{99m}Tc -S colloid, in dogs, 572*
 - ^{99m}Tc -S colloid, 71, 626
 - veno-occlusive disease, $^{99m}\text{TcO}_4^-$, 1130
- Liver imaging**
- abdominal tumor, ^{99m}Tc -S colloid, 853*
 - abscess, metastases differentiation, 250
 - ^{13}C -ethanol, in cats, 73
 - cancer, primary, ^{67}Ga -citrate, ^{99m}Tc -S colloid, 949
 - ectopic gallbladder effects, 1029
 - effect of splenectomy, ^{99m}Tc -S colloid, 194
 - focal defects, ^{99m}Tc -S colloid, 831, 896
 - Fresnel zone plate, ^{99m}Tc -S colloid, 183
 - ^{123}I -rose bengal, 629; in rabbits, 540*
 - in breast cancer, 545*
 - in hemangioendotheliomatosis, ^{99m}Tc -S colloid, 915
 - interpretation, 11
 - kala-azar, ^{99m}Tc -S colloid, 1128
 - large-field-of-view scintillation camera, 1158
 - lung uptake of ^{99m}Tc -S colloid, 188, 249, 250, 332, 439, 440, 542*, 1002; mechanism, 22
 - metastatic thyroid carcinoma, ^{131}I , ^{99m}Tc -S colloid, 669
 - refocused images, 546*, 548*
 - ^{99m}Tc -S colloid, clinical evaluation, 62, 450, 1204
 - veno-occlusive disease, ^{99m}Tc -S colloid, 626, 1130
- Liver scanning**
- benign tumor uptake of ^{67}Ga -citrate, 470
 - focal defects, ^{67}Ga -citrate, $^{113m}\text{InCl}_3$, ^{111}In -bleomycin, 583*
 - focal defects, porta hepatis region, ^{99m}Tc -S colloid, 1007
 - foramen of Morgagni hernia, ^{99m}Tc -S colloid, 261
 - hepatic artery traumatic aneurysm, ^{99m}Tc -S colloid, ^{99m}Tc -MAA, 1027
 - ^{131}I , thyroid carcinoma metastases, 919
 - ^{111}In -bleomycin, normal scan, 537*
 - in breast carcinoma, 802*
 - interpretation, Gamut approach, 1121
 - lung carcinoma staging, 538*
 - lymphoma, ^{67}Ga -citrate, 255
 - obstructive jaundice, 853*
 - pseudocyst, bile leakage, ^{131}I -bromsulphalein, ^{198}Au , 825
 - pseudotumor in acute hepatitis, ^{99m}Tc -S colloid, 799
- LSF** *see Line spread function*
- Lungs**
- ^{75}Br -dimethoxyphenylisopropylamine, preparation, distribution, 243
 - ^{11}C -aliphatic amines, uptake, in animals, 511*
 - ^{11}C -aminonitriles, distribution, in dogs, 582*
 - cancer, metastatic to liver, alpha-fetoprotein levels, 1094*
 - carcinoma staging, ^{99m}Tc , ^{67}Ga , 538*
 - ^{113}Ce -particle clearance, in dogs, 851*
 - function in mucopolysaccharidoses, ^{99m}Tc -S colloid, 541*
 - ^{67}Ga -citrate uptake, effect of contrast lymphangiography, 375

SUBJECT INDEX

- ¹³¹I-acetazolamide distribution**, in animals, 537*
pleural effusion, ^{87m}Sr secretion, 1208
pleural effusion, uptake of ^{99m}Tc-diphosphonate, 883
^{99m}Tc-S colloid retention, 188, 249, 250, 439, 440; in histiocytosis X, 332; in mucopolysaccharidoses, 542*, 1002; mechanism, 22
¹³³Xe, ¹²⁷Xe, ¹²⁵Xe, radiation dosimetry, 780
- Lungs, blood flow**
arteriovenous fistulas, ^{99m}Tc-microspheres, 328
arteriovenous malformation, ^{99m}TcO₄⁻, 180
cardiac shunt determination, ^{99m}Tc-microspheres, -MAA, ^{113m}In-Fe(OH)₃, 528*
pulmonary sequestration evaluation, 530*
systemic-pulmonic shunt assessment, ^{99m}Tc-MAA, in children, 528*
- Lung imaging**
carcinoma, ^{99m}Tc-polyphosphate uptake, 1021
cost-effectiveness, 550*
Fresnel zone plate, ^{99m}Tc-MAA, 183
hemangioendotheliomatosis, ^{99m}Tc-MAA, ¹³³Xe gas, 915
"hot spots", ^{99m}Tc-MAA, 241
large-field-of-view scintillation camera, 1158
liver-lung interface, ^{99m}Tc-MAA, 1027
multi-isotope studies, ^{99m}Tc-microspheres, ⁶⁷Ga, ¹⁰⁷Hg, 571*
particle dose effects, ^{99m}Tc-MAA, in dogs, 526*
pulmonary infarct, pneumonitis differentiation, ⁶⁷Ga, 551*
refocused images, 546*, 548*
-spleen interface, ^{99m}Tc-S colloid, -microspheres, 822
^{99m}Tc-gluconate for tumor, in children, 552*
^{99m}Tc-microspheres, statistics, 503*
tumor, ⁶⁷Co-bleomycin, 1058
ventilation/perfusion *see Lung, ventilation*
wide mediastinum, ^{99m}Tc-microspheres, 324
3D image processing system, 386
3D reconstruction, ⁶⁷Ga-microspheres, in dogs, 80
- Lung scanning**
combined with radionuclide venograms, 579*
interpretation, Gamut approach, 1121
lymphoma, ⁶⁷Ga-citrate, 255
pulmonary embolism diagnosis, 968*
^{99m}Tc-diphosphonate, metastatic osteosarcoma, 568*
- Lung ventilation**
cystic fibrosis, ¹³³Xe, 548*
inhalation injury, burn patients, ¹³³Xe washout, 547*
^{85m}Kr, 539*
large-field-of-view scintillation camera, 1158
obstructive airways disease, aerosol, 546*; aerosol, ¹³³Xe, 574*; ^{113m}In-aerosol, ^{99m}Tc-MAA, 574*
/perfusion, ⁶⁷Ga scanning, hilar tumors, 576*
/perfusion, pulmonary artery banding, ¹³³Xe, 577*
/perfusion, pulmonary embolism, 533*, 1017
/perfusion, ^{99m}Tc-microspheres crossover subtraction from ¹³³Xe, 533*
/perfusion, tetralogy of Fallot, 510*
/perfusion, Xe, diverging collimator, 552*
pulmonary embolism, 503*
radiation dose, ¹³³Xe, 580*
regional, in chronic obstructive disease, ¹³³Xe, 567*
tidal breathing, ¹³³Xe, 853*
¹³³Xe dose dispenser, 1197
¹³³Xe spirometer system, 551*
upper/lower airways relationship, ¹³³Xe, 570*
- Lymph nodes**
lymphoma, ⁶⁷Ga-citrate scanning, 255
mammary, drainage, ^{99m}Tc-Sb colloid, 526*
- Lymphocytes**
¹⁴C-carbohydrate metabolism, mitogen effects, 576*
⁶⁷Ga-, ^{113m}In-, ¹⁰⁷Hg-, labeling, 564*
^{99m}Tc-, labeling, distribution, in rabbits, 530*
- Macroaggregated albumin** *see Indium-113m; Iodine-131; albumin; Technetium-99m, macroaggregated albumin*
- Mammography**
compared to ¹¹¹In-bleomycin breast scanning, 578*
compared to ^{99m}Tc-polyphosphate imaging, 581*
- Mercury-197**
-adriamycin, -acetate, tumor uptake, in mice, 560*
-chloride, dual-isotope kidney studies, with ^{99m}Tc-DMSA, 571*
-chlormerodrin, brain tumor uptake, radiation dosimetry, in mice, 200
-chlormerodrin, kidney imaging in hemangioendotheliomatosis, 915
-chlormerodrin, radiation dosimetry, MIRD, 1095
-chlormerodrin, tumor imaging, 1212*
lymphocyte labeling, 564*
multi-isotope lung studies, ^{99m}Tc-microspheres, ⁶⁷Ga, 571*
- Mercury-203**
-chlormerodrin, kidney imaging, compared to ^{99m}Tc-complexes, 357
-chlormerodrin, radiation dosimetry, MIRD, 1095
-unsaturated fatty acid esters, preparation, distribution, in animals, 572*
- Microspheres**
see also Gallium-68; Iodine-125; Strontium-85; Technetium-99m, microspheres
radiolabeled, blood flow in skin flaps, in animals, 1212*
- MIRD**
radiation dose estimates, ¹⁹⁸Au, in liver disease, 173
radiation dose estimates, ¹⁰⁷Hg-, ²⁰³Hg-chlormerodrin, 1095
radiation dose estimates, ¹²³I-, ¹²⁴I-, ¹²⁵I-, ¹²⁶I-, ¹³⁰I-, ¹³¹I-, ¹³²I-iodides, 857
radiation dose estimates, ¹²³I-, ¹²⁴I-, ¹²⁶I-, ¹³⁰I-, ¹³¹I-rose Bengal, 1214
radiation dose estimates, ^{99m}Tc-S colloid in liver disease, 108A
- Model**
animal, species differences, 529*
compartmental, bone tumor uptake, 519*
compartmental, early thyroid kinetics, 517*
compartmental, subdural hematoma, ^{99m}TcO₄⁻ uptake, 571*
dog, adrenal cortical hyperplasia, 928
dog, myocardial infarct, 156, 569*, 573*, 582*
dog, thrombus, 521*
GI tract, radiation dosimetry, 853*
goat, myocardial infarct, 156
guinea pig, toad, lung uptake of liver colloid, 22
monkey, cerebral infarct, 514*
phantom, kidney blood flow, 576
rabbit, abscess, 583*
rabbit, thrombosis, 578*
rat, myocardial infarct, 523*, 525*
scintillation camera deadtime, 539*
tissue culture, mammalian cell, ^{99m}Tc-tetracycline uptake, 315
- Modulation transfer function**
collimators for myocardial imaging, 531*
scatter subtraction effects, 102
scintillation camera, determination, 1200
- Mössbauer**
spectroscopy, ¹⁵²Sm in tumor, in mice, 528*
- MTF** *see Modulation Transfer Function*
- Muscle**
blood flow, occlusive disease, ¹³³Xe, 1211*
^{99m}Tc-polyphosphate uptake, in polymyositis, 1125
- Neohydrin** *see Mercury-197; Mercury-203*
- Neutron activation analysis**
partial-body Ca, 116
total-body Ca by ³⁶Ar excretion, 672
total-body Ca in osteoporosis, 196
- Nitrogen-13**
-glutamine, -glutamic acid, -valine, myocardial uptake, species differences, 529*
positron range, 1174

- Nitrogen-13, ammonia**
 brain imaging, positron camera, 537*
 characteristics for myocardial imaging, 151
 heart imaging, in dogs, 429
 myocardial tomography, 521*
 myocardial uptake, species differences, 529*
 transaxial positron tomography, in dogs, 210
- Nomenclature**
 scans, 964
- Norepinephrine**
¹¹C-, characteristics for myocardial imaging, 151
- Nuclear Medicine Pioneer Citation, George V. Taplin, 504**
- Observer**
 liver image interpretation, 11
 optimum photoscan gray scale, 519*
 scan interpretation, Gamut approach, 1121
- Ovaries**
 ovulation monitoring, estrogen radioimmunoassay, 500*
 radiation dose, ¹⁰⁹Au, 173; ¹⁹⁷Hg-, ²⁰³Hg-chlormerodrin, 1095; radioiodides, 857; radioiodinated rose bengal, 1214; ^{99m}Tc-S colloid, 108A; ¹¹¹In-citrate, 769
- Oxygen-15**
¹H-¹⁶O, transaxial positron tomography, in dogs, 210
 -hemoglobin, myocardial oxygen consumption, in dogs, 551*
 LSF, 649
¹⁶O₂, brain imaging, positron camera, 537*
 positron range, 1174
- Pancreas**
 and liver scanning, obstructive jaundice, 853*
¹¹C-aminocyclopentanecarboxylic acid, preparation, 579*
¹⁴C-, ¹²³I-, ¹³¹I-diphenylhydantoin distribution, 775
 function, ⁷⁵Se-pancreozymin, 1093*
³H-putrescine uptake, in rats, 337
¹³¹I-chlorpropamide, distribution, in animals, 577*
 imaging, pseudocyst, ⁷⁵Se-selenomethionine, 326
 infected pseudocyst, ⁶⁷Ga-citrate scanning, 1132
 motilin radioimmunoassay, in dogs, 1094*
 scanning and ultrasound, 563*
 scanning, evaluation, 568*
⁷⁵Se-amino acids, imaging, 933
⁷⁵Se-selenomethionine dynamics in diabetes mellitus, 270
⁷⁵Se-selenomethionine scanning, 1090
^{99m}Tc-sulfonyleureas, preparation, distribution, in rats, 561*
 tumor, ⁹⁰Co-bleomycin, ⁷⁵Se-selenomethionine imaging, 533*
- Parasite**
 kala-azar, liver and spleen imaging, 1128
 trichinosis, radioimmunoassay, 501*
- Parathormone** see *Parathyroid*
- Parathyroid**
 hormone, ³²P therapy for bone tumor, 519*
 hyper-, ^{99m}Tc-pyrophosphate bone imaging and kinetics, 33, 543*
 pseudohyper-, ^{99m}Tc-pyrophosphate bone imaging, 543*
- Pediatrics**
 bone imaging of femoral metaphyseal irregularities, 521*
 bone scanning, disease differentiation, 547*
 brain imaging, dynamic/static, 1210*
 brain imaging, rapid sequence, ^{99m}Tc, 511*
 cardiac shunt evaluation, ^{99m}TcO₄⁻, 511*
 cisternography, ¹³¹I-HSA, 502*
 cisternography in achondroplasia, 969*
 effective thyroxine ratio measurement, 955
⁶⁷Ga-citrate scan, plague, 1031
⁶⁷Ga-citrate tumor scanning, 533*
 hip imaging, pinhole collimator, 512*
¹¹¹In-bleomycin imaging, 554*
 kidney imaging, ^{99m}Tc-DMSA, 28
 liver-spleen imaging in abdominal trauma, 525*
 pulmonary arteriovenous malformation imaging, ^{99m}TcO₄⁻, 180; ^{99m}Tc-microspheres, 328
- pulmonary sequestration evaluation, 530*
 splenogonadal fusion, ^{99m}Tc-S scan, 922
 systemic-pulmonic shunt assessment, ^{99m}Tc-MAA, 528*
^{99m}Tc-HSA ventriculography in hydronephrosis, 581*
^{99m}Tc-pyrophosphate scans in calcinosis universalis of dermatomyositis, 568*
 unilateral, ventricular reflux, ¹³¹I-HSA, 716
 ventilation in cystic fibrosis, ¹³³Xe, 548*
 ventilation, perfusion in pulmonary artery banding, ¹³³Xe, 577*
 ventilation/perfusion in tetralogy of Fallot, 510*
 vesicoureteral reflux, radionuclide cystography, 522*
- Peritoneal cavity**
^{99m}Tc-S colloid distribution before ³²P-chromic phosphate therapy, 319
- Personnel**
 cost, relative weights, 348
- Phagocytes**
^{99m}Tc-S colloid labeling, 5
- Phantom**
 bar, scintillation camera, 441, 531*
 kidney blood flow, 576*
 quality control programs for imaging, 957
- Phosphorus-32**
 bone tumor therapy, with parathormone, 519*
 chromatogram imaging, 553*
³²P-chromic phosphate, synovectomy, 442
³²P-diphosphonate for therapy, distribution, in rats, 532*
 eye tumor imaging, Cerenkov effect, 516*
 metabolism, in rats, 1106
³²P-pyrophosphate, bone uptake mechanisms, 40
³²P-pyrophosphate, myocardial infarct uptake mechanism, 525*
 radiation dosimetry, 502*
³²RBC, preparation, survival, in gerbils, 682
 red cell volume, normal, 46, 961, 962
 tumor imaging, 1212*
- Photon absorptiometry**
 bone mineral content, 196, 891
- Physician's Desk Reference**
 book review, 499
- Pituitary gland**
¹⁴C-ascorbic acid uptake, in dogs, 551*
- Placenta**
 blood flow distribution, ^{99m}Tc-microspheres, 539*
 blood flow, ¹³³Xe, 968*
⁶⁷Ga-citrate transfer, in animals, 581*
¹¹¹In uptake, in animals, 544*
- Plasma volume** see *Blood*
- Plasminogen**
¹²³I-, tumor uptake, in mice, 560*
- Platinum-195m**
 bleomycin complexes, tumor uptake, distribution, in mice, 545*
- Polyphosphate** see *Technetium-99m, polyphosphate*
- Positron**
see also Camera, positron
 range effect on spatial resolution, 649
 ranges, ¹¹C, ¹³N, ¹⁸O, ¹⁹F, ⁶⁷Ga, ⁸²Rb, 1174
- Potassium-43**
 characteristics for myocardial imaging, 151
 collimator for myocardial imaging, 531*
 myocardial blood flow, effect on infarct uptake, in dogs, 558*
 myocardial imaging, in dogs, 553*
 myocardial infarct uptake and CPK levels, in dogs, 559*
 myocardial perfusion, in animals, 851*
 myocardial scanning, coronary artery disease, 575*
 myocardium, coincidence and noncoincidence counting, in dogs, 658
- radiation dosimetry, 527*, 1070
 scanning system parameters, 562*

- Probe**
 mobile system for left ventricular ejection fraction, 289, 531*
 ultrasound guidance system, 562*
- Prostate**
 cancer, ^{99m}Tc-diphosphonate bone scanning, 579*
³H- and ¹¹C-putrescine distribution, in rats, 337
 steroid structural requirements, 570*
^{65m}Zn imaging, 495, 496
- Protein**
 binding, ⁷⁵Se, 501*
¹¹C labeling, 425
- Pyrogens**
 Limulus test, cisternography agents, 809
 Limulus test sensitivity, 552*
- Pyrophosphate** see *Phosphorous-32; Technetium-99m, pyrophosphate*
- Quality control**
 chromatographic strip counter, 225
 chromatography of ^{99m}Tc-diphosphonates, 584*
 comparison of ⁶⁷Ga-citrate preparations, 580*
 fibrinogen, single donor, 562*
 Limulus test, cisternography agents, 809
 Limulus test sensitivity, 552*
 programs for imaging, 957
 radioassay of ¹²³I, 952
 radiometric sterility assay, 798
 scintillation cameras, 564*; bar phantom, 531*; field flood, 513*
 tests and procedures for medical byproduct material licenses, 517*
¹³³Xe clinical laboratory contamination, 804*
 workshops, 550*
- Quinoline**
 -analogs, ¹²³I, distribution, in mice, 530*
- Radiation damage**
^{99m}Tc, mouse fetus, newborn and progeny, 544*
- Radiation dosimetry**
¹⁹⁸Au in liver disease, MIRD, 173
²⁰⁴Bi-, ²⁰⁸Bi-citrate, 515*
 bone agents, 502*
 brain tumor agents, in mice, 200
¹⁴C-albumin synthesis measurement test, 642
⁵⁷Co-bleomycin, 550*, 1058
 DTPA cisternography agents, 101, 570*, 1177
⁶⁷Ga-citrate, 550*
⁶⁷Ga-citrate, placental transfer, in animals, 581*
 gastrointestinal tract model, 853*
¹⁹⁷Hg-, ²⁰³Hg-chloromerodrin, MIRD, 1095
¹²³I, ¹²⁴I, ¹²⁵I, ¹²⁶I, ¹²⁷I, ¹²⁸I, ¹²⁹I, ¹³¹I, as sodium iodide, MIRD, 857
¹²³I, ¹²⁴I, ¹²⁶I, ¹²⁸I, ¹³¹I-Irose bengal, MIRD, 1214
¹²³I-bleomycin, 550*
¹³¹I-cholesterol, 247, 248
¹²³I-diphenylhydantoin for pancreas, 775
¹¹¹In-bleomycin, 550*, 554*, 854*
¹¹¹In-citrate bone marrow imaging, dose to gonads, 769
 myocardial agents, 151, 527*, 553*, 1070
 normalization of concentration data, 247, 248, 958
⁷⁵Se-selenite, 846
 specific absorbed fraction computation, 492
 specific activity effects, 541*
^{99m}Tc-bleomycin, 414
^{99m}Tc-DMSA kidney imaging, 28, 357
^{99m}Tc kidney agents, 357
^{99m}Tc-S colloid in liver disease, MIRD, 108A
²⁰⁷Tl, 151, 527*, 553*, 1070, 1089, 1090
 Xe and Kr radionuclides, 143
¹³³Xe inhalation, dose to lungs, 580*
¹³³Xe, ¹²⁷Xe, ¹²⁸Xe for lung studies, 780
¹⁶⁶Yb-DTPA, intrathecal, 570*; to brain, 101
- Radiation safety**
 procedures, medical byproduct material licenses, 517*
- Radiation therapy**
 effect on bone uptake of ^{99m}Tc-polyporphosphate, 501*
 effect on salivary gland uptake of ⁶⁷Ga-citrate, 514*
 splenic response, ^{99m}Tc-S colloid, 123
- Radioassay**
 human chorionic gonadotrophin, 500*, 501*
¹²³I, small samples, 952
 total serum Fe binding capacity, 583*
 TSH, T_s in pernicious anemia, 549*
 T_s, 514*, 662
 T_s, T, TSH following thyroid therapy, 568*
- Radioimmunoassay**
 alpha-fetoprotein, 805*, 1094*
 book review, 498
 carcinoembryonic antigen, 1094*; in ulcerative proctocolitis, 1094*; in metastatic breast carcinoma, 579*
 computer system, 559*
 digoxin, 559*; post mortem, 1212*
 estrogen, 500*
 gastrin, 805*
 gentamicin, 968*
³H-, quench correction, 570*
 hepatitis B, ¹²³I, 513*
 human chorionic gonadotrophin, 500*, 501*
 liquid scintillation vial design, 963
 motilin, in dogs, 1094*
 prostaglandins in mouse neuroblastoma, 83
 trichinosis diagnosis, 501*
 vitamin B₁₂, toadfish serum binding, 541*
- Radiometric assay**
¹⁴C-DOPA, blood metabolism, 576*
 equipment, 517*
 lymphocyte metabolism, 576*
^M. lepraeumrium metabolism, 518*
^M. tuberculosis metabolism, 518*, 1189
 sterility, 798
 streptococcus Group A, 1085
- Radium-226**
 radiation dosimetry, 502*
- Record keeping**
 computer system, 275, 575*
- Red blood cell**
see also Technetium-99m, red blood cells
⁵¹Cr-, ³²P-, survival, in gerbils, 682
 effect of ¹³¹I thyroid therapy, 963, 964
⁵⁹Fe-, bone kinetics, in rats, 40
¹⁰⁶Ru-ruthenium red for spleen, preparation, distribution, in rats, 795
^{99m}Tc labeling in vivo, 518*, 541*
^{99m}Tc-pyrophosphate labeling, 435
 volume, normal, 46, 961, 962
- Resolution**
see also FWHM; Line spread function; Modulation transfer function
 scintillation cameras, 1206
 semiconductor camera, 53
 spatial, temporal, energy, ring detector transaxial tomograph, 1166
- Rose bengal**
see also Iodine-123; Iodine-131
 myocardial infarct uptake, in rats, 523*
 radioiodinated, radiation dosimetry, MIRD, 1214
- Rubidium-81**
 characteristics for myocardial imaging, 151
 myocardial imaging, in dogs, 553*
 myocardial perfusion during stress, 515*
 myocardial perfusion, in animals, 851*
 myocardium, coincidence and noncoincidence counting, in dogs, 658
 parameters for scanning systems, 562*
 radiation dosimetry, 527*, 1070
- Rubidium-82**
 characteristics for myocardial imaging, 151
 generator, 300, 429

- heart imaging, in dogs, 429
positron range, 1174
- Ruthenium-103**
-ruthenium-red-RBC for spleen, preparation, distribution, in rats, 795
- Salivary glands**
"Ga-citrate, after radiation therapy, 514*
- Samarium-153**
tumor uptake, in mice, 528*
- Scalp**
tumor, on cerebral flow study, 462
- Scanner, fluorescent**, 530*
- Scanner, rectilinear**
comparison of ⁴²K and ⁸²Rb for heart studies, 562*
computer image correction, 523*
isocount scanning and multilevel analysis, 938
modification, ⁶⁷Ga scans, 1192
optimum gray scale, 519*
whole-body, moving bed, 570*
 4×5 -in. film, 560*
- Scanning**
see also specific organ
interpretation, Gamut approach, 1121
omnidirectional, image processing, 685
- Scatter**
computer image correction, 523*
dual-window ^{99m}Tc imaging, 513*
fraction measurement, ^{99m}Tc, camera, 535*
Fresnel zone plate imaging, 183
subtraction, effect on image contrast, 102
- Schilling test**
consecutive day, 495
- Selenium-75**
-pancreozymin, pancreas function test, 1093*
plasma protein binding, 501*
-selenite, brain scanning, 331
-selenite, radiation dosimetry, 846
-selenocholesterol, adrenal gland uptake, in animals, 565*
-selenocysteine derivatives, pancreas imaging, 933
- Selenium-75, selenomethionine**
-D, pancreas imaging, 933
pancreas dynamics in diabetes mellitus, 270
pancreas imaging, pseudocyst, 326; tumor, 533*
pancreas scanning, 1090
tumor imaging, 1212*
tumor uptake and viability, in rats, 532*
- Skin**
flap, blood flow, radiolabeled microspheres, in dogs, 1212*
- Skull**
Paget's disease, ^{99m}TcO₄⁻ and -polyphosphate imaging, 619
- Sodium-22**
radiation dosimetry, 502*
- Species**
differences, effect of iodination level of fibrinogen, 534*
differences, myocardial uptake, 529*
- Spleen**
delayed rupture, ^{99m}Tc-S colloid imaging, 912
encasement by tumor, ^{99m}Tc-S colloid image, 718
imaging, anatomic variant artifact, 99, 100
imaging in hemangiopericytoma, 915
¹¹¹In uptake, 1204, 1205
kala-azar, ^{99m}Tc-S colloid, "Ga-citrate imaging, 1128
-lung interface, ^{99m}Tc-S colloid, -microspheres, imaging, 822
perfusion, in hypersplenism, ^{99m}Tc-S colloid, 555*
response to radiation therapy, ^{99m}Tc-S colloid, 123
¹⁰³Ru-ruthenium red-RBC, preparation, distribution, in rats, 795
scan, splenogonadal fusion, ^{99m}Tc-S colloid, 922
scanning, focal defects, ⁶⁷Ga-citrate, ^{113m}InCl₃, ¹¹¹In-bleomycin, 583*
scanning, Hodgkin's disease, ^{99m}Tc-S colloid, 457, 1212*
- small, etiology, pathogenesis, 571*
splenectomy, effect of ^{99m}Tc-S colloid image, 194
^{99m}Tc-S colloid uptake in mucopolysaccharidoses, 542*, 1002
-to-liver ratio, ^{99m}Tc-S colloid uptake, in cirrhosis, 802*
^{99m}Tc-RBC imaging, 512*
- Sterility** *see Quality Control*
- Stomach** *see Gastrointestinal tract*
- Streptokinase** *see Iodine-123; Iodine-125; Iodine-131; Technetium-99m*
- Strontium-82**
-⁸²Rb generator, 300, 429
- Strontium-85**
bone imaging, 503*
bone scanning in malignancy, 559*
LSF, 649
-microspheres, bone blood flow, in rats, 40
-microspheres, myocardial perfusion, in animals, 851*
-nitrate, scan in dermatomyositis, 467
- Strontium-87m**
bone imaging, chemotherapy response monitoring, 191
bone scanning in Hodgkin's disease, 852*
-citrate, secretion into serous fluids, 1208
- Strontium-89**
in ^{99m}TcO₄⁻ eluate, 571*
- Strontium-90**
in ^{99m}TcO₄⁻ eluate, 571*
radiation dosimetry, 502*
- Sulfur-35**
-cyclamate metabolism, in rats, 970*
-dopamine analog for adrenal glands, distribution, in rats, 1147
- Synovium** *see Joint*
- Technetium-99**
carrier, ^{99m}Tc-gluconate and -diphosphonate distribution, in rats, 478
in ^{99m}TcO₄⁻ generator eluate, 570*, 639
- Technetium-99m**
-bleomycin, benign process uptake, 414
-bleomycin, ^{99m}Tc-pyrophosphate labeling, 435
-bleomycin, tumor imaging, 414, 503*, 551*
-bleomycin, tumor uptake, compared to ³H- and ⁶⁷Cu-bleomycin, in rats, 127
bone agents, current literature, 502*
-calcein blue, distribution, kidney uptake, in rabbits, 357
-caseidin, distribution, kidney uptake, in rabbits, 357
-citrate, brain imaging, 526*
-citrate, tumor uptake, in mice, 534*
collecting system evaluation in renal transplants, 557*
collimator for myocardial imaging, 531*
-colloid aerosol, imaging obstructive pulmonary disease, 546*
-Cu-HEDSPA for bone, preparation, distribution, in animals, 520*
detection efficiency, single and annihilation photon systems, 210
-dihydroxyacetone acid, myocardial infarct uptake, in rats, 523*
-diphosphonate, *see Technetium-99m, diphosphonate*
-DMSA, *see Technetium-99m, dimercaptosuccinic acid*
-DTPA *see Technetium-99m, DTPA*
-Fe ascorbate, kidney imaging, 357
-Fe-ascorbic acid and -DTPA complex, brain tumor uptake, radiation dosimetry, in mice, 200
-Fe-ascorbic acid, kidney autoradiography, in rabbits, 554*
-Fe hydroxide, perfusion in pulmonary embolism, 503*
fibrin, for thrombus, 521*
-fibrinogen, electrolytic preparation, chemistry, 343, 534*
-glucoheptonate, *see Technetium-99m, glucoheptonate*
-gluconate, distribution, kidney uptake, in rabbits, 357
-gluconate, effect of ^{99m}Tc on distribution, in rats, 478
-gluconate, tumor imaging, in children, 552*
-hepatobiliary agents, comparison, in baboons, 577*

- HSA, *see Technetium-99m, albumin*
- image intensifier camera response, 541*
- imidodiphosphate, bone imaging, 1137
- imidodiphosphate for bone, distribution, in animals, 574*
- iminodiacetic acid analog for hepatobiliary imaging, distribution, in animals, 533*
- iminodiacetic acid complexes, preparation, distribution, in animals, 546*
- inulin, distribution, kidney uptake, in rabbits, 357
- lactobionate, distribution, kidney uptake, in rabbits, 357
- leukocytes, labeling, 530*
- leukocytes, abscess and inflammation uptake, in dogs, 527*
- lymphocytes, preparation, distribution, in rabbits, 530*
- MAA, *see Technetium-99m, macroaggregated albumin*
- mannitol, distribution, kidney uptake, in rabbits, 357
- mercaptoisobutyric acid, compared to ^{131}I -rose bengal, 686, 687
- mercaptoisobutyric acid, myocardial infarct uptake, in rats, 523*
- multidentate phosphates for bone, distribution, in animals, 540*
- penicillamine, kidney uptake, in rats, 531*
- penicillamine, myocardial infarct uptake, in rats, 523*
- pertechnetate, *see Technetium-99m, pertechnetate*
- phosphate compounds, *see also Technetium-99m, diphosphonate; Technetium-99m, polyphosphate; Technetium-99m, pyrophosphate*
- phosphate compounds, bone scanning in lymphoma, 555*; in breast cancer, 532*
- phosphate compounds, distribution comparisons, in animals, 1137
- phosphate compounds, soft-tissue tumor imaging, 551*, 1087
- photopeak plus backscatter imaging, 513*
- polyamino acid-vesicle survival, in mice, 483
- polyphosphate, *see Technetium-99m, polyphosphate*
- polystyrene-TETA complex, gastric emptying, 575*
- pyridoxylidene-glutamate, gallbladder imaging, 543*, 728
- pyridoxylidene-glutamate, preparation, gallbladder imaging, in animals, 720
- pyrophosphate, *see Technetium-99m, pyrophosphate*
- radiation damage, mouse and progeny, 544*
- RBC, *see Technetium-99m, red blood cells*
- resolution indices, scintillation camera images, 228
- Sb colloid, mammary lymph node drainage, 526*
- scatter fraction measurement, 535*
- Schiff's bases, preparation, hepatobiliary imaging, in animals, 520*
- Sn(II) reduced, effect on $^{99\text{m}}\text{TcO}_4^-$ distribution, 518, 541*, 579*
- Sn(II) reduced, valence state, 555*
- specific absorbed fraction, computation, 492
- streptokinase, preparation, testing, 474, 557*
- sulfonylureas, preparation, distribution, in rats, 561*
- sulfur colloid, *see Technetium-99m, sulfur colloid*
- tetracycline, *see Technetium-99m, tetracycline*
- thio-glycerol, myocardial infarct uptake, in rats, 523*
- thiomalic acid for kidney, preparation, distribution, in rats, 531*
- thymocytes, distribution, in mice, 633
- transferrin, tumor uptake and distribution, in mice, 560*
- trifluoroacetylacetone, distribution, in animals, 561*
- trimetaphosphate for bone, distribution, in animals, 1043
- vesicles, preparation, distribution, in animals, 488
- Technetium-99m, albumin**
 - arthroscintigraphy, popliteal cyst, 580*
 - cisternography, aseptic meningitis, 809
 - distribution, kidney uptake, in rabbits, 357
 - ECG gated heart imaging, 95, 368, 865
 - electrolytic preparation, chemistry, 534*
 - labeling, role of sulfhydryl group, 573*
 - left ventricular ejection fraction, 527*
 - left ventricular function, 386
 - pericardial effusion imaging, 969*
 - tumor uptake and distribution, in mice, 560*
 - ventriculography, hydronephrosis, 581*
- Technetium-99m, dimercaptosuccinic acid**
 - dual-isotope kidney studies, with $^{197}\text{HgCl}_2$, 571*
 - kidney autoradiography, in rabbits, 554*
 - kidney imaging, 28, 357
 - kidney uptake compared to other agents, in rats, 531*
 - myocardial infarct imaging, in dogs, 582*
 - myocardial infarct uptake, in rats, 523*
- Technetium-99m, diphosphonate**
 - amyloid uptake, 238
 - bone graft and soft-tissue imaging, in dogs, 563*
 - bone imaging, compared to other agents, 744, 803*
 - bone imaging, kinetics, 744
 - bone imaging, metastatic tumor, 986
 - bone imaging, renal transplant, 538*
 - bone imaging rhinocerebral mucormycosis, 925
 - bone scanning, avascular necrosis, joint disease, 574*
 - bone scanning in breast carcinoma, 529*
 - bone scanning in malignant melanoma and prostate cancer, 579*
 - bone scanning in osteosarcoma, 423
 - bone scanning in Paget's disease, 569*
 - bone scanning, after total hip replacement, 522*
 - bone scanning, solitary lesion, 522*
 - brain imaging, 526*, 705
 - chromatographic evaluation, 584*, 1087, 1088
 - compared to other bone agents, in animals, 1137
 - jaw lesion imaging, 511*
 - kidney activity in Paget's disease, 582*
 - kidney images on bone study, 1109
 - kinetics, in man, 744, 886
 - methylene-, compared to other agents for bone imaging, 744
 - methylene-, distribution, in animals, 1137
 - myocardial infarct, tomography, 581*
 - myocardial infarct uptake, in animals, 132, 523*, 975
 - pleural effusion uptake, 883
 - soft-tissue tumor uptake, 536*, 568*
 - soft-tissue uptake in Fe-dextran injection sites, 577*
 - soft-tissue uptake, in rats, 58
 - soft-tissue uptake in renal failure, 515*
 - $^{99\text{mTc}}$ effect on distribution, in rats, 478
 - toxicity, 444
 - tumor detection, image subtraction, ^{67}Ga -citrate, 523*
 - uptake mechanism, enzymatic, 352
- Technetium-99m, DTPA**
 - brain imaging, 320, 536*, 564*, 868
 - brain tumor uptake, radiation dosimetry, in mice, 200
 - cisternography, spinal fluid leak, 616
 - combined cerebral death and kidney function, 538*
 - CSF drainage, in rabbits, 539*
 - kidney imaging, 234, 357, 525*, 947, 1158
 - kidney transplant, ERPF, 1115
 - kidney uptake, in animals, 531*, 554*
 - radiation dosimetry, cisternography, 1177
 - ureteral fistula imaging, 612
- Technetium-99m, glucoheptonate**
 - brain imaging, 580*
 - kidney autoradiography, in rabbits, 554*
 - kidney imaging, 357
 - kidney uptake, in rats, 531*
 - myocardial infarct imaging, 563*, 975; in dogs, 582*
 - myocardial infarct tomography, 581*
 - myocardial infarct uptake, in animals, 875, 975
 - tumor uptake and viability, in rats, 532*
- Technetium-99m, macroaggregated albumin**
 - cardiac shunt determination, 528*
 - liver-lung interface, 1027
 - lung, Fresnel zone plate imaging, 183
 - lung image "hot spots", 241
 - lung image in hemangiendotheliomatosis, 915

- lung perfusion in obstructive airways disease, 574*
- lung perfusion in tetralogy of Fallot, 510*
- myocardial infarct imaging, Fresnel zone plate, in dogs, 183
- myocardial perfusion, 851*
- particle dose effects, in dogs, 526*
- pericardial perfusion imaging, 969*
- systemic-pulmonic shunt assessment, in children, 528*
- tumor detection, bloodflow study, 472
- venography, in dogs, 563*
- Technetium-99m, microspheres**
- anaphylactoid reaction, 236
 - arteriovenous shunting in a hypernephroma, 569*
 - blood flow, hip, pseudoarthrosis, 167
 - cardiac shunt determination, 528*
 - CSF drainage, in rabbits, 539*
 - leukocytes, preparation, inflammation uptake, in animals, 527*
 - lung image, lung-spleen interface, 822
 - lung image, wide mediastinum, 324
 - lung imaging, arteriovenous fistulas, 328
 - lung imaging, statistics, 503*
 - lung perfusion, in pulmonary embolism, 533*, 1017
 - mini-, kit, 542*
 - multi-isotope lung studies, ¹⁷Hg, ⁶⁷Ga, 571*
 - myocardial perfusion during stress, 510*
 - myocardial tomography, in dogs, 568*
 - placental blood flow distribution, 539*
 - tumor detection, image subtraction, ⁶⁷Ga-citrate, 523*
 - venography, 579*, 993
- Technetium-99m, pertechnetate**
- angiogram, dual-channel technique, 789
 - angiogram, persistent left superior vena cava, 469
 - bone uptake mechanisms, in rats, 40
 - brain imaging, compared to other agents, 526*, 564*, 705
 - brain imaging, computer correction, 523*
 - brain imaging, "doughnut" sign, 432
 - brain imaging, glycopyrrolate blocking dose, 819
 - brain imaging, in disease, 573*, 619, 833, 915
 - brain imaging, rapid sequence, in children, 511*
 - brain perfusion, anomalous venous return, 573*, 622
 - brain perfusion, cerebral vessel displacement, 86
 - brain perfusion, hemorrhage, 459
 - brain perfusion, quantitative, 525*
 - brain perfusion, scalp flow elimination, 679
 - brain scan, blood level effects, 553*, 676
 - brain scanning, cerebral infarct, 1210*
 - brain scanning in infection, 580*
 - brain scanning, tumor therapy response, 1210*
 - brain, subdural hematoma uptake, compartmental model, 571*
 - brain tumor, CVD differentiation, 549*, 854*
 - brain tumor uptake, radiation dosimetry, in mice, 200
 - breast imaging, 293
 - cardiac shunt evaluation, in children, 511*
 - cisternography artifact, 434
 - CSF drainage, in rabbits, 539*
 - effect of previously administered Sn(II), 541*, 579*, 690
 - gastric mucosa secretion, in dogs, 535*
 - generator eluate, ⁸⁵Sr, ⁸⁵Sr contamination, 571*
 - joint imaging in periarthritis nodosa, 804*
 - kidney transplant monitoring, 529*
 - lacrimal drainage, 605
 - liver blood flow, veno-occlusive disease, 1130
 - Meckel's diverticulum diagnosis, 515*
 - pulmonary arteriovenous malformation imaging, 180
 - secretion into isolated bowel loops, in rats, 574*
 - secretion site, in stomach, 1204
 - sinusitis concentration, 89
 - Sn(II) reduction, valence state, 555*
 - ⁹⁹Tc carrier, 543*, 570*, 639
 - thyroid, early kinetics, 517*
 - thyroid imaging, 512*, 563*, 918
 - tumor uptake and viability, in rats, 532*
- Technetium-99m, polyphosphate**
- bone imaging, compared to other agents, 744, 803*
 - bone imaging, Fresnel zone plate, 183
 - bone imaging, kinetics, 744
 - bone imaging, simultaneous kidney images, 1109
 - bone scanning, cold lesions, 1013
 - bone scanning in arthritis, 510*; Hodgkin's disease, 852*; osteosarcoma, 423
 - bone scanning, metastases, 1211*
 - bone scanning, solitary lesion, 522*
 - bone uptake, radiation therapy effect, 501*
 - bone uptake, resorbing, in rats, 528*
 - breast mass imaging, 581*
 - compared to other bone agents, distribution, in animals, 1137
 - femoral scanning in cup arthroplasty, 565*
 - jaw lesion imaging, 511*
 - kidney sign on bone scan, 454, 602
 - kinetics, compared to ¹⁸F, 688, 689
 - kinetics, whole-body, 109, 958
 - lung tumor uptake, 1021
 - muscle uptake in polymyositis, 1125
 - myocardial infarct imaging, 518*, 851*
 - myocardial infarct uptake, in dogs, 132
 - secretion into serous fluids, 1208
 - soft-tissue scans, carcinosis universalis of dermatomyositis, 568*
 - soft-tissue uptake in renal failure, 515*
 - tumor uptake and viability, in rats, 532*
- Technetium-99m, pyrophosphate**
- bleomycin and red blood cell labeling, 435
 - bone imaging, compared to other agents, 744, 803*
 - bone imaging, in metabolic disease, 33, 543*
 - bone imaging, in sacro-iliac disease, 545*
 - bone scan, optimal time of study, 879
 - bone scanning, in malignancy, 559*, 1211*
 - bone scanning, in trauma, 538*
 - bone tumor imaging, 503*
 - bone uptake mechanisms, in rats, 40
 - bone uptake parameters, 520*
 - brain tumor, CVD differentiation, 549*
 - breast lesion uptake, 536*
 - compared to other bone agents, distribution, in animals, 1137
 - interference with ^{99m}TcO₄⁻ brain imaging, 518*
 - kidney images on bone study, 161, 1109
 - myocardial infarct imaging, 518*, 521*, 556*; in dogs, 582*
 - myocardial infarct quantitation, in animals, 573*, 568*
 - myocardial infarct tomography, 581*
 - myocardial infarct uptake and CPK levels, in dogs, 559*
 - myocardial infarct uptake, effect of blood flow, in dogs, 558*
 - myocardial infarct uptake, in animals, 132, 523*, 548*
 - myocardial infarct uptake, mechanism, 525*
 - myocardial infarct uptake rate, 512*
 - myocardial uptake, 944
 - soft-tissue uptake, in dermatomyositis, 467
 - soft-tissue uptake, in renal failure, 515*
 - tumor uptake and viability, in rats, 532*
 - whole-body kinetics, 109
- Technetium-99m, red blood cells**
- blood level effect on brain scans, 676
 - clinical use evaluation, 512*
 - ECG gated left ventricular blood flow, 865
 - electrolytic preparation, 533*
 - in vivo labeling, 518*, 541*
 - kit, 570*
 - local cerebral blood volume, 1092*
 - preparation, in vivo stability, 564*
 - radiometric sterility testing, 798
- Technetium-99m, sulfur colloid**
- bone marrow scanning, avascular necrosis, joint disease,

SUBJECT INDEX

- 574*; in malignancy, 559*; nonhematologic disease, 535*
- bone marrow scanning, compared to ^{111}In and ^{59}Fe , 66
- bone marrow scanning, effect of cellularity, 535*
- chromatography, paper strip counter, 225
- CSF drainage, in rabbits, 539*
- gastroesophageal reflux quantitation, 547*
- image subtraction, ^{67}Ga -citrate tumor detection, 523*, 548*
- kidney transplant monitoring, 529*
- kidney uptake mechanism, 709
- leukocytes, inflammation uptake, 566*
- leukocytes, labeling, inflammation uptake, in dogs, 527*
- liver and spleen imaging, 525*, 915, 1128
- liver and spleen perfusion in hypersplenism, 555*
- liver blood flow, 71, 595, 626, 910
- liver blood flow, quantitative, in dogs, 572*
- liver-heart imaging, 896
- liver imaging, accuracy, 62, 450, 1204
- liver imaging, benign disease, 831, 1029, 1130
- liver imaging, Fresnel zone plate, 183
- liver imaging, malignant disease, 669, 853*, 949
- liver imaging, splenectomy effect, 194
- liver scanning, focal defects, 1007; foramen of Morgagni hernia, 261; hepatic artery aneurysm, 1027; pseudotumor, 799
- liver size estimation, in rats, 380
- liver uptake, effect of injection site, in rats, 377
- liver uptake, mechanism, in rats, 532*
- lung retention, 188, 249, 250, 439, 440
- lung scan, histiocytosis X, 332
- peritoneal cavity distribution, pre- ^{32}P -chromic phosphate therapy, 318
- phagocyte labeling, 5
- RES function in mucopolysaccharidoses, 542*, 1002
- sizing, 251
- spleen imaging, hemangioendotheliomatosis, 915; Hodgkin's disease, 457; tumor encasement, 718
- spleen imaging, radiotherapy effects, 123
- spleen/liver ratio in cirrhosis, 802*
- spleen-lung interface evaluation, 822
- splenogonadal fusion, 922
- vertebral compression fracture uptake, 93
- Technetium-99m, tetracycline**
- mammalian cell autoradiography, effect of viability, 315
- myocardial infarct imaging, in dogs, 582*
- myocardial infarct uptake, in animals, 523*, 975, 1144; bloodflow effect, 558*
- myocardial uptake mechanism, 525*
- tumor uptake, viability, in rats, 532*
- Telephone**
- image transmission, 523*, 542*, 549*
- Testes**
- radiation dose, ^{196}Au colloid, 173; ^{111}In -citrate, 769; ^{197}Hg - ^{203}Hg -chlormerodrin, 1095; $^{99m}\text{Tc-S}$ colloid, 108A; radioiodides, 857; radioiodinated rose bengal, 1214
- splenogonadal fusion, $^{99m}\text{Tc-S}$ scan, 922
- Testosterone**
- analogs for prostate, in rats, 570*
- Tetracycline**
- see also Iodine-131; Technetium-99m, tetracycline*
- ^3H , myocardial infarct uptake mechanism, 525*
- Thallium-199**
- characteristics for myocardial imaging, 151
- Thallium-201**
- collimator for myocardial imaging, 531*
- distribution, in animals, 156
- distribution, myocardial imaging, 513*, 565*
- intestinal concentration, 545*
- ionophores, for heart imaging, distribution, in mice, 567*
- myocardial imaging, in dogs, 539*, 553*
- myocardial perfusion, in animals, 851*
- preparation, nuclear parameters, 151
- radiation dosimetry, 527*, 1070, 1089, 1090
- Therapy**
- see also Chemotherapy; Radiation therapy*
- ^{198}Au , synovium, 100
- ^{123}I -iododeoxyuridine for tumor, in mice, 516*
- ^{131}I , effect on thyroid function, 568*
- ^{131}I -thyroid, effect on RBC, 963, 964
- ^{131}I , thyroid, low dose, 549*, 572*
- Na-EHDP, Paget's disease, 569*
- ^{32}P -chromic phosphate synovectomy, 442
- ^{32}P -chromic phosphate, $^{99m}\text{Tc-S}$ loculation, 318
- ^{32}P -diphosphonate distribution, in rats, 532*
- ^{32}P , parathormone, bone tumors, 519*
- Thermography**
- cold thyroid nodules, 536*
- venous thrombosis, 438, 439, 566*
- Thorax**
- ^{111}In -bleomycin tumor imaging, 854*
- Thrombus**
- and cyst differentiation, $^{99m}\text{Tc-HSA}$ arthroscintigraphy, 580*
- animal model, 578*
- coronary artery, ^{123}I -fibrinogen image, 804*
- ^{123}I -fibrinogen imaging, 524*
- ^{123}I , ^{125}I , ^{131}I -streptokinase kinetics, in animals, 136
- ^{123}I -fibrinogen, single donor, safety, 562*
- ^{125}I , ^{131}I , ^{177}Br -fibrinogens, uptake, in animals, 542*
- ^{125}I , ^{131}I -fibrinogen uptake, in animals, 370, 756
- radioiodofibrin uptake, in dogs, 521*
- ^{99m}Tc -autologous fibrinogen, electrolytic preparation, 343
- ^{99m}Tc -MAA venography, in dogs, 563*
- ^{99m}Tc -streptokinase preparation, 474, 557*
- thermography, 438, 439, 566*
- venograms combined with lung scanning, ^{131}I -MAA, ^{99m}Tc -microspheres, 579*
- Thymocytes**
- ^{99m}Tc -, ^{51}Cr -distribution, in mice, 633
- Thymus**
- ^{99m}Tc -, ^{51}Cr -thymocytes, distribution, in mice, 633
- Thyroid**
- accessory, ^{131}I scan, 1135
- autonomously functioning lesions, 1092*
- carcinoma, metastatic, liver imaging, 669, 919
- cold nodule imaging, ^{131}I , $^{99m}\text{TcO}_4^-$, 918; ^{67}Ga -citrate, 793
- cold nodule, ^{113m}In perfusion study, 1187
- cold nodule scan, oblique projection, 713
- cold nodule, thermography, 536*
- ^{133}Cs scan and gray-scale echography, 522*
- early kinetics of I and $^{99m}\text{TcO}_4^-$, 517*
- effective thyroxine ratio, in pediatrics, 955
- fluorescent scanning, 530*, 557*
- function in pernicious anemia, 549*
- ^{131}I therapy, effect on RBC, 963, 964
- ^{131}I therapy, low dose, 549*, 572*
- ^{131}I therapy, post-therapy function, 568*
- imaging, Fresnel zone plate, ^{123}I , 183
- imaging, refocused images, 548*
- imaging, ^{131}I and $^{99m}\text{TcO}_4^-$, 512*; $^{99m}\text{TcO}_4^-$, 512*, 563*
- phantom for quality control program, 957
- phantom imaging, dual window, 513*; high count rate positron, 653
- radiation dosimetry, radioiodides, MIRD, 857
- serum TSH response to TRH, 538*
- thyrotoxicosis due to "silent thyroiditis", 803*
- thyroxine-binding globulin capacity, 1076
- tomography, coded-aperture, scintillation camera, 402
- T₁ radioassay, 514*, 558*, 662
- uptake, ^{131}I , 562*
- uptake, ^{131}I , depression by contrast media, 802*
- uptake, ^{131}I , normal range, 560*
- Thyroid stimulating hormone**
- response to TRH, 538*
- serum levels, in pernicious anemia, 549*
- thyroid function post ^{131}I therapy, 568*

- Thyroxine**
 -binding globulin capacity, 1076
 -binding globulin, ^{131}I -diphenylhydantoin kinetics, 305
 effective thyroxine ratio, in pediatrics, 955
 levels in pernicious anemia, 549*
 serum, TSH response to TRH in disease, 539*
 thyroid function post ^{131}I -therapy, 568*
- Tin**
 (II), previously administered, effect on $^{99m}\text{TcO}_4^-$ distribution, 518*, 541*, 579*
 (II), reduced Tc valence state, 555*
- Tomography**
 axial, computerized, 1093*, 1210*
 brain, Mark IV system, 543*
 carcinoma of the hilum, 576*
 coded aperture, camera, 402
 internal absorption corrections, 540*
 multiwire proportional chamber positron camera, 546*
 myocardial infarct, ^{99m}Tc -diphosphonate, -pyrophosphate, -gluconate, ^{18}F , 581*
 myocardial, ^{99m}Tc -microspheres, in dogs, 568*
 transaxial, editorial, 179
 transaxial, positron, 210, 521*, 558*
 transaxial reconstruction by iterative techniques, 555*
 transaxial, ring detector system, 1166
 unfocused plane subtraction, 517*
 3D image reconstruction, 80
- Toxicity**
 anaphylactoid reaction to ^{99m}Tc -microspheres, 236
 Bleomycin, 414
 digoxin, radioimmunoassay, post mortem, 1212*
 diphosphonate, 444, 744; methylene-, 744
 ^{131}I -iodocholesterol, 928
 imidodiphosphate, 1137
 pyridoxylideneglutamate, 720
 stannous glucoheptonate, 875, 877
 trimetaphosphate for bone, 1043
- Transferrin** see *Technetium-99m*
- Transmission**
 bone mineral content, photon absorption, 891
 imaging, 3D Fourier convolution reconstruction, noise, 529
- Transplant** see *Kidney, transplant*
- Trauma**
 abdominal, liver and spleen imaging, in children, 525*
 bone scanning, 538*
 hepatic artery aneurysm, ^{99m}Tc -S colloid, ^{99m}Tc -MAA, 1027
 to head, ^{133}Xe in saline, cerebral blood flow, 803*
 to spleen, delayed rupture, ^{99m}Tc -S colloid image, 912
- Triiodothyronine** see *T₃*
- Tritium** see *Hydrogen-3*
- Tuberculosis**
 CNS, $^{99m}\text{TcO}_4^-$ scanning, 580*
 mycobacterium, radiometric assay, 518*, 1189
- Tumor**
 adrenal carcinoma, ^{131}I -iodocholesterol uptake, 566*
 alpha-fetoprotein levels, liver disease, 949, 1094*
 antibody, ^{131}I , preparation, distribution, in animals, 544*
 bleomycin fractions, properties, 526*, 1033
 bone, comparison of agents, 803*
 bone, imaging, 503*
 bone, ^{99m}Tc -diphosphonate kinetics, 886
 brain, chemotherapy response, $^{99m}\text{TcO}_4^-$ scans, 1210*
 brain, comparison of 16 agents, in mice, 200
 brain, medulloblastoma, 520*
 brain, metastatic, steroid medication effect, 320
 brain, metastatic, $^{99m}\text{TcO}_4^-$ scanning, 960, 961
 brain, scan, blood activity contribution, 553*
 brain, ^{99m}Tc -glucoheptonate imaging, 580*
 breast, imaging, $^{99m}\text{TcO}_4^-$, 293, 996; ^{113}In -bleomycin, 578; $^{99m}\text{TcO}_4^-$, 293; ^{99m}Tc -polyphosphate, 581*
 breast, malignant, benign differentiation, 578*
 breast, metastatic, CEA radioimmunoassay, 579*; ^{99m}Tc -citrate scanning, 560*; liver scanning, 802*; ^{99m}Tc -pyrophosphate bone imaging, 1158
 bronchogenic carcinoma staging, 538*
 ^{113}C -diphenylhydantoin, -hydroxydiphenylhydantoin scanning, 575*
 ^{113}C -tryptophan, preparation, 579*
 ^{14}C -fluorouracil uptake, in mice, 582*
 CEA radioimmunoassay, 550*, 579*, 1094*
 chemodectoma, ^{99m}Tc -MAA flow study, 472
 ^{99m}Tc -bleomycin fractions, distribution, in rats, 1033; melanoma uptake, in rats, 556*
 ^{99m}Tc -bleomycin scanning, 839, 1058
 eye, ^{33}P imaging, Cerenkov effect, 516*
 ^{99m}Tc -citrate imaging, 414, 523*, 547*, 558*, 560*, 949; in children, 533*; in lymphoma, 255
 ^{99m}Tc -citrate, ^{99m}Tc -S colloid subtraction technique, 523*
 ^{99m}Tc -citrate uptake, benign tumor, 470
 ^{99m}Tc -Ga-, ^{197}Hg -adriamycin, ^{99m}Tc -chloride, ^{197}Hg -acetate uptake, in mice, 560*
 ^{99m}Tc -prostaglandin E, A and arachidonic acid distribution, in mice, 83
 ^{99m}Tc -, ^{99m}Tc -, ^{99m}Tc -Cu-bleomycin uptake, in rats, 127
 hemangiendotheliomatosis, RES, kidney, brain imaging, 915
 hilum carcinoma, ^{99m}Tc -Ga scans, 576*
 ^{123}I -bleomycin imaging, 524*
 ^{123}I -serum protein uptake, in mice, 560*
 ^{123}I -streptozotacin analog uptake, in hamsters, 535*
 ^{123}I -tetracycline uptake, in animals, 520*
 imaging agents, comparison, 1212*
 imaging, book review, 498
 ^{111}In -bleomycin and -chloride kinetics, in mice, 738
 ^{111}In -bleomycin imaging, 537*, 558*, 854*; in children, 554*
 ^{111}In -bleomycin uptake, 578*
 jaw, bone imaging, 511*
 kidney bloodflow study, ^{99m}Tc -MAA, 472
 kidney metastases, uptake of ^{99m}Tc -polyphosphate, 602
 liver primary, ^{99m}Tc -citrate imaging, 949
 liver scintangiography, ^{111}In -chloride, 533*; ^{99m}Tc -S colloid, 595
 lymphoma, bone scanning, 555*
 lymphoma, ^{99m}Tc -citrate staging, 255
 melanoma, ^{123}I -quinoline analogs, distribution, in mice, 530*
 melanoma, ^{111}In -bleomycin scanning, 537*
 melanoma, ^{203}Pb -Tris, ^{99m}Tc -bleomycin, in hamsters, 556*
 meningioma, extracranial, $^{99m}\text{TcO}_4^-$ brain studies, 833
 metastatic to bone, ^{33}P , parathormone therapy, 519*; chemotherapy response, ^{87}Sr imaging, 191; ^{99m}Tc -compound imaging, 532*, 579*, 986, 1158, 1211*
 multiple myeloma, ^{99m}Tc -diphosphonate bone scanning, 579*
 neuroblastoma, prostaglandin radioimmunoassay, in mice, 83
 osteosarcoma, ^{99m}Tc -polyphosphate, -diphosphonate bone scans, 423, 1211*
 pancreas, ^{14}C - ^{131}I -diphenylhydantoin imaging, 775
 pancreas, ^{99m}Tc -bleomycin, ^{75}Se -selenomethionine imaging, 533*
 pancreas, scanning evaluation, 568*
 pheochromocytoma, ^{99m}Tc -DTPA kidney angiography, 234
 posterior fossa, scanning, 556*
 prostate, ^{67}Zn imaging, 495, 496
 ^{166}Pt -bleomycin complexes, uptake, in mice, 545*
 sarcoma, spleen encasement, ^{99m}Tc -S colloid image, 718
 scalp, uptake on cerebral flow study, 462
 size, semiconductor camera detection, 53
 ^{113}Sm uptake, in mice, 528*
 soft-tissue, ^{99m}Tc -polyphosphate uptake, 568*, 581*, 602, 1021
 ^{99m}Tc -bleomycin imaging, 414, 551*
 ^{99m}Tc -gluconate imaging, in children, 552*

- ^{99m}Tc-Sn-citrate uptake**, in mice, 534*
- ^{99m}Tc-sulfonylureas**, preparation, distribution, in rats, 561*
- therapy**, ¹²⁵I-iododeoxyuridine, in mice, 516*
- thyroid carcinoma**, metastatic, liver imaging, 669, 919
- uptake**, comparison of labeled bleomycins and ⁶⁷Ga-citrate, 524*
- uptake of ¹³¹I-tetracycline**, ⁶⁷Ga and ^{99m}Tc-compounds, in rats, 532*
- viability**, uptake of ²⁰³Pb and ⁷⁵Se-selenomethionine, in rats, 532*
- viability**, uptake of six agents, 532*
- T_s**
- kit, 514*, 558*
- levels in pernicious anemia, 549*
- radioassay, resin-strip, 662
- thyroid function post ¹³¹I therapy, 568*
- thyroxine-binding globulin capacity, 1076
- TSH response to TRH in thyroid disease, 538*
- Ultrasound**
- cold thyroid nodule studies, 713
- gamma-ray probe guidance, 562*
- gray-scale echography, thyroid, 522*
- left ventricular ejection fraction, 565*
- pancreatic disease, 563*
- Urinary tract**
- blind-ending ureteral duplication, ¹³¹I-Hippuran image, 208
- evaluation in renal transplants, ^{99m}Tc, ¹³¹I-Hippuran, 557*
- obstruction, in pregnancy, renogram, 803*
- radionuclide cystography, in children, 522*
- ureteral fistula, ^{99m}Tc-DTPA, ¹³¹I-Hippuran, 612
- vesicoureteral reflux, ¹³¹I-Hippuran, scintillation camera studies, 968*
- vesicoureteral reflux, radionuclide cystography, in children, 522*
- Vascular system**
- see also Thrombus*
- chemodectoma, ^{99m}Tc-MAA flow study, 472
- hemangioendotheliomatosis, 915
- obstructed mediastinal venous return, effect on brain bloodflow studies, 622
- peripheral, blood flow in occlusive disease, ¹³³Xe, 1211*
- peripheral, perfusion imaging, ^{99m}Tc-RBC, 512*
- peripheral perfusion, ischemic ulcer, ^{99m}Tc-microspheres, 993
- tetralogy of Fallot, ventilation/perfusion studies, 510*
- Ventriculography** *see Cerebrospinal fluid*
- Vesicles**
- polyamino acid and antibody interactions, survival, in mice, 483
- ^{99m}Tc-, preparation, distribution, in animals, 488
- Vitamin B₁₂**
- consecutive day Schilling tests, 495
- deficiency, ¹⁴C-formaldehyde, -propionate metabolism, in rats, 553*
- oyster toad fish serum binding, 541*
- serum, chicken serum binding assay, 551*
- White blood cells** *see Leukocytes; Lymphocytes*
- Whole body**
- Ca, neutron activation analysis, 196, 672
- imaging, scintillation camera, 582*
- scanner, unidirectional, 516*
- Xenon-122**
- radiation dosimetry, 143
- Xenon-123**
- radiation dosimetry, nuclear parameters, 143
- Xenon-125**
- radiation dosimetry, lung studies, 780
- preparation, characteristics, 143
- Xenon-127**
- nuclear parameters, 143
- radiation dosimetry, 143, 780
- Xenon-129m**
- nuclear parameters, radiation dosimetry, 143
- Xenon-131m**
- nuclear parameters, radiation dosimetry, 143
- Xenon-133**
- contamination in a clinical laboratory, 804*
- dose rate, 539*
- nuclear parameters, 143
- radiation dosimetry, 143, 780
- trioxide, Na xenate, Ba xenate, distribution, 545*
- Xenon-133, gas**
- calibrated dose dispenser, 1197
- lung ventilation in cystic fibrosis, 548*
- lung ventilation in hemangioendotheliomatosis, 915
- lung ventilation in obstructive disease, 567*, 574*
- lung ventilation in pulmonary artery banding, 577*
- lung ventilation in pulmonary embolism, 503*, 553*, 1017
- lung ventilation in tetralogy of Fallot, 510*
- lung ventilation, tidal breathing, 853*
- radiation dose to lungs, 580*
- regional cerebral blood flow, 1093*
- spirometer system, 551*
- upper and lower airways relationship, 570*
- Xenon-133, in saline**
- cerebral blood flow, infarct effect, 853*; in monkeys, 514*
- cerebral blood flow, regional, 264, 577*, 803*; data processing system, 386
- cerebral infarct imaging, in baboons, 852*
- eye blood flow, 517*
- inhalation injury in burn patients, 547*
- intrarenal blood flow, 899
- lung perfusion in pulmonary artery banding, 577*
- muscle blood flow, occlusive disease, 1211*
- placental blood flow, 968*
- regional myocardial blood flow, 536*, 567*
- Xenon-135**
- nuclear parameters, radiation dosimetry, 143
- X-ray**
- fluorescence, GFR, iothalamate, in dogs, 510*
- therapy, long-range effects, 512*
- Ytterbium-169**
- DTPA, brain tumor uptake, radiation dosimetry, in mice, 200
- DTPA, intrathecal retention, 570*
- DTPA, radiation dosimetry, cisternography, 101, 1177
- Yttrium-90**
- radiation dosimetry, 502*
- Zinc-69m**
- prostate imaging, 495, 496

INDEX TO ADVERTISERS

Analytical Development Associates Corp.	
Cupertino, Calif.	60A
Atomic Energy of Canada	
Ottawa, Canada	26A
Atomic Products Corp.	
Center Moriches, N.Y.	30A
Baird-Atomic	
Bedford, Mass.	14A, 24A, 25A
Brattle Instrument Corp.	
Cambridge, Mass.	IBC
Capintec, Inc.	
Mt. Vernon, N.Y.	1259
CIS Radiopharmaceuticals	
Bedford, Mass.	14A, 15A
Cleon Corp.	
Needham, Mass.	32A, 33A
Clinical Assays, Inc.	
Cambridge, Mass.	40A
Diagnostic Biochemistry	
San Diego, Calif.	43A
Diagnostic Isotopes, Inc.	
Upper Saddle River, N.J.	2A
Diagnostic Products Corp.	
Los Angeles, Calif.	22A
Digital Equipment Corp.	
Maynard, Mass.	41A
Dunn Instruments	
San Francisco, Calif.	3A
Elscint, Inc.	
Palisades Park, N.J.	20A, 21A
G. E. Medical Systems	
Milwaukee, Wis.	36A, 37A
Hoechst AG	
Frankfurt, Germany	5A
Isolab, Inc.	
Akron, Ohio	38A
Jasins & Sayles Associates	
Wellesley, Mass.	42A
Kevex Corp.	
Burlingame, Calif.	44A
Mallinckrodt, Inc.	
St. Louis, Mo.	31A
Matrix Instruments	
Closter, N.J.	23A, 79A
Medical Data Systems	
Ann Arbor, Mich.	28A, 29A
Medi-Physics, Inc.	
Emeryville, Calif.	IFC, 1A
Medi-Ray, Inc.	
Tuckahoe, N.Y.	46A
Micromedic Systems	
Horsham, Penn.	56A, 57A
C. V. Mosby Co.	
St. Louis, Mo.	18A
New England Nuclear	
Boston, Mass.	8A, 16A, 17A, 68A, 69A, 72A
Nise, Inc.	
Cerritos, Calif.	80A
Nuclear Associates, Inc.	
Westbury, N.Y.	39A
Nuclear Endocrine Labs.	
Cleveland, Ohio	73A
Ohio-Nuclear, Inc.	
Solon, Ohio	52A, 53A, 55A
Omnimedical Services, Inc.	
Paramount, Calif.	54A, 76A
Oxford Labs.	
Foster City, Calif.	27A
Picker Corp.	
Cleveland, Ohio	49A, 50A, 72B, 72C
Procter & Gamble	
Cincinnati, Ohio	61A, 62A, 63A, 64A
Professional Education Assoc.	
Des Plaines, Ill.	51A
Radiochemical Centre	
Amersham, England	19A, 48A, 77A
Radx Corp.	
Houston, Texas	74A, 75A
Raytheon Co.	
Burlington, Mass.	6A
RCA/Photo Tubes	
Lancaster, Pa.	47A
Schwarz/Mann	
Orangeburg, N.Y.	35A
Searle Radiographics, Inc.	
Des Plaines, Ill.	58A, 59A, BC
SNM Placement	
New York, N.Y.	65A, 66A, 67A
E. R. Squibb & Sons, Inc.	
Princeton, N.J.	10A, 11A, 70A, 71A
Technical Associates	
Canoga Park, Calif.	34A
Tennelec, Inc.	
Oak Ridge, Tenn.	67A
Varian Associates	
Walton-on-Thames, England	12A, 13A
Williams & Wilkins	
Baltimore, Md.	45A